#seasonalinfluenza — Public Fediverse posts

"Cough into your bent elbow, or use a tissue and dispose of it afterwards in the nearest bin."

I find it astonishing how many people don't bother, or don't know about this elementary precaution.

How to avoid catching flu, COVID-19 and other respiratory illnesses this winter  – UK Health Security Agency
https://ukhsa.blog.gov.uk/2025/12/02/how-to-avoid-catching-flu-covid-19-and-other-respiratory-illnesses-this-winter/

#flu #SeasonalInfluenza #RespiratoryInfections

Don't panic, it's worldwide already, and you've likely already had it.

#HMPV #seasonalInfluenza #socialmedia #diseases #diseaseprevention

HMPV: What to know about China's human metapneumovirus cases https://www.bbc.com/news/articles/c23vjg7v7k0o?utm_source=firefox-newtab-en-us

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Dec. 7 ’24)

1. SCHERGER SJ, Kalil AC
   In persons exposed to influenza, zanamivir, oseltamivir, laninamivir, and baloxavir reduce symptomatic seasonal influenza.
   Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-03197.
   PubMed         Abstract available
2. SCHERGER SJ, Kalil AC
   In hospitalized patients with influenza, oseltamivir or peramivir may reduce hospital length of stay (low-certainty evidence).
   Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-03198.
   PubMed         Abstract available

   Antimicrob Agents Chemother

3. SHIN JS, Jang Y, Kim D-S, Jung E, et al
   Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate.
   Antimicrob Agents Chemother. 2024;68:e0034124.
   PubMed         Abstract available
4. MENDES S, Guimaraes LC, Costa PAC, Fernandez CC, et al
   Intranasal liposomal angiotensin-(1-7) administration reduces inflammation and viral load in the lungs during SARS-CoV-2 infection in K18-hACE2 transgenic mice.
   Antimicrob Agents Chemother. 2024;68:e0083524.
   PubMed         Abstract available

   Arch Virol

5. MISHRA S, Pandey A, Verma J, Rajala MS, et al
   Analysis of the interaction of influenza a virus nucleoprotein with host cell nucleolin.
   Arch Virol. 2024;170:1.
   PubMed         Abstract available

   BMJ

6. MAHASE E
   UK secures five million doses of human H5 influenza vaccine.
   BMJ. 2024;387:q2717.
   PubMed        

   Epidemiol Infect

7. SANOGO IN, Fusade-Boyer M, Molia S, Koita OA, et al
   Identification of risk areas for avian influenza outbreaks in domestic poultry in Mali using the GIS-MCDA approach.
   Epidemiol Infect. 2024;152:e152.
   PubMed         Abstract available

   J Exp Med

8. VALERI E, Kajaste-Rudnitski A
   Antiviral immunity lassoed down by excess RNA.
   J Exp Med. 2025;222:e20241743.
   PubMed         Abstract available

   J Infect

9. LUO H, Cui Y, Yu W, Li G, et al
   The impact of urbanization in China on influenza incidence across neighboring cities.
   J Infect. 2024 Nov 28:106370. doi: 10.1016/j.jinf.2024.106370.
   PubMed         Abstract available

   J Virol

10. LV H, Teo QW, Lee C-CD, Liang W, et al
    Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model.
    J Virol. 2024 Dec 5:e0169524. doi: 10.1128/jvi.01695.
    PubMed         Abstract available
11. YANG K, Nizami S, Hu S, Zou L, et al
    Genetic diversity of highly pathogenic avian influenza H5N6 and H5N8 viruses in poultry markets in Guangdong, China, 2020-2022.
    J Virol. 2024 Dec 4:e0114524. doi: 10.1128/jvi.01145.
    PubMed         Abstract available

    Pediatrics

12. HINDERSTEIN S, Aragona E, Loyal J
    Parent Perspectives on Nirsevimab for Their Newborn.
    Pediatrics. 2024 Nov 26:e2024067532. doi: 10.1542/peds.2024-067532.
    PubMed         Abstract available
13. HUTTON DW, Prosser LA, Rose AM, Mercon K, et al
    Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children.
    Pediatrics. 2024 Nov 25:e2024066461. doi: 10.1542/peds.2024-066461.
    PubMed         Abstract available
14. HUTTON DW, Prosser LA, Rose AM, Mercon K, et al
    Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness.
    Pediatrics. 2024 Nov 25:e2024066481. doi: 10.1542/peds.2024-066481.
    PubMed         Abstract available

    PLoS Comput Biol

15. SHE B, Smith RL, Pytlarz I, Sundaram S, et al
    A framework for counterfactual analysis, strategy evaluation, and control of epidemics using reproduction number estimates.
    PLoS Comput Biol. 2024;20:e1012569.
    PubMed         Abstract available
16. ZAARAOUI H, Schumer C, Duval X, Hoen B, et al
    Modelling the effectiveness of antiviral treatment strategies to prevent household transmission of acute respiratory viruses.
    PLoS Comput Biol. 2024;20:e1012573.
    PubMed         Abstract available

    PLoS One

17. MOSANYA AU, Ezekwelu A, Ugochukwu EJ, Ukoha-Kalu BO, et al
    Factors associated with post-pandemic acceptance of COVID-19 vaccines among students in three Nigerian universities.
    PLoS One. 2024;19:e0312271.
    PubMed         Abstract available
18. SIBANDA M, Burnett RJ, Godman B, Meyer JC, et al
    Vaccine uptake, associated factors and reasons for vaccination status among the South African elderly; findings and next steps.
    PLoS One. 2024;19:e0314098.
    PubMed         Abstract available
19. BERRY I, Cole M, Silk B, Havers FP, et al
    SARS-CoV-2 coinfections among pertussis cases identified through the Enhanced Pertussis Surveillance system in the United States, January 2020-February 2023.
    PLoS One. 2024;19:e0311488.
    PubMed         Abstract available
20. SIMS S, Desai A, Harris R, Rafferty AM, et al
    Living restricted lives – Understanding the impact of isolation, social distancing and other restriction measures on older care home residents and their relatives in England during the COVID-19 pandemic: A qualitative study.
    PLoS One. 2024;19:e0312509.
    PubMed         Abstract available
21. HURST JR, Naghibosadat M, Budowski P, Liu J, et al
    Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice.
    PLoS One. 2024;19:e0314061.
    PubMed         Abstract available
22. GOPALAN M, Jung J, Shou-Chun C, Linden-Carmichael A, et al
    College students’ sense of belonging and alcohol use amidst COVID-19: Evidence from a 21-day daily diary study.
    PLoS One. 2024;19:e0310496.
    PubMed         Abstract available
23. METWALY AM, El-Fakharany EM, Alsfouk AA, Ibrahim IM, et al
    Integrated study of Quercetin as a potent SARS-CoV-2 RdRp inhibitor: Binding interactions, MD simulations, and In vitro assays.
    PLoS One. 2024;19:e0312866.
    PubMed         Abstract available
24. VACHUSKA K
    Do neighborhoods have boundaries? A novel empirical test for a historic question.
    PLoS One. 2024;19:e0313282.
    PubMed         Abstract available
25. ALFARO M, Rubio C, Fuertes G, Vargas M, et al
    Biomathematical model to analyze the transmission dynamics of Covid-19: Case study, Santiago de Cali, Colombia.
    PLoS One. 2024;19:e0311414.
    PubMed         Abstract available
26. LIU A, Waldman RN, Deal B, Duff J, et al
    Preparing for the next pandemic: Reflections and recommendations from Florida.
    PLoS One. 2024;19:e0314570.
    PubMed         Abstract available
27. LIN M, Li W, Cao Y, Gao Y, et al
    New profit models for property management in the post-pandemic era: A study on consumer attitudes towards community value-added services.
    PLoS One. 2024;19:e0314328.
    PubMed         Abstract available
28. TSUGAWA Y, Furukawa K, Ise T, Takayama M, et al
    Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo.
    PLoS One. 2024;19:e0300297.
    PubMed         Abstract available
29. ULAS E, Deutscher C
    Bundesliga team values: Deciphering the impact of performance and economics.
    PLoS One. 2024;19:e0312810.
    PubMed         Abstract available
30. GILLESPIE KM, Branjerdporn G, Woerwag Mehta S, Glegg J, et al
    The impact of screen time and social media on youth self-harm behaviour and suicide: A protocol for a systematic reviews.
    PLoS One. 2024;19:e0314621.
    PubMed         Abstract available
31. KAUR BP, Singh H, Hans R, Sharma SK, et al
    A Genetic algorithm aided hyper parameter optimization based ensemble model for respiratory disease prediction with Explainable AI.
    PLoS One. 2024;19:e0308015.
    PubMed         Abstract available
32. HORTON H, Marshall SA, Gu M, Tody B, et al
    Randomized controlled trial of a pilot PrEP linkage intervention for individuals leaving incarceration in a southern state: Design and baseline characteristics.
    PLoS One. 2024;19:e0312667.
    PubMed         Abstract available
33. IDRISS-WHEELER D, Bancroft X, Bouraleh S, Buy M, et al
    Exploring access to health and social supports for intimate partner violence (IPV) survivors during stressful life events (SLEs)-A scoping review.
    PLoS One. 2024;19:e0313613.
    PubMed         Abstract available
34. BUNDI JM, Morema EN, Shisanya MS
    Predictors of Generalized Anxiety Disorder (GAD) among health care providers during the COVID-19 pandemic at a regional teaching and referral hospital in Western Kenya.
    PLoS One. 2024;19:e0310240.
    PubMed         Abstract available
35. SHAHRBABAKI PM, Zeidabadinejad S, Abolghaseminejad P, Dehghan M, et al
    The relationship between COVID-19 anxiety and self-efficacy among adolescent students: A cross-sectional study.
    PLoS One. 2024;19:e0310434.
    PubMed         Abstract available
36. BAKKER H, Govindakarnavar A, Krishnan Krishnakumari P, Gromicho J, et al
    Coordination strategies to improve COVID-19 PCR laboratory testing scale up in Nepal: An analysis.
    PLoS One. 2024;19:e0314746.
    PubMed         Abstract available
37. MARIN D, Fernandez GJ, Hernandez JC, Taborda N, et al
    A systems biology approach unveils different gene expression control mechanisms governing the immune response genetic program in peripheral blood mononuclear cells exposed to SARS-CoV-2.
    PLoS One. 2024;19:e0314754.
    PubMed         Abstract available
38. RODRIGUES DA SILVA TP, Moreira CM, Souza JFA, Fernandes EG, et al
    Risk classification for the transmission of vaccine-preventable diseases in the state of Minas Gerais, Brazil: 2018 to 2022.
    PLoS One. 2024;19:e0311932.
    PubMed         Abstract available
39. MARTELL M, Salazar C, Errett NA, Miles SB, et al
    Outdoor social distancing behaviors changed during a pandemic: A longitudinal analysis using street view imagery.
    PLoS One. 2024;19:e0315132.
    PubMed         Abstract available
40. SIDDIQUI N, Mohamad Hasim H
    Risk contagion of COVID-19 to oil prices: A Markov switching GARCH and PCA approach.
    PLoS One. 2024;19:e0312718.
    PubMed         Abstract available
41. FREY LM, Venugopal D, Dev VS
    Prevalence and predictors of suicide ideation among university and high-school students during India’s 2nd wave of the COVID-19 pandemic.
    PLoS One. 2024;19:e0311403.
    PubMed         Abstract available
42. MIZERA-PECZEK P, Krasnova A, Sasin M, Sieczych-Kukawska A, et al
    Dual careers as sustainable careers for performing artists in times of crisis. A contextual approach to the construct of a sustainable arts career.
    PLoS One. 2024;19:e0314933.
    PubMed         Abstract available
43. QUINCHO-LOPEZ A
    Comparison of journal and top publisher self-citation rates in COVID-19 research.
    PLoS One. 2024;19:e0314976.
    PubMed         Abstract available
44. SANDERS C, Burnett K, Ray L, Ulanova M, et al
    An exploration of the role of trust and rapport in enhancing vaccine uptake among Anishinaabe in rural northern Ontario.
    PLoS One. 2024;19:e0308876.
    PubMed         Abstract available
45. BROTONS P, Cisneros M, Perez-Arguello A, Henares D, et al
    Pneumococcal nasopharyngeal carriage in children and adults self-confined at home during a COVID-19 national lockdown.
    PLoS One. 2024;19:e0315081.
    PubMed         Abstract available
46. ABUTAIMA R, Barakat M, Sawan HM, Al Omari SM, et al
    Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study.
    PLoS One. 2024;19:e0314407.
    PubMed         Abstract available
47. SHAN J, Huang B, Xin Y, Li R, et al
    The clinical characteristics and SARS-CoV-2 infection in children of acute hepatitis with unknown aetiology: A meta-analysis and systematic review.
    PLoS One. 2024;19:e0311772.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

48. GLAUBITZ A, Fu F
    Social dilemma of nonpharmaceutical interventions: Determinants of dynamic compliance and behavioral shifts.
    Proc Natl Acad Sci U S A. 2024;121:e2407308121.
    PubMed         Abstract available

    Vaccine

49. GONG S, Beukema M, De Vries-Idema J, Huckriede A, et al
    Assessing human B cell responses to influenza virus vaccines and adjuvants in a PBMC-derived in vitro culture system.
    Vaccine. 2024;44:126563.
    PubMed         Abstract available
50. HODGSON D, Sanchez-Ovando S, Carolan L, Liu Y, et al
    Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity.
    Vaccine. 2024 Dec 4:126579. doi: 10.1016/j.vaccine.2024.126579.
    PubMed         Abstract available

    Virology

51. SULTANA R, Stahelin RV
    Strengths and limitations of SARS-CoV-2 virus-like particle systems.
    Virology. 2025;601:110285.
    PubMed         Abstract available

#AVIANINFLUENZA #covid #COVID19 #health #influenzaA #news #research #SEASONALINFLUENZA #vaccine

Structural Convergence and Water-Mediated Substrate Mimicry Enable Broad #Neuraminidase #Inhibition by #Human #Antibodies

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.27.625426v1?rss=1

Abstract
Influenza has been responsible for multiple global pandemics and seasonal epidemics and claimed millions of lives. The imminent threat of a panzootic outbreak of avian influenza H5N1 virus underscores the urgent need for pandemic preparedness and effective countermeasures, including monoclonal antibodies (mAbs). Here, we characterize human mAbs that target the highly conserved catalytic site of viral neuraminidase (NA), termed NCS mAbs, and the molecular basis of their broad specificity. Cross-reactive NA-specific B cells were isolated by using stabilized NA probes of non-circulating subtypes. We found that NCS mAbs recognized multiple NAs of influenza A as well as influenza B NAs and conferred prophylactic protections in mice against H1N1, H5N1, and influenza B viruses. Cryo-electron microscopy structures of two NCS mAbs revealed that they rely on structural mimicry of sialic acid, the substrate of NA, by coordinating not only amino acid side chains but also water molecules, enabling inhibition of NA activity across multiple influenza A and B viruses, including avian influenza H5N1 clade 2.3.4.4b viruses. Our results provide a molecular basis for the broad reactivity and inhibitory activity of NCS mAbs targeting the catalytic site of NA through substrate mimicry.

____

#aH1n1 #aH5n1 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #h5n1 #health #influenzaB #monoclonalAntibodies #news #research #SEASONALINFLUENZA

A #vaccine #platform targeting #lung-resident memory #CD4+ T-cells provides #protection against heterosubtypic #influenza infections in mice and #ferrets

Source: Nature Communications, https://www.nature.com/articles/s41467-024-54620-4

Abstract
Lung tissue-resident memory T (TRM) cells induced by influenza vaccination are crucial for heterosubtypic immunity upon re-exposure to the influenza virus, enabling rapid and robust responses upon reactivation. To enhance the efficacy of influenza vaccines, we induce the generation of lung TRM cells following intranasal vaccination with a commercial influenza vaccine adjuvanted with NexaVant (NVT), a TLR3 agonist-based adjuvant. We demonstrate that intranasal immunization with the NVT-adjuvanted vaccine provides improved protection against influenza virus infections by inducing the generation of CD4+ TRM cells in the lungs in a type I interferon-dependent manner. These pulmonary CD4+ TRM cells provide potent mucosal immunity and cross-protection against heterosubtypic infections in both mouse and ferret models. This vaccine platform has the potential to significantly improve conventional intramuscular influenza vaccines by providing broader protection.

____

#abstract #animalModels #ferrets #research #SEASONALINFLUENZA #vaccines

1. IACOBUCCI G.
   Covid inquiry: Hancock is grilled on care homes, lockdowns, and testing.
   BMJ. 2023;383:p2868.
   PubMed: https://www.amedeo.com/p2.php?id=38052467&s=flu&pm=2
    
   Share: https://m.amedeo.com/38052467
2. ELGERSMA IH, Fretheim A, Elstrom P, Aavitsland P, et al.
   Association between face mask use and risk of SARS-CoV-2 infection:
   Cross-sectional study.
   Epidemiol Infect. 2023;151:e194.
   PubMed: https://www.amedeo.com/p2.php?id=37952983&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37952983
3. WEST AC, Harpur CM, Le Page MA, Lam M, et al.
   Harnessing endogenous peptide compounds as potential therapeutics for severe
   influenza.
   J Infect Dis. 2023 Dec 7:jiad566. doi: 10.1093.
   PubMed: https://www.amedeo.com/p2.php?id=38060822&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38060822
4. TENFORDE MW, Weber ZA, Yang DH, DeSilva MB, et al.
   Influenza vaccine effectiveness against influenza-A-associated emergency
   department, urgent care, and hospitalization encounters among U.S. adults,
   2022-2023.
   J Infect Dis. 2023 Dec 2:jiad542. doi: 10.1093.
   PubMed: https://www.amedeo.com/p2.php?id=38041853&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38041853
5. ZHANG L, Shao Y, Wang Y, Yang Q, et al.
   Twenty natural amino acid substitution screening at the last residue 121 of
   influenza A virus NS2 protein reveals the critical role of NS2 in promoting virus
   genome replication by coordinating with viral polymerase.
   J Virol. 2023 Dec 6:e0116623. doi: 10.1128/jvi.01166.
   PubMed: https://www.amedeo.com/p2.php?id=38054704&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38054704
6. MATHEW P, Feldmann M.
   Treatment of Adults Hospitalized With COVID-19 Pneumonia.
   JAMA. 2023;330:2122-2123.
   PubMed: https://www.amedeo.com/p2.php?id=38051331&s=flu&pm=2
    
   Share: https://m.amedeo.com/38051331
7. POWDERLY WG, LaVange L, Bozzette SA.
   Treatment of Adults Hospitalized With COVID-19 Pneumonia-Reply.
   JAMA. 2023;330:2123.
   PubMed: https://www.amedeo.com/p2.php?id=38051329&s=flu&pm=2
    
   Share: https://m.amedeo.com/38051329
8. HARRIS E.
   Combined COVID-19, Flu Vaccine Candidate Headed to Phase 3 Trials.
   JAMA. 2023 Nov 15. doi: 10.1001/jama.2023.22353.
   PubMed: https://www.amedeo.com/p2.php?id=37966868&s=flu&pm=2
    
   Share: https://m.amedeo.com/37966868
9. TANNIS A, Englund JA, Perez A, Harker EJ, et al.
   SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and
   Children Aged 6 Months-4 Years – New Vaccine Surveillance Network, United States,
   July 2022-September 2023.
   MMWR Morb Mortal Wkly Rep. 2023;72:1300-1306.
   PubMed: https://www.amedeo.com/p2.php?id=38032834&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38032834
10. BENEZECH S, Khoryati L, Cognard J, Netea SA, et al.
    Pre-Covid-19, SARS-CoV-2-Negative Multisystem Inflammatory Syndrome in Children.
    N Engl J Med. 2023;389:2105-2107.
    PubMed: https://www.amedeo.com/p2.php?id=38048195&s=flu&pm=2
     
    Share: https://m.amedeo.com/38048195
11. PRASERT K, Praphasiri P, Lerdsamran H, Nakphook S, et al.
    Safety and immunogenicity of locally produced trivalent inactivated influenza
    vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A
    Phase III double blinded, three-arm, randomized, controlled trial.
    Vaccine. 2023 Dec 1:S0264-410X(23)01396-8. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=38042698&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38042698
12. WANG B, McDonough J, Chen G, Ong JJ, et al.
    Sociodemographic factors and attitudes associated with Australian parental
    acceptance of paediatric COVID-19 vaccination.
    Vaccine. 2023 Nov 22:S0264-410X(23)01336-1. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37996291&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37996291
13. NAUGLE D, Tibbels N, Dosso A, Benie W, et al.
    “I’d do it for my baby”: Lessons learned from qualitative research on COVID-19
    vaccination among pregnant women in Cote d’Ivoire.
    Vaccine. 2023 Nov 19:S0264-410X(23)01333-6. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37989611&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37989611
14. CHENG DR, Reimer H, Le D, Crawford NW, et al.
    Analyzing an immunization resource website: User browsing trends.
    Vaccine. 2023;41:7498-7502.
    PubMed: https://www.amedeo.com/p2.php?id=37977940&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37977940
15. CHOI Y, Park S, Lee J, Kim Y, et al.
    Who gets COVID-19 booster vaccination? Trust in public health institutions and
    promotion strategies post-pandemic in the Republic of Korea.
    Vaccine. 2023 Nov 15:S0264-410X(23)01294-X. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37977939&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37977939
16. SARAFIAN JT, Eucker SA, Gillman M, DeLaroche AM, et al.
    Impact of a hypothetical COVID-19 vaccine mandate on parental likelihood to
    vaccinate children: Exploring school-related concerns and vaccination
    decision-making.
    Vaccine. 2023 Nov 14:S0264-410X(23)01334-8. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37973509&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37973509
17. LAMICHHANE P, Schmidt ME, Terhuja M, Varga SM, et al.
    A live single-cycle RSV vaccine expressing prefusion F protein.
    Virology. 2022;577:51-64.
    PubMed: https://www.amedeo.com/p2.php?id=36306605&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/36306605
18. ZIMMERMAN D, Shwayder M, Souza A, Su JA, et al.
    Cardiovascular Follow-up of Patients Treated for MIS-C.
    Pediatrics. 2023;152:e2023063002.
    PubMed: https://www.amedeo.com/p2.php?id=37964674&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37964674
19. ALMENDARES OM, Ruffin JD, Collingwood AH, Nolen LD, et al.
    Previous Infection and Effectiveness of COVID-19 Vaccination in Middle- and
    High-School Students.
    Pediatrics. 2023 Nov 14:e2023062422. doi: 10.1542/peds.2023-062422.
    PubMed: https://www.amedeo.com/p2.php?id=37960897&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37960897

https://etidioh.wordpress.com/2023/12/09/influenza-and-covid19-research-references-by-amedeo-december-9-23/

#avianInfluenza #coronavirus #COVID19 #fluSeason #health #healthScienceBlogging #healthyfruit #healthylife #influenzaA #research #seasonalInfluenza #SPANISHFLU

13th #Meeting of #WHO Expert Working #Group on #Surveillance of #Antiviral Susceptibility of #Influenza Viruses for WHO #GISRS

Source: World Health Organization, Weekly Epidemiological Record: https://www.who.int/publications/journals/weekly-epidemiological-record

{Excerpt, edited}

Executive summary

The WHO Expert Working Group on Surveillance of Influenza Antiviral Susceptibility (AVWG) supports the WHO Global Influenza Surveillance and Response System (GISRS) by providing practical guidance for monitoring the antiviral susceptibility of seasonal and emerging influenza viruses The 13th WHO AVWG meeting was held in hybrid format (faceto-face and virtually) on 13–14 June 2024 in Lyon, France.

Update on susceptibility of seasonal influenza viruses to approved antiviral agents

Between May 2023 and May 2024, WHO collaborating centres (CCs) and participating national influenza centres (NICs) reported that seasonal influenza activity in various regions had resumed to levels before the coronavirus disease 2019 (COVID-19) pandemic. Co-circulation of A(H1N1)pdm09, A(H3N2) and influenza B/Victoria lineage viruses was detected in most regions. Overall, influenza A and B viruses with reduced inhibition (RI) or highly reduced inhibition (HRI) to neuraminidase (NA) inhibitors (NAIs) were detected at low frequency. The most frequently identified substitution associated with RI or HRI by NAIs was NA-H275Y in A(H1N1)pdm09 viruses, which was detected at <2%. Double amino acid substitutions (NA-I223V+ NA-S247N) in A(H1N1)pdm09 viruses (referred to as dual mutant viruses) that resulted in RI by oseltamivir were first detected in May 2023 and spread rapidly to several regions of the world.{1,2} Influenza A and B viruses with amino acid substitutions in the polymerase acidic (PA) protein associated with reduced susceptibility to endonuclease inhibitor (baloxavir) were detected at low frequency. The PA-I38X (including I38T, I38N, I38M and I38V) amino acid substitution being the most frequently reported, but the overall detection frequency has remained low (<2%).

Update on susceptibility of zoonotic and animal influenza viruses to approved antiviral agents

From May 2023 to May 2024, clade 2.3.4.4b A(H5N1) highly pathogenic avian influenza (HPAI) viruses continued to be detected in various regions of the world. Since early 2024, there has been an outbreak of clade 2.3.4.4b A(H5N1) genotype B3.13 viruses in dairy cattle in several states in the United States of America, resulting in sporadic zoonotic infections in humans. In addition, human infection with clade 2.3.2.1c A(H5N1) HPAI has been reported in Cambodia and Viet Nam. WHO CCs, participating NICs and WHO H5 reference laboratories reported antiviral susceptibility testing of A(H5N1) HPAI, low pathogenic avian influenza (LPAI) of various subtypes and swine influenza viruses. Of the clade 2.3.4.4b A(H5N1) HPAI viruses, the NA-T438I substitution, which confers RI by zanamivir and peramivir, was detected at <2% frequency. NA-H275Y, NA-N295S and NA-N295S+NA-T438N associated with RI or HRI by NAIs were also detected among A(H5N1) viruses. NA-T438I has been detected in A(H5N1) viruses isolated from dairy cattle. PA-I38T, PA-A37T and PA-I38M, associated with reduced susceptibility to baloxavir, were detected in A(H5N1) viruses. Most A(H5N1) HPAI viruses remain susceptible to M2 ion channel blockers. Among LPAI, NA-H274Y with HRI by oseltamivir was detected in one A(H8N4) isolate. PA-E199G with reduced susceptibility to baloxavir was detected in one A(H9N2) virus. Overall, animal or zoonotic influenza viruses with reduced susceptibility to NAIs or baloxavir were detected at very low frequencies.

Update of protocols and guidance for GISRS laboratories

Genotypic and/or phenotypic assays can be used to monitor the susceptibility of influenza viruses to NAIs and baloxavir. The WHO AVWG routinely reviews and updates information on NA{3,4} and PA{5} amino acid substitutions associated with reduced susceptibility to NAIs and baloxavir, respectively. Reference virus panels that can be used for NAI and baloxavir susceptibility testing are available for GISRS laboratories at the International Reagent Resource.{6} The WHO AVWG will develop an algorithm for NICs to decide on testing strategies (genotypic versus phenotypic) and methods according to their capacity. Guidance on phenotypic assays for NAI susceptibility testing is provided in a WHO guidance document to NICs, which was updated in 2018.{7} A new phenotypic assay has been developed for testing susceptibility to baloxavir.{8} The protocol will be posted on the WHO website. The WHO-AVWG will also update the WHO guidance document to NICs to include the new phenotypic assay for baloxavir susceptibility testing. In addition, the WHO AVWG will work with the Global Initiative on Sharing All Influenza Data{9} to facilitate identification of NA and PA substitutions in submitted sequences.

Review of external quality assessment programme (EQAP) panels

EQAP was initiated in 2007, and the antiviral panel was introduced in 2013 (panel 12) as an optional component of EQAP to evaluate the ability of NICs to identify influenza viruses with reduced susceptibility to NAIs. Genotypic testing for baloxavir susceptibility was introduced in 2020 (panel 19) for educational purpose (i.e. not scored). Results for the 2023 Global EQAP panel were reported at the 13th WHO AVWG meeting. A total of 178 laboratories participated in the 2023 EQAP; 46 (25.8%) participated in NAI susceptibility testing and 16 (9.0%) in baloxavir susceptibility testing. The results from the Global EQAP antiviral panel are used by members of the WHO AVWG to assess the training requirements of NICs.

Way forward

Two reports, on global antiviral surveillance in 2020-2023 and in 2023–2024, are being prepared for publication. The next WHO AVWG meeting is scheduled for June 2025.

___

{1} Leung RC et al. Global emergence of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses with I223V and S247N mutations: implications for antiviral resistance monitoring. Lancet Microbe. 2024;5(7):627–8. doi:10.1016/S26665247(24)00037-5.

{2} Patel MC et al. Multicountry spread of influenza A(H1N1)pdm09 viruses with reduced oseltamivir inhibition, May 2023-February 2024. Emerg Infect Dis. 2024;30(7):1410–5. doi:10.3201/eid3007.240480.

{3} Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs). Geneva: World Health Organization; 2023 (https://www.who.int/publications/m/item/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais).

{4} Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs) among avian influenza viruses of Group 1 and Group 2 NAs. Geneva: World Health Organization; 2024 (https://www. who.int/publications/m/item/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais)among-avian-influenza-viruses-of-group-1-and-group-2-nas).

{5} Summary of polymerase acidic (PA) protein amino acid substitutions analysed for their effects on baloxavir susceptibility. Geneva: World Health Organization; 2024 (https://www.who.int/publications/m/item/summary-of-polymerase-acidic-(pa)-protein-amino-acid-substitutions-analysed-for-their-effects-on-baloxavirsusceptibility).

{6} See https://www.internationalreagentresource.org.

{7} Practical guidance for national influenza centres establishing or implementing neuraminidase inhibitor susceptibility surveillance. Geneva: World Health Organization; 2024 (https://www.who.int/publications/i/item/practical-guidance-for-national-inf luenza-centres-establishing-or-implementing-neuraminidase-inhibitor-susceptibility-surveillance).

{8} Baloxavir susceptibility assessment using influenza replication inhibition neuraminidase-based assay (IRINA). Atlanta (GA): Centers for Disease Control and Prevention; 2023 (https://cdn.who.int/media/docs/default-source/influenza/avwg/ cdc-phenotypic-lp-492rev01d—baloxavir-susceptibility-assessment-using-irina. pdf?sfvrsn=f24254ac_3).

{9} See https://gisaid.org.

_____

#aH3n2 #aH5n1 #aH9n2 #amantadine #antivirals #AVIANINFLUENZA #baloxavir #birdFlu #drugsResistance #h1n1pdm09 #h5n1 #health #influenza #oseltamivir #science #SEASONALINFLUENZA #updates #WHO #zanamivir

#Benefit of early #oseltamivir #therapy for #adults hospitalized with #influenza A: an observational study

Source: Clinical Infectious Diseases, https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae584/7912192

Abstract
Background
clinical guidelines recommend initiation of antiviral therapy as soon as possible for patients hospitalized with confirmed or suspected influenza.

Methods
A multicenter US observational sentinel surveillance network prospectively enrolled adults (aged ≥18 years) hospitalized with laboratory-confirmed influenza at 24 hospitals during October 1, 2022–July 21, 2023. A multivariable proportional odds model was used to compare peak pulmonary disease severity (no oxygen support, standard supplemental oxygen, high-flow oxygen/non-invasive ventilation, invasive mechanical ventilation, or death) after the day of hospital admission among patients starting oseltamivir treatment on the day of admission (early) versus those who did not (late or not treated), adjusting for baseline (admission day) severity, age, sex, site, and vaccination status. Multivariable logistic regression models were used to evaluate the odds of intensive care unit (ICU) admission, acute kidney replacement therapy or vasopressor use, and in-hospital death.

Results
A total of 840 influenza-positive patients were analyzed, including 415 (49%) who started oseltamivir treatment on the day of admission, and 425 (51%) who did not. Compared with late or not treated patients, those treated early had lower peak pulmonary disease severity (proportional aOR: 0.60, 95% CI: 0.49–0.72), and lower odds of intensive care unit admission (aOR: 0.24, 95% CI: 0.13–0.47), acute kidney replacement therapy or vasopressor use (aOR: 0.40, 95% CI: 0.22–0.67), and in-hospital death (aOR: 0.36, 95% CI: 0.18–0.72).

Conclusion
Among adults hospitalized with influenza, treatment with oseltamivir on day of hospital admission was associated reduced risk of disease progression, including pulmonary and extrapulmonary organ failure and death.

____

#abstract #antivirals #health #healthcare #news #oseltamivir #research #SEASONALINFLUENZA #vaccine #wellness

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Nov. 16 ’24)

1. ZHANG W, Lin X, Li ZY, Zhang LJ, et al
   Novel intercellular spread mode of respiratory syncytial virus contributes to neutralization escape.
   Antiviral Res. 2024;231:106023.
   PubMed         Abstract available
2. LO CW, Kariv O, Hao C, Gammeltoft KA, et al
   Replication Capacity and Susceptibility of Nirmatrelvir-Resistant Mutants to Next-Generation Mpro Inhibitors in a SARS-CoV-2 Replicon System.
   Antiviral Res. 2024 Oct 16:106022. doi: 10.1016/j.antiviral.2024.106022.
   PubMed         Abstract available
3. VAN DER HORST D, Carter-Timofte ME, Danneels A, Silva da Costa L, et al
   Large-scale deep learning identifies the antiviral potential of PKI-179 and MTI-31 against coronaviruses.
   Antiviral Res. 2024;231:106012.
   PubMed         Abstract available
4. HERRMANN A, Gege C, Wangen C, Wagner S, et al
   Orally Bioavailable RORgamma/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity.
   Antiviral Res. 2024 Sep 19:106008. doi: 10.1016/j.antiviral.2024.106008.
   PubMed         Abstract available
5. ZHANG K, Yang XM, Sun H, Cheng ZS, et al
   Modulating apoptosis as a novel therapeutic strategy against Respiratory Syncytial Virus infection: insights from Rotenone.
   Antiviral Res. 2024;231:106007.
   PubMed         Abstract available
6. KUMAR P, Zhang X, Shaha R, Kschischo M, et al
   Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis.
   Antiviral Res. 2024;231:106006.
   PubMed         Abstract available
7. DO TND, Abdelnabi R, Boda B, Constant S, et al
   The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
   Antiviral Res. 2024 Sep 3:105994. doi: 10.1016/j.antiviral.2024.105994.
   PubMed         Abstract available
8. RICHTER M, Khrenova M, Kazakova E, Riabova O, et al
   Dynamic features of virus protein 1 and substitutions in the 3-phenyl ring determine the potency and broad-spectrum activity of capsid-binding pyrazolo[3,4-d]pyrimidines against rhinoviruses.
   Antiviral Res. 2024;231:105993.
   PubMed         Abstract available
9. LEE P, Kim J, Oh H, Kim CU, et al
   Coronavirus Nucleocapsid-based Vaccine Provides Partial Protection against Hetero-species Coronavirus in Murine Models.
   Antiviral Res. 2024 Aug 22:105991. doi: 10.1016/j.antiviral.2024.105991.
   PubMed         Abstract available

   Biochem Biophys Res Commun

10. ZHAN Y, Li M, Gong R
    Protein mimics of fusion core from SARS-CoV-1 can inhibit SARS-CoV-2 entry.
    Biochem Biophys Res Commun. 2024;736:150857.
    PubMed         Abstract available
11. UCHIKUBO-KAMO T, Ishimoto N, Umezawa H, Hirohama M, et al
    Structural insights into Influenza A virus RNA polymerase PB1 binding to nuclear import host factor RanBP5.
    Biochem Biophys Res Commun. 2024;739:150952.
    PubMed         Abstract available

    Epidemiol Infect

12. GANDINI S, Conly J, Spencer EA, Evans D, et al
    Oro-faecal transmission of SARS-CoV-2: A systematic review of studies employing viral culture from gastrointestinal and other potential oro-faecal sources and evidence for transmission to humans.
    Epidemiol Infect. 2024;152:e138.
    PubMed         Abstract available
13. MAO S, Gu D, Wang D, Li P, et al
    Prevalence and prognosis of tinnitus in post-COVID-19 patients: a cross-sectional survey.
    Epidemiol Infect. 2024;152:e137.
    PubMed         Abstract available

    J Infect Dis

14. COHEN C, du Plessis M, Martinson N, Moyes J, et al
    A potential platform for future vaccine trials identifies high incidence of symptomatic and asymptomatic influenza infection among children aged 6-23 months in South Africa.
    J Infect Dis. 2024 Nov 14:jiae550. doi: 10.1093.
    PubMed         Abstract available

    J Virol

15. LI C, Culhane MR, Schroeder DC, Cheeran MC-J, et al
    Quantifying the impact of vaccination on transmission and diversity of influenza A variants in pigs.
    J Virol. 2024 Nov 12:e0124524. doi: 10.1128/jvi.01245.
    PubMed         Abstract available
16. POWELL JD, Thomas MN, Anderson TK, Zeller MA, et al
    2018-2019 human seasonal H3N2 influenza A virus spillovers into swine with demonstrated virus transmission in pigs were not sustained in the pig population.
    J Virol. 2024 Nov 11:e0008724. doi: 10.1128/jvi.00087.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

17. MELLIS AM, Coyle J, Marshall KE, Frutos AM, et al
    Serologic Evidence of Recent Infection with Highly Pathogenic Avian Influenza A(H5) Virus Among Dairy Workers – Michigan and Colorado, June-August 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1004-1009.
    PubMed         Abstract available
18. MARSHALL KE, Drehoff CC, Alden N, Montoya S, et al
    Personal Protective Equipment Use by Dairy Farmworkers Exposed to Cows Infected with Highly Pathogenic Avian Influenza A(H5N1) Viruses – Colorado, 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:999-1003.
    PubMed         Abstract available
19. FRUTOS AM, Ahmad HM, Ujamaa D, O’Halloran AC, et al
    Underutilization of Influenza Antiviral Treatment Among Children and Adolescents at Higher Risk for Influenza-Associated Complications – United States, 2023-2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1022-1029.
    PubMed         Abstract available
20. LEFFERTS B, Bressler S, Keck JW, Desnoyers C, et al
    Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children – Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1015-1021.
    PubMed         Abstract available
21. MINTA AA, Ferrari M, Antoni S, Lambert B, et al
    Progress Toward Measles Elimination – Worldwide, 2000-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1036-1042.
    PubMed         Abstract available

    PLoS Biol

22. DADONAITE B, Ahn JJ, Ort JT, Yu J, et al
    Deep mutational scanning of H5 hemagglutinin to inform influenza virus surveillance.
    PLoS Biol. 2024;22:e3002916.
    PubMed         Abstract available
23. HAY JA, Zhu H, Jiang CQ, Kwok KO, et al
    Reconstructed influenza A/H3N2 infection histories reveal variation in incidence and antibody dynamics over the life course.
    PLoS Biol. 2024;22:e3002864.
    PubMed         Abstract available

    PLoS One

24. ZHOU Y, Jin L, Lai X, Li Y, et al
    Adverse events associated with oseltamivir and baloxavir marboxil in against influenza virus therapy: A pharmacovigilance study using the FAERS database.
    PLoS One. 2024;19:e0308998.
    PubMed         Abstract available
25. GARZON DIAZ K, Villamil Duarte A, Velasco Forero S, Herrera Jacobo S, et al
    Post-pandemic face-to-face learning environments for undergraduate students: A scoping review protocol.
    PLoS One. 2024;19:e0309932.
    PubMed         Abstract available
26. LEITNER SM
    Working from home and mental well-being at different stages of the COVID-19 pandemic.
    PLoS One. 2024;19:e0312299.
    PubMed         Abstract available
27. WANG SB, Hanson JL
    Childhood socioeconomic position relates to adult decision-making: Evidence from a large cross-cultural investigation.
    PLoS One. 2024;19:e0310972.
    PubMed         Abstract available
28. AHMED S, Raza B, Hussain L, Sadiq T, et al
    Enhancing multiclass COVID-19 prediction with ESN-MDFS: Extreme smart network using mean dropout feature selection technique.
    PLoS One. 2024;19:e0310011.
    PubMed         Abstract available
29. CAROLIN A, Yan K, Bishop CR, Tang B, et al
    Tracking inflammation resolution signatures in lungs after SARS-CoV-2 omicron BA.1 infection of K18-hACE2 mice.
    PLoS One. 2024;19:e0302344.
    PubMed         Abstract available
30. VIVES-RODRIGUEZ AL, Marin A, Schiloski KA, Hajos GP, et al
    Impact of remote social interaction during the COVID-19 pandemic on the cognitive and psychological status of older adults with and without cognitive impairment: A randomized controlled study.
    PLoS One. 2024;19:e0311792.
    PubMed         Abstract available
31. COUGHENOUR C, Chien LC, Labus B, Gakh M, et al
    Shifting employment and perceptions of household responsibilities during early stages of the COVID-19 pandemic in Nevada, USA.
    PLoS One. 2024;19:e0309906.
    PubMed         Abstract available
32. STOCKL KM, Tucker J, Beaubrun A, Certa JM, et al
    Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample.
    PLoS One. 2024;19:e0313660.
    PubMed         Abstract available
33. LI Y, Kong D, Ding Y, Wang J, et al
    The potential impact of COVID-19 vaccination on patients with immune thrombocytopenic purpura: A protocol for systematic review and meta-analysis.
    PLoS One. 2024;19:e0308546.
    PubMed         Abstract available
34. TANAKA R, Tamao K, Ono M, Yamayoshi S, et al
    In vitro one-pot construction of influenza viral genomes for virus particle synthesis based on reverse genetics system.
    PLoS One. 2024;19:e0312776.
    PubMed         Abstract available
35. FEATHER J, Liverpool S, Allen E, Owen M, et al
    Locating the evidence for children and young people social prescribing: Where to start? A scoping review protocol.
    PLoS One. 2024;19:e0310644.
    PubMed         Abstract available
36. TANG F, Yang W, Wu W, Yao Y, et al
    Comparative analysis of state-level policy responses in global health governance: A scoping review using COVID-19 as a case.
    PLoS One. 2024;19:e0313430.
    PubMed         Abstract available
37. KNEDLIKOVA L, Dedkova L, Kolar S, Ceska K, et al
    The impact of the COVID-19 pandemic on stress and coping in parents of children with Autism Spectrum Disorder.
    PLoS One. 2024;19:e0313426.
    PubMed         Abstract available
38. EZEZIKA O, Kotsaftis TS, Amponsah-Dacosta E, Demi S, et al
    A protocol for modeling the factors influencing the deployment of the COVID-19 vaccine across African countries.
    PLoS One. 2024;19:e0311800.
    PubMed         Abstract available
39. XIAO J, Liu B, Matsika J, Wu R, et al
    Evaluating male sexual function and reproductive health during Omicron outbreak in China.
    PLoS One. 2024;19:e0310145.
    PubMed         Abstract available
40. PARK HR, Lee SY, Moon HJ, Kim JH, et al
    Longitudinal changes in sleep and sleep-related symptoms among Korean adults between 2010 to 2022, including the COVID-19 pandemic period.
    PLoS One. 2024;19:e0311600.
    PubMed         Abstract available
41. CHEWASKULYONG B, Satjaritanun P, Ketpueak T, Suksombooncharoen T, et al
    Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients.
    PLoS One. 2024;19:e0310781.
    PubMed         Abstract available
42. SHUKLA I, Wilmers CC
    Waste reduction decreases rat activity from peri-urban environment.
    PLoS One. 2024;19:e0308917.
    PubMed         Abstract available
43. AMER A, Ayoub A, Brousseau E, Auger N, et al
    Risk of severe influenza infection in women with a history of pregnancy complications: A longitudinal cohort study.
    PLoS One. 2024;19:e0313653.
    PubMed         Abstract available
44. MIYAKITA K, Sato F, Nakano K
    Performance evaluation of virtually deployed road networks for inter-drone communications.
    PLoS One. 2024;19:e0313400.
    PubMed         Abstract available
45. HOFFSTADT HE, Verhoef MJ, Akkermans A, van der Steen JT, et al
    “Are you listening?”: Experiences shared online by family caregivers of patients in the palliative phase during the Covid-19-pandemic.
    PLoS One. 2024;19:e0310624.
    PubMed         Abstract available
46. LI X, Han J, Lin H
    The effects of psychological flexibility and night shifts on mental health and well-being in nurses.
    PLoS One. 2024;19:e0313634.
    PubMed         Abstract available
47. KENNEDY L, Hirdes JP, Heckman G, Searle SD, et al
    The effect of the COVID-19 pandemic on delirium incidence in Ontario long-term care homes: A retrospective cohort study.
    PLoS One. 2024;19:e0311098.
    PubMed         Abstract available
48. GAO W, Yang S
    Higher-order moments spillovers among energy, carbon and tourism markets: Time- and frequency-domain evidence.
    PLoS One. 2024;19:e0313002.
    PubMed         Abstract available
49. SIX S, Israel D, Bilsen J, Kharagjitsing A, et al
    Insights into cultural and compliance challenges in type 2 diabetes care: A qualitative study of Moroccan and Belgian patients in Belgium.
    PLoS One. 2024;19:e0310800.
    PubMed         Abstract available
50. CHAIR SY, Kilpatrick K, Heffernan C, Hays SM, et al
    Impact of the COVID-19 pandemic on clinical care and patient-focused outcomes of advanced nursing practice: A cross-sectional study.
    PLoS One. 2024;19:e0313751.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

51. IYANIWURA SA, Ribeiro RM, Zitzmann C, Phan T, et al
    The kinetics of SARS-CoV-2 infection based on a human challenge study.
    Proc Natl Acad Sci U S A. 2024;121:e2406303121.
    PubMed         Abstract available
52. NGUYEN MH, Palfy G, Fogeron ML, Ninot Pedrosa M, et al
    Analysis of the structure and interactions of the SARS-CoV-2 ORF7b accessory protein.
    Proc Natl Acad Sci U S A. 2024;121:e2407731121.
    PubMed         Abstract available

    Vaccine

53. IRALA S, Hamid S, Penayo E, Michel F, et al
    COVID-19 vaccine effectiveness against hospitalizations in Paraguay, May 2021-April 2022: A test-negative design.
    Vaccine. 2023 Sep 14:S0264-410X(23)01069-1. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
54. LEWIS NM, Harker EJ, Leis A, Zhu Y, et al
    Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses – IVY Network, September 1, 2022-March 30, 2023.
    Vaccine. 2024;43.
    PubMed         Abstract available
55. KOUASSI KS, Chisupa E, Clarke A, Massenon I, et al
    Pandemic-related resilience in HPV vaccination programmes – Perspectives from selected countries in Africa on what it will take to vaccinate 90 % of girls by 2030.
    Vaccine. 2024;42 Suppl 2:S33-S36.
    PubMed         Abstract available

    Virology

56. NOWAK R, Gazecka M, Hoffmann M, Kierzek R, et al
    TMPRSS2-specific antisense oligonucleotides inhibit host cell entry of emerging viruses.
    Virology. 2024;600:110218.
    PubMed         Abstract available
57. OO A, Chen Z, Cao D, Cho YJ, et al
    Biochemical simulation of mutation synthesis and repair during SARS-CoV-2 RNA polymerization.
    Virology. 2024;600:110255.
    PubMed         Abstract available
58. WANG C, Zhang Y, Yang C, Ren W, et al
    Receptor binding mechanism and immune evasion capacity of SARS-CoV-2 BQ.1.1 lineage.
    Virology. 2024;600:110241.
    PubMed         Abstract available
59. WANG M, Valadez-Ingersoll M, Gilmore TD
    Control of nuclear localization of the nucleocapsid protein of SARS-CoV-2.
    Virology. 2024;600:110232.
    PubMed         Abstract available

#aH5n1 #abstract #antivirals #covid #COVID19 #health #influenzaA #news #research #SEASONALINFLUENZA #vaccine

Adverse #events associated with #oseltamivir and #baloxavir marboxil in against #influenza virus #therapy: A #pharmacovigilance study using the FAERS database

Source: PLoS One, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0308998

Abstract
Background
Influenza virus is a widespread pathogen that poses significant health risks to humans. Oseltamivir and Baloxavir Marboxil are commonly utilized medications for both treating and preventing influenza infections. Despite their widespread use, there remains a need to thoroughly investigate their safety profiles and potential adverse reactions.

Objective
This study aims to comprehensively analyze the adverse events associated with oseltamivir and baloxavir marboxil in real-world clinical settings, with the goal of assessing their safety and potential risks in the management of influenza virus infections.

Methods
We conducted a retrospective analysis utilizing data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database, spanning from the first quarter of 2004 to the third quarter of 2023. The analysis encompassed examination of drug utilization patterns, types of adverse events reported, patient demographics, and other pertinent factors.

Results
From the first quarter of 2004 to the third quarter of 2023, FAERS collected over 17,035,521 adverse event reports (AE reports). Among these reports, there were 38,384 reports associated with oseltamivir, and 3,364 reports associated with baloxavir marboxil. Oseltamivir and Baloxavir Marboxil were primarily used for the treatment of influenza virus infections, accounting for 62.43% and 67.49% of their total usage, respectively. The main adverse reactions reported for oseltamivir were vomiting (case reports = 1402) followed by confusional state (case reports = 353), while for baloxavir marboxil, adverse reactions mainly centered around off-label use (case reports = 378) and intentional product use issues (case reports = 278). In terms of systemic adverse reactions, oseltamivir primarily affected psychiatric disorders (n = 45), whereas baloxavir marboxil mainly impacted the gastrointestinal system (n = 7). Additionally, regarding adverse reactions in pregnant women, the occurrence of normal newborns was a significant signal for oseltamivir, suggesting a certain level of safety during maternal use. Conversely, reports of adverse reactions such as respiratory arrest were documented for baloxavir marboxil, while no such reports were associated with oseltamivir.

Conclusion
This study provides a comprehensive analysis of the adverse reactions observed with the clinical use of oseltamivir and baloxavir marboxil, revealing the safety and risks associated with these two drugs in the treatment and prevention of influenza virus infections. Firstly, although both drugs are used for influenza treatment, they exhibit different types of adverse reactions. Oseltamivir predominantly affects the psychiatric system, while baloxavir marboxil primarily impacts the gastrointestinal system. Additionally, oseltamivir demonstrates a certain level of safety for use in pregnant women, while reports of adverse reactions such as respiratory arrest are associated with baloxavir marboxil. Despite the clinical significance of this study, limitations exist due to the voluntary nature of data reporting, which may lead to reporting biases and incomplete information. Future research could employ more rigorous prospective study designs, integrating clinical trials and epidemiological studies, to more accurately assess the safety risks of oseltamivir and baloxavir marboxil.

____

#abstract #antivirals #baloxavir #birdFlu #drugsSafety #health #healthcare #news #oseltamivir #pregnancy #research #seasonalInfluenza

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.00087-24?af=R

ABSTRACT
Human seasonal H3 clade 3C3a influenza A viruses (IAV) were detected four times in U.S. pigs from commercial swine farms in Michigan, Illinois, and Virginia in 2019. To evaluate the relative risk of this spillover to the pig population, whole genome sequencing and phylogenetic characterization were conducted, and the results revealed that all eight viral gene segments were closely related to 2018–2019 H3N2 human seasonal IAV. Next, a series of in vitro viral kinetics, receptor binding, and antigenic characterization studies were performed using a representative A/swine/Virginia/A02478738/2018(H3N2) (SW/VA/19) isolate. Viral replication kinetic studies of SW/VA/19 demonstrated less efficient replication curves than all 10 swine H3N2 viruses tested but higher than three human H3N2 strains. Serial passaging experiments of SW/VA/19 in swine cells did not increase virus replication, but changes at HA amino acid positions 9 and 159 occurred. In swine transmission studies, wild-type SW/VA/19 was shed in nasal secretions and transmitted to all indirect contact pigs, whereas the human seasonal strain A/Switzerland/9715293/2013(H3N2) from the same 3C3a clade failed to transmit. SW/VA/19 induced minimal macroscopic and microscopic lung lesions. Collectively, these findings demonstrate that these human seasonal H3N2 3C3a-like viruses did not require reassortment with endemic swine IAV gene segments for virus shedding and transmission in pigs. Limited detections in the U.S. pig population in the subsequent period of time suggest a yet-unknown restriction factor likely limiting the spread of these viruses in the U.S. pig population.

____

https://etidioh.wordpress.com/2024/11/12/2018-2019-human-seasonal-h3n2-influenza-a-virus-spillovers-into-swine-with-demonstrated-virus-transmission-in-pigs-were-not-sustained-in-the-pig-population/

#aH3n2 #abstract #pigs #research #seasonalInfluenza #USA

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.06.622244v1

Abstract
The current situation with H5N1 highly pathogenic avian influenza virus (HPAI) is causing a worldwide concern due to multiple outbreaks in wild birds, poultry, and mammals. Moreover, multiple zoonotic infections in humans have been reported. Importantly, HPAI H5N1 viruses with genetic markers of adaptation to mammals have been detected. Together with HPAI H5N1, avian influenza viruses H7N9 (high and low pathogenic) stand out due to their high mortality rates in humans. This raises the question of how prepared we are serologically and whether seasonal vaccines are capable of inducing protective immunity against these influenza subtypes. An observational study was conducted in which sera from people born between years 1925-1967, 1968-1977, and 1978-1997 were collected before or after 28 days or 6 months post-vaccination with an inactivated seasonal influenza vaccine. Then, haemagglutination inhibition, viral neutralization, and immunoassays were performed to assess the basal protective immunity of the population as well as the ability of seasonal influenza vaccines to induce protective responses. Our results indicate that subtype-specific serological protection against H5N1 and H7N9 in the representative Spanish population evaluated was limited or nonexistent. However, seasonal vaccination was able to increase the antibody titers to protective levels in a moderate percentage of people, probably due to cross-reactive responses. These findings demonstrate the importance of vaccination and suggest that seasonal influenza vaccines could be used as a first line of defense against an eventual pandemic caused by avian influenza viruses, to be followed immediately by the use of more specific pandemic vaccines.

____

https://etidioh.wordpress.com/2024/11/09/are-we-serologically-prepared-against-an-avian-influenza-pandemic-and-could-seasonal-flu-vaccines-help-us/

#aH5n1 #aH7n9 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #h5n1 #health #human #news #pandemicInfluenza #research #seasonalInfluenza #serology #vaccination

1. BAKER JB, Ghatak A, Cullen MR, Horwitz RI, et al.
   Development of a Novel Clinical Risk Score for COVID-19 Infections.
   Am J Med. 2023;136:1169-1178.
   PubMed: https://www.amedeo.com/p2.php?id=37704073&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37704073
2. TENFORDE MW, Dawood FS, Ellington SR, Grohskopf LA, et al.
   Communicating the Value of Influenza Vaccines to Patients: Translating Vaccine
   Effectiveness to Acceptance.
   Ann Intern Med. 2023 Nov 28. doi: 10.7326/M23-2802.
   PubMed: https://www.amedeo.com/p2.php?id=38011706&s=flu&pm=2
    
   Share: https://m.amedeo.com/38011706
3. HWANG CS, Kesselheim AS, Sarpatwari A, Huybrechts KF, et al.
   Changes in Induced Medical and Procedural Abortion Rates in a Commercially
   Insured Population, 2018 to 2022 : An Interrupted Time-Series Analysis.
   Ann Intern Med. 2023 Oct 24. doi: 10.7326/M23-1609.
   PubMed: https://www.amedeo.com/p2.php?id=37871317&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37871317
4. JAMSHIDINIA N, Saadatpour F, Arefian E, Mohammadipanah F, et al.
   Augmented antiviral activity of chlorhexidine gluconate on herpes simplex virus
   type 1, H1N1 influenza A virus, and adenovirus in combination with salicylic
   acid.
   Arch Virol. 2023;168:302.
   PubMed: https://www.amedeo.com/p2.php?id=38036721&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38036721
5. LOOI MK.
   “We weren’t that great at treating flu-it should not be our model for covid”:
   America’s covid-19 tsar speaks.
   BMJ. 2023;383:p2743.
   PubMed: https://www.amedeo.com/p2.php?id=38030216&s=flu&pm=2
    
   Share: https://m.amedeo.com/38030216
6. O’CALLAGHAN C, Cloutman-Green E, Brierley J.
   Pandemic preparedness: is the UK ready for a pandemic that affects children?
   BMJ. 2023;383:2804.
   PubMed: https://www.amedeo.com/p2.php?id=38016735&s=flu&pm=2
    
   Share: https://m.amedeo.com/38016735
7. MAHASE E.
   Swine flu: UK reports its first human case of A(H1N2)v strain.
   BMJ. 2023;383:2819.
   PubMed: https://www.amedeo.com/p2.php?id=38016716&s=flu&pm=2
    
   Share: https://m.amedeo.com/38016716
8. DYER O.
   Pfizer sues Poland over unclaimed covid vaccines.
   BMJ. 2023;383:2810.
   PubMed: https://www.amedeo.com/p2.php?id=38016715&s=flu&pm=2
    
   Share: https://m.amedeo.com/38016715
9. LOOI MK.
   China: Rising cases of respiratory disease and pneumonia spark WHO concern.
   BMJ. 2023;383:2770.
   PubMed: https://www.amedeo.com/p2.php?id=37996101&s=flu&pm=2
    
   Share: https://m.amedeo.com/37996101
10. KASEYA J, Machingaidze S.
    How African countries can prepare for the next pandemic.
    BMJ. 2023;383:2762.
    PubMed: https://www.amedeo.com/p2.php?id=37996100&s=flu&pm=2
     
    Share: https://m.amedeo.com/37996100
11. RIMMER A.
    Clinicians with long covid must get financial support, say unions.
    BMJ. 2023;383:2723.
    PubMed: https://www.amedeo.com/p2.php?id=37977571&s=flu&pm=2
     
    Share: https://m.amedeo.com/37977571
12. ZHANG L, Zhang X, Deng X, Wang P, et al.
    Cytokines as drivers: Unraveling the mechanisms of epithelial-mesenchymal
    transition in COVID-19 lung fibrosis.
    Biochem Biophys Res Commun. 2023;686:149118.
    PubMed: https://www.amedeo.com/p2.php?id=37931361&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37931361
13. DE GERMAY S, Singier A, Salvo F, Pariente A, et al.
    Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in
    France.
    Drug Saf. 2023;46:1381-1389.
    PubMed: https://www.amedeo.com/p2.php?id=37926785&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37926785
14. ALEEM MA, Macintyre CR, Rahman B, Islam AKMM, et al.
    Association of recent respiratory illness and influenza with acute myocardial
    infarction among the Bangladeshi population – a case-control study.
    Epidemiol Infect. 2023 Nov 30:1-38. doi: 10.1017/S0950268823001863.
    PubMed: https://www.amedeo.com/p2.php?id=38031480&s=flu&pm=2
     
    Share: https://m.amedeo.com/38031480
15. ALICANDRO G, La Vecchia C, Islam N, Pizzato M, et al.
    A comprehensive analysis of all-cause and cause-specific excess deaths in 30
    countries during 2020.
    Eur J Epidemiol. 2023;38:1153-1164.
    PubMed: https://www.amedeo.com/p2.php?id=37684387&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37684387
16. SASIDHARAN A, Selvarangan R, Konrad K, Faron ML, et al.
    Multi-center clinical evaluation of the Panther Fusion SARS-CoV-2/Flu A/B/RSV
    assay in nasopharyngeal swab specimens from symptomatic individuals.
    J Clin Microbiol. 2023;61:e0082723.
    PubMed: https://www.amedeo.com/p2.php?id=37902331&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37902331
17. JIN Z, Wu J, Wang Y, Huang T, et al.
    Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized,
    double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical
    trial in healthy Chinese adults.
    J Infect. 2023 Oct 26:S0163-4453(23)00543-1. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37898410&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37898410
18. PAN D, Hui DSC, Tang JW.
    Defining infection transmission pathways for future pandemic preparedness – An
    urgent public health research priority.
    J Infect. 2023;87:595-597.
    PubMed: https://www.amedeo.com/p2.php?id=37865295&s=flu&pm=2
     
    Share: https://m.amedeo.com/37865295
19. HA L, Levian C, Greene N, Goldfarb I, et al.
    Association between acceptance of routine pregnancy vaccinations and COVID-19
    vaccine uptake in pregnant patients.
    J Infect. 2023 Oct 19:S0163-4453(23)00541-8. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37865294&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37865294
20. MARJANEH MM, Challenger JD, Salas A, Gomez-Carballa A, et al.
    Analysis of blood and nasal epithelial transcriptomes to identify mechanisms
    associated with control of SARS-CoV-2 viral load in the upper respiratory tract.
    J Infect. 2023 Oct 18:S0163-4453(23)00540-6. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37863321&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37863321
21. FENWICK C, Turelli P, Duhoo Y, Lau K, et al.
    Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and
    provides full protection in monkeys.
    J Infect. 2023 Oct 16:S0163-4453(23)00539-X. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37852477&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37852477
22. BEARD KR, Borca F, Phan H, Brown E, et al.
    Routine, molecular point-of-care testing for SARS-CoV-2 and other respiratory
    viruses within an acute oncology service improves patient care.
    J Infect. 2023 Oct 4:S0163-4453(23)00514-5. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37802471&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37802471
23. TIAN S, Liu T, Zhao XJ, Liu XL, et al.
    Neutralization against emerging Omicron subvariants after SARS-CoV-2 reinfection.
    J Infect. 2023 Oct 4:S0163-4453(23)00515-7. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37802470&s=flu&pm=2
     
    Share: https://m.amedeo.com/37802470
24. VELLAS C, Latour J, Tremeaux P, Ranger N, et al.
    Molecular Evolution of Omicron Variant in Immunocompromised Individuals with
    Chronic SARS-CoV-2 Infection.
    J Infect. 2023 Sep 30:S0163-4453(23)00513-3. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37783375&s=flu&pm=2
     
    Share: https://m.amedeo.com/37783375
25. ANTONELLI M, Penfold RS, Canas LDS, Sudre C, et al.
    SARS-CoV-2 infection following booster vaccination: illness and symptom profile
    in a prospective, observational community-based case-control study.
    J Infect. 2023 Sep 28:S0163-4453(23)00461-9. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37777159&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37777159
26. GAO Y, Zhang Y, Mou K, Man S, et al.
    Alterations in the outer retina and choroid in patients after COVID-19 infection.
    J Infect. 2023 Sep 27:S0163-4453(23)00512-1. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37774846&s=flu&pm=2
     
    Share: https://m.amedeo.com/37774846
27. YAMAMOTO S, Mizoue T, Konishi M, Oshiro Y, et al.
    Kinetics and durability of nucleocapsid-specific antibodies after SARS-CoV-2
    reinfection.
    J Infect. 2023 Sep 26:S0163-4453(23)00511-X. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37769951&s=flu&pm=2
     
    Share: https://m.amedeo.com/37769951
28. SNOW TAC, Arulkumaran N, Singer M, Choi SH, et al.
    Effect of dexamethasone dose on outcomes in acute COVID-19 disease: a systematic
    review and meta-analysis.
    J Infect. 2023 Sep 25:S0163-4453(23)00510-8. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37757919&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37757919
29. MATSUO OM, Lindoso L, Sousa Marques HH, Polanczyk GV, et al.
    Mental health among children and adolescents after SARS-CoV-2 infection: a
    prospective study in a tertiary university hospital.
    J Infect. 2023 Sep 20:S0163-4453(23)00507-8. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37739272&s=flu&pm=2
     
    Share: https://m.amedeo.com/37739272
30. FELL DB, Russell M, Fung SG, Swayze S, et al.
    Effectiveness of maternal influenza vaccination during pregnancy against
    laboratory-confirmed seasonal influenza among infants under 6 months of age in
    Ontario, Canada.
    J Infect Dis. 2023 Nov 29:jiad539. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38029414&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38029414
31. LEE K, Williams KV, Englund JA, Sullivan SG, et al.
    The potential benefits of delaying seasonal influenza vaccine selections for the
    Northern Hemisphere: a retrospective modeling study in the United States.
    J Infect Dis. 2023 Nov 29:jiad541. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38019883&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38019883
32. FRANKLIN A, John TM, Khawaja F, Jiang Y, et al.
    Utility of Bronchoalveolar Lavage for the Diagnosis and Management of COVID-19 in
    Patients With Cancer.
    J Infect Dis. 2023;228:1549-1558.
    PubMed: https://www.amedeo.com/p2.php?id=37983000&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37983000
33. ERNST T, Ryan MC, Liang HJ, Wang JP, et al.
    Neuronal and Glial Metabolite Abnormalities in Participants With Persistent
    Neuropsychiatric Symptoms After COVID-19: A Brain Proton Magnetic Resonance
    Spectroscopy Study.
    J Infect Dis. 2023;228:1559-1570.
    PubMed: https://www.amedeo.com/p2.php?id=37540098&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37540098
34. BRAUNSTEIN SL, Wahnich A, Lazar R.
    COVID-19 outcomes among people with HIV and COVID-19 in New York City.
    J Infect Dis. 2023 Aug 3:jiad311. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37534822&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37534822
35. ONWUCHEKWA C, Atwell J, Moreo LM, Menon S, et al.
    Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A
    Systematic Review and Meta-analysis.
    J Infect Dis. 2023;228:1516-1527.
    PubMed: https://www.amedeo.com/p2.php?id=37285396&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37285396
36. OSEI-YEBOAH R, Spreeuwenberg P, Del Riccio M, Fischer TK, et al.
    Estimation of the Number of Respiratory Syncytial Virus-Associated
    Hospitalizations in Adults in the European Union.
    J Infect Dis. 2023;228:1539-1548.
    PubMed: https://www.amedeo.com/p2.php?id=37246742&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37246742
37. DEL RICCIO M, Spreeuwenberg P, Osei-Yeboah R, Johannesen CK, et al.
    Burden of Respiratory Syncytial Virus in the European Union: estimation of
    RSV-associated hospitalizations in children under 5 years.
    J Infect Dis. 2023;228:1528-1538.
    PubMed: https://www.amedeo.com/p2.php?id=37246724&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37246724
38. ALRUWAILI M, Armstrong S, Prince T, Erdmann M, et al.
    SARS-CoV-2 NSP12 associates with TRiC and the P323L substitution acts as a host
    adaption.
    J Virol. 2023 Nov 6:e0042423. doi: 10.1128/jvi.00424.
    PubMed: https://www.amedeo.com/p2.php?id=37929963&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37929963
39. PAHMEIER F, Lavacca T-M, Goellner S, Neufeldt CJ, et al.
    Identification of host dependency factors involved in SARS-CoV-2 replication
    organelle formation through proteomics and ultrastructural analysis.
    J Virol. 2023 Oct 31:e0087823. doi: 10.1128/jvi.00878.
    PubMed: https://www.amedeo.com/p2.php?id=37905840&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37905840
40. BARTSCH YC, Cizmeci D, Yuan D, Mehta N, et al.
    Vaccine-induced antibody Fc-effector functions in humans immunized with a
    combination Ad26.RSV.preF/RSV preF protein vaccine.
    J Virol. 2023 Oct 30:e0077123. doi: 10.1128/jvi.00771.
    PubMed: https://www.amedeo.com/p2.php?id=37902399&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37902399
41. UNDI RB, Ahsan N, Larabee JL, Darlene-Reuter N, et al.
    Blocking of doublecortin-like kinase 1-regulated SARS-CoV-2 replication cycle
    restores cell signaling network.
    J Virol. 2023 Oct 20:e0119423. doi: 10.1128/jvi.01194.
    PubMed: https://www.amedeo.com/p2.php?id=37861336&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37861336
42. KUMAR S, Delipan R, Chakraborty D, Kanjo K, et al.
    Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its
    conformation, fusogenicity, and neutralization sensitivity.
    J Virol. 2023 Oct 20:e0092223. doi: 10.1128/jvi.00922.
    PubMed: https://www.amedeo.com/p2.php?id=37861334&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37861334
43. YE G, Pan R, Bu F, Zheng J, et al.
    Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum
    therapeutic nanobody candidates against COVID-19.
    J Virol. 2023 Oct 19:e0144823. doi: 10.1128/jvi.01448.
    PubMed: https://www.amedeo.com/p2.php?id=37855638&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37855638
44. SUN H, Wang Y, Chen X, Jiang Y, et al.
    Structural basis for broad neutralization of human antibody against Omicron
    sublineages and evasion by XBB variant.
    J Virol. 2023 Oct 19:e0113723. doi: 10.1128/jvi.01137.
    PubMed: https://www.amedeo.com/p2.php?id=37855619&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37855619
45. JOHNSON RM, Ardanuy J, Hammond H, Logue J, et al.
    Diet-induced obesity and diabetes enhance mortality and reduce vaccine efficacy
    for SARS-CoV-2.
    J Virol. 2023 Oct 17:e0133623. doi: 10.1128/jvi.01336.
    PubMed: https://www.amedeo.com/p2.php?id=37846985&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37846985
46. WU Y, Shi J, He X, Lu J, et al.
    Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its
    variants.
    J Virol. 2023 Oct 16:e0127923. doi: 10.1128/jvi.01279.
    PubMed: https://www.amedeo.com/p2.php?id=37843372&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37843372
47. BERGMAN C.
    Treatment of SARS-CoV-2 Infection in US Nursing Homes.
    JAMA. 2023;330:2021-2022.
    PubMed: https://www.amedeo.com/p2.php?id=38015226&s=flu&pm=2
     
    Share: https://m.amedeo.com/38015226
48. MCGARRY BE, Sommers BD, Barnett ML.
    Treatment of SARS-CoV-2 Infection in US Nursing Homes-Reply.
    JAMA. 2023;330:2022.
    PubMed: https://www.amedeo.com/p2.php?id=38015222&s=flu&pm=2
     
    Share: https://m.amedeo.com/38015222
49. HARRIS E.
    FDA Will Evaluate First Self-Administered FluMist Vaccine.
    JAMA. 2023 Nov 8. doi: 10.1001/jama.2023.21870.
    PubMed: https://www.amedeo.com/p2.php?id=37938864&s=flu&pm=2
     
    Share: https://m.amedeo.com/37938864
50. HARRIS E.
    Convalescent Plasma Lowered Risk of Death in COVID-19 ARDS.
    JAMA. 2023 Nov 8. doi: 10.1001/jama.2023.21872.
    PubMed: https://www.amedeo.com/p2.php?id=37938859&s=flu&pm=2
     
    Share: https://m.amedeo.com/37938859
51. HARRIS E.
    HRSA Study: US Abortions Decreased 14% During COVID-19.
    JAMA. 2023 Nov 1. doi: 10.1001/jama.2023.21178.
    PubMed: https://www.amedeo.com/p2.php?id=37910083&s=flu&pm=2
     
    Share: https://m.amedeo.com/37910083
52. ZIAUDDEEN N, Pantelic M, O’Hara ME, Hastie C, et al.
    Impact of long COVID-19 on work: a co-produced survey.
    Lancet. 2023;402 Suppl 1:S98.
    PubMed: https://www.amedeo.com/p2.php?id=37997145&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997145
53. VAN YPEREN J, Campillo-Funollet E, Memon A, Allman P, et al.
    The Sussex COVID-19 Modelling Cell: the methods and successes of a collaboration
    between public health teams in local authorities, NHS hospital trusts, NHS
    commissioners, and universities.
    Lancet. 2023;402 Suppl 1:S94.
    PubMed: https://www.amedeo.com/p2.php?id=37997141&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997141
54. Nowcasting waiting lists for elective procedures and surgery in England: a
    modelling study.
    Lancet. 2023;402 Suppl 1:S74.
    PubMed: https://www.amedeo.com/p2.php?id=37997119&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997119
55. MORENO-AGOSTINO D, Das-Munshi J, Ploubidis GB.
    Differences in the impact of the COVID-19 pandemic in the long-term trajectories
    of life satisfaction by sex in the UK: a prospective cohort study.
    Lancet. 2023;402 Suppl 1:S71.
    PubMed: https://www.amedeo.com/p2.php?id=37997116&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997116
56. MARTIN A, Jamieson S.
    Exploring the experiences of junior doctors who were shielding during the
    COVID-19 pandemic: a qualitative study of semi-structured interviews.
    Lancet. 2023;402 Suppl 1:S68.
    PubMed: https://www.amedeo.com/p2.php?id=37997112&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997112
57. KROMYDAS T, Demou E, Leyland AH, Katikireddi SV, et al.
    Effect of trade unions on the mental health of UK workers before and during the
    COVID-19 pandemic: a longitudinal analysis using Understanding Society data.
    Lancet. 2023;402 Suppl 1:S62.
    PubMed: https://www.amedeo.com/p2.php?id=37997106&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997106
58. KHAN Y, Verhaeghe N, Devleesschauwer B, Cavillot L, et al.
    Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in
    Europe: a systematic review.
    Lancet. 2023;402 Suppl 1:S61.
    PubMed: https://www.amedeo.com/p2.php?id=37997105&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997105
59. KALBUS A, Cornelsen L, Ballatore A, Cummins S, et al.
    Changes in food and drink purchasing behaviour in England during the first 3
    months of the COVID-19 pandemic: an interrupted time-series analysis.
    Lancet. 2023;402 Suppl 1:S60.
    PubMed: https://www.amedeo.com/p2.php?id=37997104&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997104
60. HAZIR SG, Ryan C, Moore A, Lewis C, et al.
    The role of the multiple Index of deprivation in predicting mental health
    outcomes after the COVID-19 pandemic in adolescents: a cross-sectional study.
    Lancet. 2023;402 Suppl 1:S47.
    PubMed: https://www.amedeo.com/p2.php?id=37997089&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997089
61. DU Z, Wang L, Bai Y, Pei Y, et al.
    Mitigation of respiratory syncytial virus epidemics by RSVpreF vaccines after the
    COVID-19 pandemic in the UK: a modelling study.
    Lancet. 2023;402 Suppl 1:S39.
    PubMed: https://www.amedeo.com/p2.php?id=37997080&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997080
62. ARNOTT J, Troya MI, Joyce M, Khashan A, et al.
    Untangling the association between COVID-19 health literacy, trust in the
    pandemic response, and mental distress, during the COVID-19 pandemic in Ireland:
    a repeated cross-sectional study.
    Lancet. 2023;402 Suppl 1:S23.
    PubMed: https://www.amedeo.com/p2.php?id=37997063&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997063
63. QuickStats: Age-Adjusted Percentage* of Adults Aged >/=18 Years Who Received an
    Influenza Vaccination During the Past 12 Months,(dagger) by Sex and Race and
    Ethnicity( section sign) – National Health Interview Survey, United States, 2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:1313.
    PubMed: https://www.amedeo.com/p2.php?id=38032840&s=flu&pm=2
     
    Share: https://m.amedeo.com/38032840
64. IOANNIDIS JPA, Zonta F, Levitt M.
    Variability in excess deaths across countries with different vulnerability during
    2020-2023.
    Proc Natl Acad Sci U S A. 2023;120:e2309557120.
    PubMed: https://www.amedeo.com/p2.php?id=38019858&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38019858
65. TURNER CA, Khalil H, Murphy-Weinberg V, Hagenauer MH, et al.
    The impact of COVID-19 on a college freshman sample reveals genetic and
    nongenetic forms of susceptibility and resilience to stress.
    Proc Natl Acad Sci U S A. 2023;120:e2305779120.
    PubMed: https://www.amedeo.com/p2.php?id=38011555&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38011555
66. TORCHE F, Nobles J.
    Vaccination, immunity, and the changing impact of COVID-19 on infant health.
    Proc Natl Acad Sci U S A. 2023;120:e2311573120.
    PubMed: https://www.amedeo.com/p2.php?id=38011548&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38011548
67. CHENG CW, Wu CY, Wang SW, Chen JY, et al.
    Low-sugar universal mRNA vaccine against coronavirus variants with deletion of
    glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA).
    Proc Natl Acad Sci U S A. 2023;120:e2314392120.
    PubMed: https://www.amedeo.com/p2.php?id=38011546&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38011546
68. CONDOR CAPCHA JM, Kamiar A, Robleto E, Saad AG, et al.
    Growth hormone-releasing hormone receptor antagonist MIA-602 attenuates
    cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice.
    Proc Natl Acad Sci U S A. 2023;120:e2308342120.
    PubMed: https://www.amedeo.com/p2.php?id=37983492&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37983492
69. PAYNE AB, Ciesla AA, Rowley EAK, Weber ZA, et al.
    Impact of accounting for correlation between COVID-19 and influenza vaccination
    in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
    Vaccine. 2023 Nov 23:S0264-410X(23)01337-3. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=38000964&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38000964
70. HERZIG VAN WEES S, Stalgren M, Viberg N, Puranen B, et al.
    “Who is Anders Tegnell?” Unanswered questions hamper COVID-19 vaccine uptake: A
    qualitative study among ethnic minorities in Sweden.
    Vaccine. 2023 Nov 10:S0264-410X(23)01328-2. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37953100&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37953100
71. BRUXVOORT KJ, Sy LS, Hong V, Lewin B, et al.
    Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US
    health care system.
    Vaccine. 2023 Nov 10:S0264-410X(23)01324-5. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37953096&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37953096
72. DUDLEY MZ, Schwartz B, Brewer J, Kan L, et al.
    COVID-19 vaccination attitudes, values, intentions: US parents for their
    children, September 2021.
    Vaccine. 2023 Nov 9:S0264-410X(23)01295-1. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37951793&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37951793
73. ANDERSON EC, Blair PS, Finn A, Ingram J, et al.
    Maternal vaccination provision in NHS maternity trusts across England.
    Vaccine. 2023 Nov 9:S0264-410X(23)01284-7. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37951792&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37951792
74. YANG C, Zheng Z, Zheng P, Chen J, et al.
    Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for
    both pregnant women and neonates.
    Vaccine. 2023 Nov 8:S0264-410X(23)01322-1. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37949755&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37949755
75. INOUE Y, Li Y, Yamamoto S, Fukunaga A, et al.
    The association between antipyretic analgesics use and SARS-CoV-2 antibody titers
    following the second dose of the BNT162b2 mRNA vaccine: An observational study.
    Vaccine. 2023 Nov 7:S0264-410X(23)01220-3. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37945490&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37945490
76. HANSEN LG, Larsen LE, Rasmussen TB, Miar Y, et al.
    Investigation of the SARS-CoV-2 post-vaccination antibody response in Canadian
    farmed mink.
    Vaccine. 2023 Nov 4:S0264-410X(23)01288-4. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37932134&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37932134
77. JONES G, Perry M, Bailey R, Arumugam S, et al.
    Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A
    multivariable linked data population analysis.
    Vaccine. 2023 Nov 4:S0264-410X(23)01279-3. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37932133&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37932133
78. HONDA-OKUBO Y, Bowen R, Barker M, Bielefeldt-Ohmann H, et al.
    Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike
    protein vaccine protects hamsters against heterologous infection with Beta or
    Delta variants.
    Vaccine. 2023 Oct 18:S0264-410X(23)01190-8. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37863669&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37863669
79. PREVOT AA, Wisner EL.
    Influenza Vaccine Effectiveness Among Children: 2011-2020.
    Pediatrics. 2023;152.
    PubMed: https://www.amedeo.com/p2.php?id=38038578&s=flu&pm=2
     
    Share: https://m.amedeo.com/38038578

https://etidioh.wordpress.com/2023/12/02/influenza-and-covid19-research-references-by-amedeo-december-2nd-2023/

#avianInfluenza #ayurvedic #coronavirus #COVID19 #fluSeason #fluSeason #health #influenza #research #seasonalInfluenza #texturedCable

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.06.622244v1

Abstract
The current situation with H5N1 highly pathogenic avian influenza virus (HPAI) is causing a worldwide concern due to multiple outbreaks in wild birds, poultry, and mammals. Moreover, multiple zoonotic infections in humans have been reported. Importantly, HPAI H5N1 viruses with genetic markers of adaptation to mammals have been detected. Together with HPAI H5N1, avian influenza viruses H7N9 (high and low pathogenic) stand out due to their high mortality rates in humans. This raises the question of how prepared we are serologically and whether seasonal vaccines are capable of inducing protective immunity against these influenza subtypes. An observational study was conducted in which sera from people born between years 1925-1967, 1968-1977, and 1978-1997 were collected before or after 28 days or 6 months post-vaccination with an inactivated seasonal influenza vaccine. Then, haemagglutination inhibition, viral neutralization, and immunoassays were performed to assess the basal protective immunity of the population as well as the ability of seasonal influenza vaccines to induce protective responses. Our results indicate that subtype-specific serological protection against H5N1 and H7N9 in the representative Spanish population evaluated was limited or nonexistent. However, seasonal vaccination was able to increase the antibody titers to protective levels in a moderate percentage of people, probably due to cross-reactive responses. These findings demonstrate the importance of vaccination and suggest that seasonal influenza vaccines could be used as a first line of defense against an eventual pandemic caused by avian influenza viruses, to be followed immediately by the use of more specific pandemic vaccines.

____

https://etidioh.wordpress.com/2024/11/09/are-we-serologically-prepared-against-an-avian-influenza-pandemic-and-could-seasonal-flu-vaccines-help-us/

#aH5n1 #aH7n9 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #h5n1 #health #human #news #pandemicInfluenza #research #seasonalInfluenza #serology #vaccination

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.06.622244v1

Abstract
The current situation with H5N1 highly pathogenic avian influenza virus (HPAI) is causing a worldwide concern due to multiple outbreaks in wild birds, poultry, and mammals. Moreover, multiple zoonotic infections in humans have been reported. Importantly, HPAI H5N1 viruses with genetic markers of adaptation to mammals have been detected. Together with HPAI H5N1, avian influenza viruses H7N9 (high and low pathogenic) stand out due to their high mortality rates in humans. This raises the question of how prepared we are serologically and whether seasonal vaccines are capable of inducing protective immunity against these influenza subtypes. An observational study was conducted in which sera from people born between years 1925-1967, 1968-1977, and 1978-1997 were collected before or after 28 days or 6 months post-vaccination with an inactivated seasonal influenza vaccine. Then, haemagglutination inhibition, viral neutralization, and immunoassays were performed to assess the basal protective immunity of the population as well as the ability of seasonal influenza vaccines to induce protective responses. Our results indicate that subtype-specific serological protection against H5N1 and H7N9 in the representative Spanish population evaluated was limited or nonexistent. However, seasonal vaccination was able to increase the antibody titers to protective levels in a moderate percentage of people, probably due to cross-reactive responses. These findings demonstrate the importance of vaccination and suggest that seasonal influenza vaccines could be used as a first line of defense against an eventual pandemic caused by avian influenza viruses, to be followed immediately by the use of more specific pandemic vaccines.

____

https://etidioh.wordpress.com/2024/11/09/are-we-serologically-prepared-against-an-avian-influenza-pandemic-and-could-seasonal-flu-vaccines-help-us/

#aH5n1 #aH7n9 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #h5n1 #health #human #news #pandemicInfluenza #research #seasonalInfluenza #serology #vaccination

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.06.622244v1

Abstract
The current situation with H5N1 highly pathogenic avian influenza virus (HPAI) is causing a worldwide concern due to multiple outbreaks in wild birds, poultry, and mammals. Moreover, multiple zoonotic infections in humans have been reported. Importantly, HPAI H5N1 viruses with genetic markers of adaptation to mammals have been detected. Together with HPAI H5N1, avian influenza viruses H7N9 (high and low pathogenic) stand out due to their high mortality rates in humans. This raises the question of how prepared we are serologically and whether seasonal vaccines are capable of inducing protective immunity against these influenza subtypes. An observational study was conducted in which sera from people born between years 1925-1967, 1968-1977, and 1978-1997 were collected before or after 28 days or 6 months post-vaccination with an inactivated seasonal influenza vaccine. Then, haemagglutination inhibition, viral neutralization, and immunoassays were performed to assess the basal protective immunity of the population as well as the ability of seasonal influenza vaccines to induce protective responses. Our results indicate that subtype-specific serological protection against H5N1 and H7N9 in the representative Spanish population evaluated was limited or nonexistent. However, seasonal vaccination was able to increase the antibody titers to protective levels in a moderate percentage of people, probably due to cross-reactive responses. These findings demonstrate the importance of vaccination and suggest that seasonal influenza vaccines could be used as a first line of defense against an eventual pandemic caused by avian influenza viruses, to be followed immediately by the use of more specific pandemic vaccines.

____

https://etidioh.wordpress.com/2024/11/09/are-we-serologically-prepared-against-an-avian-influenza-pandemic-and-could-seasonal-flu-vaccines-help-us/

#aH5n1 #aH7n9 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #h5n1 #health #human #news #pandemicInfluenza #research #seasonalInfluenza #serology #vaccination

#Vietnam, Binh Dinh urgently reacts after recording 4 #deaths due to #influenza A #H1N1pdm09

Source: TuoiTre, https://tuoitre.vn/binh-dinh-chi-dao-khan-sau-khi-ghi-nhan-4-ca-tu-vong-do-cum-a-h1pdm-20241125145635432.htm

{Excerpt, original text in Vietnamese}

On November 25, Mr. Nguyen Van Trung – Deputy Director of the Department of Health of Binh Dinh province – said that the province had 9 cases of A/H1pdm flu, of which 4 died. According to Mr. Trung, the latest recorded data as of November 20, of the 22 cases put under surveillance due to severe pneumonia suspected to be caused by a virus infection, 9 cases tested positive for influenza A/H1pdm scattered in Quy Nhon City (4 cases), Phu My District (3 cases), An Nhon Town (1 case) and Vinh Thanh District (1 case).

(…)

____

#h1n1pdm09 #SEASONALINFLUENZA #vietnam

From consensus to action: sharing best practice for childhood flu vaccination [Promoted content] https://www.euractiv.com/section/health-consumers/opinion/from-consensus-to-action-sharing-best-practice-for-childhood-flu-vaccination/?utm_source=dlvr.it&utm_medium=mastodon #childhoodvaccination #EUhealth #immunisation #seasonalinfluenza

1. ZABRODSKAYA YA, Gavrilova NV, Elpaeva EA, Lozhkov AA, et al
   mRNA encoding antibodies against hemagglutinin and nucleoprotein prevents influenza virus infection in vitro.
   Biochem Biophys Res Commun. 2024;738:150945.
   PubMed         Abstract available

   Biochemistry

2. YUE Z, Wu J, Teng D, Wang Z, et al
   Activation of the Influenza B M2 Proton Channel (BM2).
   Biochemistry. 2024 Nov 3. doi: 10.1021/acs.biochem.4c00607.
   PubMed         Abstract available
3. MCMINN SE, Miller DV, Yur D, Stone K, et al
   High-Throughput Algorithmic Optimization of In Vitro Transcription for SARS-CoV-2 mRNA Vaccine Production.
   Biochemistry. 2024;63:2793-2802.
   PubMed         Abstract available

   J Gen Virol

4. BOE CA, Fiskebeck EMLZ, Reiten MR, Akerstedt J, et al
   Emergence of highly pathogenic avian influenza viruses H5N1 and H5N5 in white-tailed eagles, 2021-2023.
   J Gen Virol. 2024;105:002035.
   PubMed         Abstract available

   J Immunol

5. DICK JK, Sangala JA, Krishna VD, Khaimraj A, et al
   NK Cell and Monocyte Dysfunction in Multisystem Inflammatory Syndrome in Children.
   J Immunol. 2024;213:1452-1466.
   PubMed         Abstract available

   J Infect

6. WANG H, Zhou Y, Chu L, Chen K, et al
   Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
   J Infect. 2024;89:106333.
   PubMed        
7. HO A, McInnes N, Blunsum A, Quinn J, et al
   Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
   J Infect. 2024;89:106338.
   PubMed         Abstract available

   J Infect Dis

8. YEGOROV S, Brewer A, Cyr L, Ward BJ, et al
   Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children.
   J Infect Dis. 2024 Nov 6:jiae489. doi: 10.1093.
   PubMed         Abstract available
9. ALARCON PC, Ulanowicz CJ, Damen MSMA, Eom J, et al
   Obesity uncovers presence of inflammatory lung macrophage subsets with adipose tissue transcriptomic signature in influenza virus infection.
   J Infect Dis. 2024 Nov 4:jiae535. doi: 10.1093.
   PubMed         Abstract available

   J Neurosurg Pediatr

10. STUART MJ, Harbison AM, Ma N, Campbell RAJ, et al
    Ten-year statewide cross-sectional review of pediatric sinogenic intracranial abscess and empyema in Queensland, Australia: microbial profile before and after COVID-19.
    J Neurosurg Pediatr. 2024;34:489-494.
    PubMed         Abstract available
11. FLANDERS TM, Kumar NK, Zhao C, Joerger TA, et al
    Intracranial complications secondary to acute bacterial sinusitis requiring neurosurgical intervention before and after the onset of the COVID-19 pandemic.
    J Neurosurg Pediatr. 2024;34:479-488.
    PubMed         Abstract available

    J Virol

12. SUN X, Belser JA, Pulit-Penaloza JA, Brock N, et al
    Dissecting the role of the HA1-226 leucine residue in the fitness and airborne transmission of an A(H9N2) avian influenza virus.
    J Virol. 2024 Nov 4:e0092824. doi: 10.1128/jvi.00928.
    PubMed         Abstract available

    JAMA

13. AGARWAL SD, Cook BL, Liebman JB
    Effect of Cash Benefits on Health Care Utilization and Health: A Randomized Study.
    JAMA. 2024 Jul 22:e2413004. doi: 10.1001/jama.2024.13004.
    PubMed         Abstract available

    Pediatrics

14. WILKINS D, Wahlby Hamren U, Chang Y, Clegg LE, et al
    RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.
    Pediatrics. 2024;154:e2024067174.
    PubMed         Abstract available

    PLoS One

15. LI X
    Where are the cruise ships? mobility and immobility of cruises under COVID-19.
    PLoS One. 2024;19:e0303216.
    PubMed         Abstract available
16. AYAZ H, Celik MH, Koytak HZ, Yanik IE, et al
    Exploring vaccine hesitancy in digital public discourse: From tribal polarization to socio-economic disparities.
    PLoS One. 2024;19:e0308122.
    PubMed         Abstract available
17. GAGNON C, Vincent T, Bherer L, Gayda M, et al
    Oxygen supplementation and cognitive function in long-COVID.
    PLoS One. 2024;19:e0312735.
    PubMed         Abstract available
18. KONDURU L, Dahia SS, Kothari-Speakman G
    Registered report: The effectiveness of a Bhagavad Gita intervention to reduce psychological distress in homeless people-A randomised controlled trial.
    PLoS One. 2024;19:e0310795.
    PubMed         Abstract available
19. PALACIOS AM, Keko M, Rochani H, Nazaruk D, et al
    A quasi-experimental study assessing the effectiveness of a community-based egg intervention in the nutritional and health status of young children from rural Honduras.
    PLoS One. 2024;19:e0312825.
    PubMed         Abstract available
20. NANTEZA MB, Nanyonjo G, Kyakuwa N, Nakanjako F, et al
    COVID-19 vaccine uptake and associated factors among individuals living in a peri-urban area in Uganda: A cross-sectional study.
    PLoS One. 2024;19:e0312377.
    PubMed         Abstract available
21. MASCLE O, Dupuis C, Brailova M, Bonnet B, et al
    Clustering based on renal and inflammatory admission parameters in critically ill patients admitted to the ICU.
    PLoS One. 2024;19:e0307938.
    PubMed         Abstract available
22. WANG M, Chi S, Wang X, Wang T, et al
    Effects of Tai Chi on anxiety and theta oscillation power in college students during the COVID-19 pandemic: A randomized controlled trial.
    PLoS One. 2024;19:e0312804.
    PubMed         Abstract available
23. AL EID NA, Arnout BA, Al-Qahtani TA, Farhan ND, et al
    Psychological flow and mental immunity as predictors of job performance for mental health care practitioners during COVID-19.
    PLoS One. 2024;19:e0311909.
    PubMed         Abstract available
24. SHABUZ ZR, Bachmann M, Cullum R, Burke A, et al
    Changes in urgent and emergency care activity associated with COVID-19 lockdowns in a sub-region in the East of England: Interrupted times series analyses.
    PLoS One. 2024;19:e0311901.
    PubMed         Abstract available
25. KUDDUS MA, Mohiuddin M, Paul AK, Rahman A, et al
    Insights from qualitative and bifurcation analysis of COVID-19 vaccination model in Bangladesh.
    PLoS One. 2024;19:e0312780.
    PubMed         Abstract available
26. ANBARCI N, Ismail MS
    AI-powered mechanisms as judges: Breaking ties in chess.
    PLoS One. 2024;19:e0305905.
    PubMed         Abstract available
27. KLEGERMAN ME, Peng T, Seferovich I, Rahbar MH, et al
    Absolute concentration estimation of COVID-19 convalescent and post-vaccination IgG antibodies.
    PLoS One. 2024;19:e0311777.
    PubMed         Abstract available

    Vaccine

28. KASAMATSU A, Yahata Y, Fukushima W, Sakamoto H, et al
    Estimating influenza vaccine effectiveness among older adults using an integrated administrative database and the implications of potential bias: A population-based cohort study in Japan.
    Vaccine. 2024;42:126488.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/10/influenza-and-other-respiratory-viruses-research-references-by-amedeo-nov-10-24/

#avianInfluenza #COVID19 #exercise #health #influenzaA #mentalHealth #news #pandemicInfluenza #research #seasonalInfluenza #vaccines

1. WU YJ, Feng WW, Wu ZL, Zhang YY, et al
   Prim-O-glucosylcimifugin alleviates influenza virus-induced pneumonia in mice by inhibiting the TGF-beta1/PI3KCD/MSK2/RELA signalling pathway.
   Arch Virol. 2024;169:232.
   PubMed         Abstract available

   Biochem Soc Trans

2. PELLMAN J, Goldstein A, Slabicki M
   Human E3 ubiquitin ligases: accelerators and brakes for SARS-CoV-2 infection.
   Biochem Soc Trans. 2024;52:2009-2021.
   PubMed         Abstract available

   J Gen Virol

3. SAENKHAM-HUNTSINGER P, Drelich AK, Huang P, Peng BH, et al
   BALB/c mice challenged with SARS-CoV-2 B.1.351 beta variant cause pathophysiological and neurological changes within the lungs and brains.
   J Gen Virol. 2024;105:002039.
   PubMed         Abstract available

   MMWR Morb Mortal Wkly Rep

4. SUN J, Zhang Y, Zhou S, Song Y, et al
   Laboratory-Confirmed Influenza Hospitalizations During Pregnancy or the Early Postpartum Period – Suzhou City, Jiangsu Province, China, 2018-2023.
   MMWR Morb Mortal Wkly Rep. 2024;73:958-964.
   PubMed         Abstract available
5. JONES CE, Danovaro-Holliday MC, Mwinnyaa G, Gacic-Dobo M, et al
   Routine Vaccination Coverage – Worldwide, 2023.
   MMWR Morb Mortal Wkly Rep. 2024;73:978-984.
   PubMed         Abstract available
6. BELL J, Meng L, Barbre K, Wong E, et al
   Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel – National Healthcare Safety Network, United States, 2023-24 Respiratory Virus Season.
   MMWR Morb Mortal Wkly Rep. 2024;73:966-972.
   PubMed         Abstract available

   Pediatrics

7. DYKSTRA HK, Pilkey D, Tautges J, Schnitzer PG, et al
   Characteristics of Children Ages 1-17 Who Died of COVID-19 in 2020-2022 in the United States.
   Pediatrics. 2024;154.
   PubMed         Abstract available

   PLoS Comput Biol

8. ANDRONICO A, Paireau J, Cauchemez S
   Integrating information from historical data into mechanistic models for influenza forecasting.
   PLoS Comput Biol. 2024;20:e1012523.
   PubMed         Abstract available

   PLoS One

9. PANDE S, Shamu S, Abdelhamed A, Munyao Kingoo J, et al
   COVID-19 and Female Genital Mutilation/Cutting and child marriage: An online multi-country cross sectional survey.
   PLoS One. 2024;19:e0304671.
   PubMed         Abstract available
10. IDEGUCHI S, Miyagi K, Kami W, Tasato D, et al
    Clinical features of and severity risk factors for COVID-19 in adults during the predominance of SARS-CoV-2 XBB variants in Okinawa, Japan.
    PLoS One. 2024;19:e0309808.
    PubMed         Abstract available
11. TANIGUCHI I
    The SARS-CoV-2 ORF6 protein inhibits nuclear export of mRNA and spliceosomal U snRNA.
    PLoS One. 2024;19:e0312098.
    PubMed         Abstract available
12. IMAI M, Kawakami F, Uematsu T, Matsumoto T, et al
    SARS-CoV-2 propagation to the TPH2-positive neurons in the ventral tegmental area induces cell death via GSK3beta-dependent accumulation of phosphorylated tau.
    PLoS One. 2024;19:e0312834.
    PubMed         Abstract available
13. LIU X, Luvsandagva B, Wang D, Zhu S, et al
    Impact of preexisting digestive problems on the gastrointestinal symptoms of patients with omicron variant of SARS-CoV-2 infection.
    PLoS One. 2024;19:e0312545.
    PubMed         Abstract available
14. ABERA A, Fenta EH, Woldehanna BT, Wolde FB, et al
    Impact of COVID-19 on essential healthcare services in Addis Ababa, Ethiopia: Implications for future pandemics.
    PLoS One. 2024;19:e0308861.
    PubMed         Abstract available
15. DUESTERWALD L, Nguyen M, Christensen P, Long SW, et al
    Using intrahost single nucleotide variant data to predict SARS-CoV-2 detection cycle threshold values.
    PLoS One. 2024;19:e0312686.
    PubMed         Abstract available
16. MOATASIM Y, Aboulhoda BE, Gomaa M, El Taweel A, et al
    Genetic and pathogenic potential of highly pathogenic avian influenza H5N8 viruses from live bird markets in Egypt in avian and mammalian models.
    PLoS One. 2024;19:e0312134.
    PubMed         Abstract available
17. YAMAGUCHI N, Fukumoto T, Imagita H
    Relationship between physical activity and neighborhood environment in preschool children during COVID-19.-A cross-sectional study using 24-hour activity records.
    PLoS One. 2024;19:e0304848.
    PubMed         Abstract available
18. SORNLORM K, U ES, Laohasiriwong W, Thi WM, et al
    Exploring demographic, healthcare, and socio-economic factors as predictors of COVID-19 incidence rate: A spatial regression analysis.
    PLoS One. 2024;19:e0312717.
    PubMed         Abstract available
19. ZANIB SA, Zubair T, Ramzan S, Riaz MB, et al
    A conformable fractional finite difference method for modified mathematical modeling of SAR-CoV-2 (COVID-19) disease.
    PLoS One. 2024;19:e0307707.
    PubMed         Abstract available
20. NAIDU SB, Saigal A, Shah AJ, Ogbonnaya C, et al
    Associations between ethnicity and persistent physical and mental health symptoms experienced as part of ongoing symptomatic COVID-19.
    PLoS One. 2024;19:e0312719.
    PubMed         Abstract available
21. DEZECACHE G, Chevalere J, Martinelli N, Gil S, et al
    Affiliation in times of pandemics: Determinants and consequences.
    PLoS One. 2024;19:e0306310.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

22. GARAIZAR A, Diaz-Oviedo D, Zablowsky N, Rissanen S, et al
    Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments.
    Proc Natl Acad Sci U S A. 2024;121:e2404555121.
    PubMed         Abstract available
23. ZHANG H, Wang Z, Nguyen HTT, Cornejo Pontelli M, et al
    Facilitating and restraining virus infection using cell-attachable soluble viral receptors.
    Proc Natl Acad Sci U S A. 2024;121:e2414583121.
    PubMed         Abstract available

    Vaccine

24. R MUGALI R, Ip H, Zikusooka A, Vong L, et al
    Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.
    Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
25. MANANDHAR P, Katz J, Lama TP, Khatry SK, et al
    COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
    Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
26. D’SOUZA S, Ghatole B, Raghuram H, Sukhija S, et al
    Understanding structural inequities in Covid-19 vaccine access and uptake among disability, transgender and gender-diverse communities in India.
    Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174.
    PubMed         Abstract available
27. AL-DAHIR S, Hassan TAL, Moss W, Khalil A, et al
    The impact of coronavirus pandemic shutdowns on immunization completion in Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering healthcare system.
    Vaccine. 2024 Sep 21:126383. doi: 10.1016/j.vaccine.2024.126383.
    PubMed         Abstract available
28. MWAMBA G, Gibson EM, Toko C, Tunda C, et al
    Effective integration of COVID-19 vaccination with routine immunization: A case study from Kinshasa, DRC.
    Vaccine. 2024 Oct 4:126392. doi: 10.1016/j.vaccine.2024.126392.
    PubMed         Abstract available
29. LEIS AM, Wagner A, Flannery B, Chung JR, et al
    Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses.
    Vaccine. 2024;42:126493.
    PubMed         Abstract available
30. MACINTYRE CR, Akhtar Z, Moa A
    Corrigendum to “Influenza B/Yamagata – extinct, eradicated or hiding? [Vaccine 42/26 (2024) 126450]”.
    Vaccine. 2024 Oct 29:126486. doi: 10.1016/j.vaccine.2024.126486.
    PubMed        
31. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Akache B, et al
    SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.
    Vaccine. 2024;42:126463.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/03/influenza-and-other-respiratory-viruses-research-references-by-amedeo-nov-3-24/

#avianInfluenza #covid #COVID19 #health #influenzaA #news #pandemicInfluenza #research #seasonalInfluenza #vaccine

13th #Meeting of #WHO Expert Working #Group on #Surveillance of #Antiviral Susceptibility of #Influenza Viruses for WHO #GISRS

Source: World Health Organization, Weekly Epidemiological Record: https://www.who.int/publications/journals/weekly-epidemiological-record

{Excerpt, edited}

Executive summary

The WHO Expert Working Group on Surveillance of Influenza Antiviral Susceptibility (AVWG) supports the WHO Global Influenza Surveillance and Response System (GISRS) by providing practical guidance for monitoring the antiviral susceptibility of seasonal and emerging influenza viruses The 13th WHO AVWG meeting was held in hybrid format (faceto-face and virtually) on 13–14 June 2024 in Lyon, France.

Update on susceptibility of seasonal influenza viruses to approved antiviral agents

Between May 2023 and May 2024, WHO collaborating centres (CCs) and participating national influenza centres (NICs) reported that seasonal influenza activity in various regions had resumed to levels before the coronavirus disease 2019 (COVID-19) pandemic. Co-circulation of A(H1N1)pdm09, A(H3N2) and influenza B/Victoria lineage viruses was detected in most regions. Overall, influenza A and B viruses with reduced inhibition (RI) or highly reduced inhibition (HRI) to neuraminidase (NA) inhibitors (NAIs) were detected at low frequency. The most frequently identified substitution associated with RI or HRI by NAIs was NA-H275Y in A(H1N1)pdm09 viruses, which was detected at <2%. Double amino acid substitutions (NA-I223V+ NA-S247N) in A(H1N1)pdm09 viruses (referred to as dual mutant viruses) that resulted in RI by oseltamivir were first detected in May 2023 and spread rapidly to several regions of the world.{1,2} Influenza A and B viruses with amino acid substitutions in the polymerase acidic (PA) protein associated with reduced susceptibility to endonuclease inhibitor (baloxavir) were detected at low frequency. The PA-I38X (including I38T, I38N, I38M and I38V) amino acid substitution being the most frequently reported, but the overall detection frequency has remained low (<2%).

Update on susceptibility of zoonotic and animal influenza viruses to approved antiviral agents

From May 2023 to May 2024, clade 2.3.4.4b A(H5N1) highly pathogenic avian influenza (HPAI) viruses continued to be detected in various regions of the world. Since early 2024, there has been an outbreak of clade 2.3.4.4b A(H5N1) genotype B3.13 viruses in dairy cattle in several states in the United States of America, resulting in sporadic zoonotic infections in humans. In addition, human infection with clade 2.3.2.1c A(H5N1) HPAI has been reported in Cambodia and Viet Nam. WHO CCs, participating NICs and WHO H5 reference laboratories reported antiviral susceptibility testing of A(H5N1) HPAI, low pathogenic avian influenza (LPAI) of various subtypes and swine influenza viruses. Of the clade 2.3.4.4b A(H5N1) HPAI viruses, the NA-T438I substitution, which confers RI by zanamivir and peramivir, was detected at <2% frequency. NA-H275Y, NA-N295S and NA-N295S+NA-T438N associated with RI or HRI by NAIs were also detected among A(H5N1) viruses. NA-T438I has been detected in A(H5N1) viruses isolated from dairy cattle. PA-I38T, PA-A37T and PA-I38M, associated with reduced susceptibility to baloxavir, were detected in A(H5N1) viruses. Most A(H5N1) HPAI viruses remain susceptible to M2 ion channel blockers. Among LPAI, NA-H274Y with HRI by oseltamivir was detected in one A(H8N4) isolate. PA-E199G with reduced susceptibility to baloxavir was detected in one A(H9N2) virus. Overall, animal or zoonotic influenza viruses with reduced susceptibility to NAIs or baloxavir were detected at very low frequencies.

Update of protocols and guidance for GISRS laboratories

Genotypic and/or phenotypic assays can be used to monitor the susceptibility of influenza viruses to NAIs and baloxavir. The WHO AVWG routinely reviews and updates information on NA{3,4} and PA{5} amino acid substitutions associated with reduced susceptibility to NAIs and baloxavir, respectively. Reference virus panels that can be used for NAI and baloxavir susceptibility testing are available for GISRS laboratories at the International Reagent Resource.{6} The WHO AVWG will develop an algorithm for NICs to decide on testing strategies (genotypic versus phenotypic) and methods according to their capacity. Guidance on phenotypic assays for NAI susceptibility testing is provided in a WHO guidance document to NICs, which was updated in 2018.{7} A new phenotypic assay has been developed for testing susceptibility to baloxavir.{8} The protocol will be posted on the WHO website. The WHO-AVWG will also update the WHO guidance document to NICs to include the new phenotypic assay for baloxavir susceptibility testing. In addition, the WHO AVWG will work with the Global Initiative on Sharing All Influenza Data{9} to facilitate identification of NA and PA substitutions in submitted sequences.

Review of external quality assessment programme (EQAP) panels

EQAP was initiated in 2007, and the antiviral panel was introduced in 2013 (panel 12) as an optional component of EQAP to evaluate the ability of NICs to identify influenza viruses with reduced susceptibility to NAIs. Genotypic testing for baloxavir susceptibility was introduced in 2020 (panel 19) for educational purpose (i.e. not scored). Results for the 2023 Global EQAP panel were reported at the 13th WHO AVWG meeting. A total of 178 laboratories participated in the 2023 EQAP; 46 (25.8%) participated in NAI susceptibility testing and 16 (9.0%) in baloxavir susceptibility testing. The results from the Global EQAP antiviral panel are used by members of the WHO AVWG to assess the training requirements of NICs.

Way forward

Two reports, on global antiviral surveillance in 2020-2023 and in 2023–2024, are being prepared for publication. The next WHO AVWG meeting is scheduled for June 2025.

___

{1} Leung RC et al. Global emergence of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses with I223V and S247N mutations: implications for antiviral resistance monitoring. Lancet Microbe. 2024;5(7):627–8. doi:10.1016/S26665247(24)00037-5.

{2} Patel MC et al. Multicountry spread of influenza A(H1N1)pdm09 viruses with reduced oseltamivir inhibition, May 2023-February 2024. Emerg Infect Dis. 2024;30(7):1410–5. doi:10.3201/eid3007.240480.

{3} Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs). Geneva: World Health Organization; 2023 (https://www.who.int/publications/m/item/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais).

{4} Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs) among avian influenza viruses of Group 1 and Group 2 NAs. Geneva: World Health Organization; 2024 (https://www. who.int/publications/m/item/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais)among-avian-influenza-viruses-of-group-1-and-group-2-nas).

{5} Summary of polymerase acidic (PA) protein amino acid substitutions analysed for their effects on baloxavir susceptibility. Geneva: World Health Organization; 2024 (https://www.who.int/publications/m/item/summary-of-polymerase-acidic-(pa)-protein-amino-acid-substitutions-analysed-for-their-effects-on-baloxavirsusceptibility).

{6} See https://www.internationalreagentresource.org.

{7} Practical guidance for national influenza centres establishing or implementing neuraminidase inhibitor susceptibility surveillance. Geneva: World Health Organization; 2024 (https://www.who.int/publications/i/item/practical-guidance-for-national-inf luenza-centres-establishing-or-implementing-neuraminidase-inhibitor-susceptibility-surveillance).

{8} Baloxavir susceptibility assessment using influenza replication inhibition neuraminidase-based assay (IRINA). Atlanta (GA): Centers for Disease Control and Prevention; 2023 (https://cdn.who.int/media/docs/default-source/influenza/avwg/ cdc-phenotypic-lp-492rev01d—baloxavir-susceptibility-assessment-using-irina. pdf?sfvrsn=f24254ac_3).

{9} See https://gisaid.org.

_____

#aH3n2 #aH5n1 #aH9n2 #amantadine #antivirals #AVIANINFLUENZA #baloxavir #birdFlu #drugsResistance #h1n1pdm09 #h5n1 #health #influenza #oseltamivir #science #SEASONALINFLUENZA #updates #WHO #zanamivir

13th #Meeting of #WHO Expert Working #Group on #Surveillance of #Antiviral Susceptibility of #Influenza Viruses for WHO #GISRS

Source: World Health Organization, Weekly Epidemiological Record: https://www.who.int/publications/journals/weekly-epidemiological-record

{Excerpt, edited}

Executive summary

The WHO Expert Working Group on Surveillance of Influenza Antiviral Susceptibility (AVWG) supports the WHO Global Influenza Surveillance and Response System (GISRS) by providing practical guidance for monitoring the antiviral susceptibility of seasonal and emerging influenza viruses The 13th WHO AVWG meeting was held in hybrid format (faceto-face and virtually) on 13–14 June 2024 in Lyon, France.

Update on susceptibility of seasonal influenza viruses to approved antiviral agents

Between May 2023 and May 2024, WHO collaborating centres (CCs) and participating national influenza centres (NICs) reported that seasonal influenza activity in various regions had resumed to levels before the coronavirus disease 2019 (COVID-19) pandemic. Co-circulation of A(H1N1)pdm09, A(H3N2) and influenza B/Victoria lineage viruses was detected in most regions. Overall, influenza A and B viruses with reduced inhibition (RI) or highly reduced inhibition (HRI) to neuraminidase (NA) inhibitors (NAIs) were detected at low frequency. The most frequently identified substitution associated with RI or HRI by NAIs was NA-H275Y in A(H1N1)pdm09 viruses, which was detected at <2%. Double amino acid substitutions (NA-I223V+ NA-S247N) in A(H1N1)pdm09 viruses (referred to as dual mutant viruses) that resulted in RI by oseltamivir were first detected in May 2023 and spread rapidly to several regions of the world.{1,2} Influenza A and B viruses with amino acid substitutions in the polymerase acidic (PA) protein associated with reduced susceptibility to endonuclease inhibitor (baloxavir) were detected at low frequency. The PA-I38X (including I38T, I38N, I38M and I38V) amino acid substitution being the most frequently reported, but the overall detection frequency has remained low (<2%).

Update on susceptibility of zoonotic and animal influenza viruses to approved antiviral agents

From May 2023 to May 2024, clade 2.3.4.4b A(H5N1) highly pathogenic avian influenza (HPAI) viruses continued to be detected in various regions of the world. Since early 2024, there has been an outbreak of clade 2.3.4.4b A(H5N1) genotype B3.13 viruses in dairy cattle in several states in the United States of America, resulting in sporadic zoonotic infections in humans. In addition, human infection with clade 2.3.2.1c A(H5N1) HPAI has been reported in Cambodia and Viet Nam. WHO CCs, participating NICs and WHO H5 reference laboratories reported antiviral susceptibility testing of A(H5N1) HPAI, low pathogenic avian influenza (LPAI) of various subtypes and swine influenza viruses. Of the clade 2.3.4.4b A(H5N1) HPAI viruses, the NA-T438I substitution, which confers RI by zanamivir and peramivir, was detected at <2% frequency. NA-H275Y, NA-N295S and NA-N295S+NA-T438N associated with RI or HRI by NAIs were also detected among A(H5N1) viruses. NA-T438I has been detected in A(H5N1) viruses isolated from dairy cattle. PA-I38T, PA-A37T and PA-I38M, associated with reduced susceptibility to baloxavir, were detected in A(H5N1) viruses. Most A(H5N1) HPAI viruses remain susceptible to M2 ion channel blockers. Among LPAI, NA-H274Y with HRI by oseltamivir was detected in one A(H8N4) isolate. PA-E199G with reduced susceptibility to baloxavir was detected in one A(H9N2) virus. Overall, animal or zoonotic influenza viruses with reduced susceptibility to NAIs or baloxavir were detected at very low frequencies.

Update of protocols and guidance for GISRS laboratories

Genotypic and/or phenotypic assays can be used to monitor the susceptibility of influenza viruses to NAIs and baloxavir. The WHO AVWG routinely reviews and updates information on NA{3,4} and PA{5} amino acid substitutions associated with reduced susceptibility to NAIs and baloxavir, respectively. Reference virus panels that can be used for NAI and baloxavir susceptibility testing are available for GISRS laboratories at the International Reagent Resource.{6} The WHO AVWG will develop an algorithm for NICs to decide on testing strategies (genotypic versus phenotypic) and methods according to their capacity. Guidance on phenotypic assays for NAI susceptibility testing is provided in a WHO guidance document to NICs, which was updated in 2018.{7} A new phenotypic assay has been developed for testing susceptibility to baloxavir.{8} The protocol will be posted on the WHO website. The WHO-AVWG will also update the WHO guidance document to NICs to include the new phenotypic assay for baloxavir susceptibility testing. In addition, the WHO AVWG will work with the Global Initiative on Sharing All Influenza Data{9} to facilitate identification of NA and PA substitutions in submitted sequences.

Review of external quality assessment programme (EQAP) panels

EQAP was initiated in 2007, and the antiviral panel was introduced in 2013 (panel 12) as an optional component of EQAP to evaluate the ability of NICs to identify influenza viruses with reduced susceptibility to NAIs. Genotypic testing for baloxavir susceptibility was introduced in 2020 (panel 19) for educational purpose (i.e. not scored). Results for the 2023 Global EQAP panel were reported at the 13th WHO AVWG meeting. A total of 178 laboratories participated in the 2023 EQAP; 46 (25.8%) participated in NAI susceptibility testing and 16 (9.0%) in baloxavir susceptibility testing. The results from the Global EQAP antiviral panel are used by members of the WHO AVWG to assess the training requirements of NICs.

Way forward

Two reports, on global antiviral surveillance in 2020-2023 and in 2023–2024, are being prepared for publication. The next WHO AVWG meeting is scheduled for June 2025.

___

{1} Leung RC et al. Global emergence of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses with I223V and S247N mutations: implications for antiviral resistance monitoring. Lancet Microbe. 2024;5(7):627–8. doi:10.1016/S26665247(24)00037-5.

{2} Patel MC et al. Multicountry spread of influenza A(H1N1)pdm09 viruses with reduced oseltamivir inhibition, May 2023-February 2024. Emerg Infect Dis. 2024;30(7):1410–5. doi:10.3201/eid3007.240480.

{3} Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs). Geneva: World Health Organization; 2023 (https://www.who.int/publications/m/item/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais).

{4} Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs) among avian influenza viruses of Group 1 and Group 2 NAs. Geneva: World Health Organization; 2024 (https://www. who.int/publications/m/item/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais)among-avian-influenza-viruses-of-group-1-and-group-2-nas).

{5} Summary of polymerase acidic (PA) protein amino acid substitutions analysed for their effects on baloxavir susceptibility. Geneva: World Health Organization; 2024 (https://www.who.int/publications/m/item/summary-of-polymerase-acidic-(pa)-protein-amino-acid-substitutions-analysed-for-their-effects-on-baloxavirsusceptibility).

{6} See https://www.internationalreagentresource.org.

{7} Practical guidance for national influenza centres establishing or implementing neuraminidase inhibitor susceptibility surveillance. Geneva: World Health Organization; 2024 (https://www.who.int/publications/i/item/practical-guidance-for-national-inf luenza-centres-establishing-or-implementing-neuraminidase-inhibitor-susceptibility-surveillance).

{8} Baloxavir susceptibility assessment using influenza replication inhibition neuraminidase-based assay (IRINA). Atlanta (GA): Centers for Disease Control and Prevention; 2023 (https://cdn.who.int/media/docs/default-source/influenza/avwg/ cdc-phenotypic-lp-492rev01d—baloxavir-susceptibility-assessment-using-irina. pdf?sfvrsn=f24254ac_3).

{9} See https://gisaid.org.

_____

#aH3n2 #aH5n1 #aH9n2 #amantadine #antivirals #AVIANINFLUENZA #baloxavir #birdFlu #drugsResistance #h1n1pdm09 #h5n1 #health #influenza #oseltamivir #science #SEASONALINFLUENZA #updates #WHO #zanamivir

13th #Meeting of #WHO Expert Working #Group on #Surveillance of #Antiviral Susceptibility of #Influenza Viruses for WHO #GISRS

Source: World Health Organization, Weekly Epidemiological Record: https://www.who.int/publications/journals/weekly-epidemiological-record

{Excerpt, edited}

Executive summary

The WHO Expert Working Group on Surveillance of Influenza Antiviral Susceptibility (AVWG) supports the WHO Global Influenza Surveillance and Response System (GISRS) by providing practical guidance for monitoring the antiviral susceptibility of seasonal and emerging influenza viruses The 13th WHO AVWG meeting was held in hybrid format (faceto-face and virtually) on 13–14 June 2024 in Lyon, France.

Update on susceptibility of seasonal influenza viruses to approved antiviral agents

Between May 2023 and May 2024, WHO collaborating centres (CCs) and participating national influenza centres (NICs) reported that seasonal influenza activity in various regions had resumed to levels before the coronavirus disease 2019 (COVID-19) pandemic. Co-circulation of A(H1N1)pdm09, A(H3N2) and influenza B/Victoria lineage viruses was detected in most regions. Overall, influenza A and B viruses with reduced inhibition (RI) or highly reduced inhibition (HRI) to neuraminidase (NA) inhibitors (NAIs) were detected at low frequency. The most frequently identified substitution associated with RI or HRI by NAIs was NA-H275Y in A(H1N1)pdm09 viruses, which was detected at <2%. Double amino acid substitutions (NA-I223V+ NA-S247N) in A(H1N1)pdm09 viruses (referred to as dual mutant viruses) that resulted in RI by oseltamivir were first detected in May 2023 and spread rapidly to several regions of the world.{1,2} Influenza A and B viruses with amino acid substitutions in the polymerase acidic (PA) protein associated with reduced susceptibility to endonuclease inhibitor (baloxavir) were detected at low frequency. The PA-I38X (including I38T, I38N, I38M and I38V) amino acid substitution being the most frequently reported, but the overall detection frequency has remained low (<2%).

Update on susceptibility of zoonotic and animal influenza viruses to approved antiviral agents

From May 2023 to May 2024, clade 2.3.4.4b A(H5N1) highly pathogenic avian influenza (HPAI) viruses continued to be detected in various regions of the world. Since early 2024, there has been an outbreak of clade 2.3.4.4b A(H5N1) genotype B3.13 viruses in dairy cattle in several states in the United States of America, resulting in sporadic zoonotic infections in humans. In addition, human infection with clade 2.3.2.1c A(H5N1) HPAI has been reported in Cambodia and Viet Nam. WHO CCs, participating NICs and WHO H5 reference laboratories reported antiviral susceptibility testing of A(H5N1) HPAI, low pathogenic avian influenza (LPAI) of various subtypes and swine influenza viruses. Of the clade 2.3.4.4b A(H5N1) HPAI viruses, the NA-T438I substitution, which confers RI by zanamivir and peramivir, was detected at <2% frequency. NA-H275Y, NA-N295S and NA-N295S+NA-T438N associated with RI or HRI by NAIs were also detected among A(H5N1) viruses. NA-T438I has been detected in A(H5N1) viruses isolated from dairy cattle. PA-I38T, PA-A37T and PA-I38M, associated with reduced susceptibility to baloxavir, were detected in A(H5N1) viruses. Most A(H5N1) HPAI viruses remain susceptible to M2 ion channel blockers. Among LPAI, NA-H274Y with HRI by oseltamivir was detected in one A(H8N4) isolate. PA-E199G with reduced susceptibility to baloxavir was detected in one A(H9N2) virus. Overall, animal or zoonotic influenza viruses with reduced susceptibility to NAIs or baloxavir were detected at very low frequencies.

Update of protocols and guidance for GISRS laboratories

Genotypic and/or phenotypic assays can be used to monitor the susceptibility of influenza viruses to NAIs and baloxavir. The WHO AVWG routinely reviews and updates information on NA{3,4} and PA{5} amino acid substitutions associated with reduced susceptibility to NAIs and baloxavir, respectively. Reference virus panels that can be used for NAI and baloxavir susceptibility testing are available for GISRS laboratories at the International Reagent Resource.{6} The WHO AVWG will develop an algorithm for NICs to decide on testing strategies (genotypic versus phenotypic) and methods according to their capacity. Guidance on phenotypic assays for NAI susceptibility testing is provided in a WHO guidance document to NICs, which was updated in 2018.{7} A new phenotypic assay has been developed for testing susceptibility to baloxavir.{8} The protocol will be posted on the WHO website. The WHO-AVWG will also update the WHO guidance document to NICs to include the new phenotypic assay for baloxavir susceptibility testing. In addition, the WHO AVWG will work with the Global Initiative on Sharing All Influenza Data{9} to facilitate identification of NA and PA substitutions in submitted sequences.

Review of external quality assessment programme (EQAP) panels

EQAP was initiated in 2007, and the antiviral panel was introduced in 2013 (panel 12) as an optional component of EQAP to evaluate the ability of NICs to identify influenza viruses with reduced susceptibility to NAIs. Genotypic testing for baloxavir susceptibility was introduced in 2020 (panel 19) for educational purpose (i.e. not scored). Results for the 2023 Global EQAP panel were reported at the 13th WHO AVWG meeting. A total of 178 laboratories participated in the 2023 EQAP; 46 (25.8%) participated in NAI susceptibility testing and 16 (9.0%) in baloxavir susceptibility testing. The results from the Global EQAP antiviral panel are used by members of the WHO AVWG to assess the training requirements of NICs.

Way forward

Two reports, on global antiviral surveillance in 2020-2023 and in 2023–2024, are being prepared for publication. The next WHO AVWG meeting is scheduled for June 2025.

___

{1} Leung RC et al. Global emergence of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses with I223V and S247N mutations: implications for antiviral resistance monitoring. Lancet Microbe. 2024;5(7):627–8. doi:10.1016/S26665247(24)00037-5.

{2} Patel MC et al. Multicountry spread of influenza A(H1N1)pdm09 viruses with reduced oseltamivir inhibition, May 2023-February 2024. Emerg Infect Dis. 2024;30(7):1410–5. doi:10.3201/eid3007.240480.

{3} Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs). Geneva: World Health Organization; 2023 (https://www.who.int/publications/m/item/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais).

{4} Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs) among avian influenza viruses of Group 1 and Group 2 NAs. Geneva: World Health Organization; 2024 (https://www. who.int/publications/m/item/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais)among-avian-influenza-viruses-of-group-1-and-group-2-nas).

{5} Summary of polymerase acidic (PA) protein amino acid substitutions analysed for their effects on baloxavir susceptibility. Geneva: World Health Organization; 2024 (https://www.who.int/publications/m/item/summary-of-polymerase-acidic-(pa)-protein-amino-acid-substitutions-analysed-for-their-effects-on-baloxavirsusceptibility).

{6} See https://www.internationalreagentresource.org.

{7} Practical guidance for national influenza centres establishing or implementing neuraminidase inhibitor susceptibility surveillance. Geneva: World Health Organization; 2024 (https://www.who.int/publications/i/item/practical-guidance-for-national-inf luenza-centres-establishing-or-implementing-neuraminidase-inhibitor-susceptibility-surveillance).

{8} Baloxavir susceptibility assessment using influenza replication inhibition neuraminidase-based assay (IRINA). Atlanta (GA): Centers for Disease Control and Prevention; 2023 (https://cdn.who.int/media/docs/default-source/influenza/avwg/ cdc-phenotypic-lp-492rev01d—baloxavir-susceptibility-assessment-using-irina. pdf?sfvrsn=f24254ac_3).

{9} See https://gisaid.org.

_____

#aH3n2 #aH5n1 #aH9n2 #amantadine #antivirals #AVIANINFLUENZA #baloxavir #birdFlu #drugsResistance #h1n1pdm09 #h5n1 #health #influenza #oseltamivir #science #SEASONALINFLUENZA #updates #WHO #zanamivir

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Dec. 1 ’24)

1. ISMAIL A, Shadid HR, Huang Y, Hutten CG, et al
   Statin Therapy, Inflammation, and Outcomes in Patients Hospitalized for COVID-19: A Prospective Multicenter Cohort Study.
   Am J Med. 2024;137:1264-1271.
   PubMed         Abstract available
2. KENNEDY BS, Richeson RP, Houde AJ
   Justice-Involved Status and In-Hospital Mortality Among Nonelderly Adults During the COVID-19 Pandemic, 2021.
   Am J Med. 2024;137:1216-1226.
   PubMed         Abstract available

   Antiviral Res

3. AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
   Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
   Antiviral Res. 2024;232:106041.
   PubMed         Abstract available
4. SRIWILAIJAROEN N, Hanamatsu H, Yokota I, Nishikaze T, et al
   Edible bird’s nest: N- and O-glycan analysis and synergistic anti-avian influenza virus activity with neuraminidase inhibitors.
   Antiviral Res. 2024 Nov 20:106040. doi: 10.1016/j.antiviral.2024.106040.
   PubMed         Abstract available

   Biochem Biophys Res Commun

5. ROY A, Paul I, Paul T, Dihidar A, et al
   Exploring B-cell epitope conservation and antigenicity shift in current COVID-19 variants: Analyzing spike-antibody interactions for therapeutic uses.
   Biochem Biophys Res Commun. 2024;739:150948.
   PubMed         Abstract available
6. BEGUM F, Chandra S, Mallik MH, Dey J, et al
   A SARS-CoV-2 peptide antigen purified from bacteria and displayed in a high-density repetitive manner on a virus-like particle could generate anti-SARS-CoV-2 neutralizing antibodies unlike free peptide.
   Biochem Biophys Res Commun. 2024;739:150579.
   PubMed         Abstract available

   BMC Pediatr

7. BAIDYA S, Thapa J, Kadel A, Kharal N, et al
   Maple syrup urine disease diagnosed in a resource-limited setting in an infant in Nepal: a case report.
   BMC Pediatr. 2024;24:770.
   PubMed         Abstract available
8. YE F, Chen J, Gao X, Lin H, et al
   Effect of pandemic-induced PTSD in pregnant women on infant physical growth: a prospective cohort study.
   BMC Pediatr. 2024;24:771.
   PubMed         Abstract available
9. SARGSYAN V, Walea H, Mahat B, Tamale R, et al
   Effect of a playful parenting programme on early childhood development and care outcomes of young children in vulnerable communities: findings from a quasi-experimental study.
   BMC Pediatr. 2024;24:767.
   PubMed         Abstract available
10. BRAY KO, Durbin O, Hartanto S, Khetan M, et al
    Puberty and NeuroDevelopment in adolescents (PANDA): a study protocol.
    BMC Pediatr. 2024;24:768.
    PubMed         Abstract available

    BMJ

11. ZERAATKAR D, Ling M, Kirsh S, Jassal T, et al
    Interventions for the management of long covid (post-covid condition): living systematic review.
    BMJ. 2024;387:e081318.
    PubMed         Abstract available

    Cell

12. XIANG Y, Xu J, McGovern BL, Ranzenigo A, et al
    Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy.
    Cell. 2024;187:6966-6980.
    PubMed         Abstract available

    Eur J Epidemiol

13. MAGNUS MC, Caspersen IH, Wensaas KA, Eide HN, et al
    Covid-19 vaccination and menstrual bleeding disturbances among women of fertile age: a Norwegian registry study.
    Eur J Epidemiol. 2024;39:1127-1138.
    PubMed         Abstract available

    J Infect Dis

14. BIDDLE JE, Nguyen HQ, Talbot HK, Rolfes MA, et al
    Asymptomatic and mildly symptomatic influenza virus infections by season –Case-ascertained household transmission studies, United States, 2017-2023.
    J Infect Dis. 2024 Nov 27:jiae591. doi: 10.1093.
    PubMed         Abstract available

    J Virol

15. SHETTY N, Shephard MJ, Rockey NC, Macenczak H, et al
    Influenza virus infection and aerosol shedding kinetics in a controlled human infection model.
    J Virol. 2024 Nov 26:e0161224. doi: 10.1128/jvi.01612.
    PubMed         Abstract available

    PLoS Med

16. HO FK, Dale C, Mizani MA, Bolton T, et al
    Routine measurement of cardiometabolic disease risk factors in primary care in England before, during, and after the COVID-19 pandemic: A population-based cohort study.
    PLoS Med. 2024;21:e1004485.
    PubMed         Abstract available

    PLoS One

17. KUMWENDA MK, Mukoka M, Reipold-Ivanova E, Mhango O, et al
    Optimising instructional materials for Covid-19 rapid tests for self-sampling and testing: Mapping the optimization process of manufacturer’s instructions for use for self-testing RDTs intended for low-literacy contexts.
    PLoS One. 2024;19:e0314273.
    PubMed         Abstract available
18. JU X
    A social media competitive intelligence framework for brand topic identification and customer engagement prediction.
    PLoS One. 2024;19:e0313191.
    PubMed         Abstract available
19. SITA L, Caserotti M, Zamparini M, Lotto L, et al
    Impact of COVID-19 vaccination on preventive behavior: The importance of confounder adjustment in observational studies.
    PLoS One. 2024;19:e0313117.
    PubMed         Abstract available
20. ANDREASSON I, Persson HC, Bjorkdahl A
    Fatigue and cognitive dysfunction in previously hospitalized patients with COVID-19: A 1-year follow-up.
    PLoS One. 2024;19:e0314131.
    PubMed         Abstract available
21. GAL M, Cooper A, Joseph-Williams N, Doe E, et al
    Knowledge mobilisation of rapid evidence reviews to inform health and social care policy and practice in a public health emergency: Appraisal of the Wales COVID-19 Evidence Centre processes and impact, 2021-23.
    PLoS One. 2024;19:e0314461.
    PubMed         Abstract available
22. JUNGKUNZ S
    Asymmetric polarization by vaccination status identification during the COVID-19 pandemic.
    PLoS One. 2024;19:e0311962.
    PubMed         Abstract available
23. GARNEAU WM, Lankiewicz MJ, Lesko CR, Lauriello AP, et al
    Clinical effects of dexamethasone among patients with sickle cell disease hospitalized with COVID-19: Outcomes from a single academic health system.
    PLoS One. 2024;19:e0313289.
    PubMed         Abstract available
24. REZAPOUR M, Walker SJ, Ornelles DA, Niazi MKK, et al
    Exploring the host response in infected lung organoids using NanoString technology: A statistical analysis of gene expression data.
    PLoS One. 2024;19:e0308849.
    PubMed         Abstract available
25. AKHTER R, Stukel TA, Chung H, Bell CM, et al
    Comparison of physician-delivered models of virtual and home-based in-person care for adults in the last 90 days of life with cancer and terminal noncancer illness during the COVID-19 pandemic.
    PLoS One. 2024;19:e0301813.
    PubMed         Abstract available
26. CORRIN T, Kennedy EB
    The evolution and adaptation of evidence synthesis during the COVID-19 pandemic in Canada: Perspectives of evidence synthesis producers.
    PLoS One. 2024;19:e0314657.
    PubMed         Abstract available
27. PHAM H, Tran TND, Nguyen NTT, Duong KD, et al
    The reversal in the cryptocurrency market before and during the Covid-19 pandemic: Does investor attention matter?
    PLoS One. 2024;19:e0304377.
    PubMed         Abstract available
28. EIKEN A, Bliddal S, Villumsen M, Iversen KK, et al
    Susceptibility to and severity of SARS-CoV-2 infection according to prescription drug use-an observational study of 46,506 Danish healthcare workers.
    PLoS One. 2024;19:e0311260.
    PubMed         Abstract available
29. BLANCHFLOWER DG, Bryson A
    Were COVID and the Great Recession well-being reducing?
    PLoS One. 2024;19:e0305347.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

30. TOPPER MJ, Guarnieri JW, Haltom JA, Chadburn A, et al
    Lethal COVID-19 associates with RAAS-induced inflammation for multiple organ damage including mediastinal lymph nodes.
    Proc Natl Acad Sci U S A. 2024;121:e2401968121.
    PubMed         Abstract available
31. Correction for Shahriar et al., Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections.
    Proc Natl Acad Sci U S A. 2024;121:e2422717121.
    PubMed        
32. ABT ER, Lam AK, Noguchi M, Rashid K, et al
    Staggered immunization with mRNA vaccines encoding SARS-CoV-2 polymerase or spike antigens broadens the T cell epitope repertoire.
    Proc Natl Acad Sci U S A. 2024;121:e2406332121.
    PubMed         Abstract available

    Vaccine

33. CHOI YJ, Jung J, Kang M, Choi MJ, et al
    The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination.
    Vaccine. 2024;44:126506.
    PubMed         Abstract available
34. WOOLFORK MN, Haire K, Farinu O, Ruffin J, et al
    A health equity science approach to assessing drivers of COVID-19 vaccination coverage disparities over the course of the COVID-19 pandemic, United States, December 2020-December 2022.
    Vaccine. 2024 Aug 1:126158. doi: 10.1016/j.vaccine.2024.126158.
    PubMed         Abstract available
35. TIPPINS A, Acevedo JC, Palomeque FS, Coy KC, et al
    Strategies to strengthen COVID-19 vaccine uptake and improve vaccine equity in U.S. Territories and Freely Associated States during the first six months of vaccine rollout.
    Vaccine. 2024 May 7:S0264-410X(24)00541-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
36. PIASECKI AM, Hall DM, Zajac J, Miller SA, et al
    A programmatic update on COVID-19 vaccination in rural communities in the United States.
    Vaccine. 2024 Apr 25:S0264-410X(24)00469-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
37. GEE J, Shimabukuro TT, Su JR, Shay D, et al
    Overview of U.S. COVID-19 vaccine safety surveillance systems.
    Vaccine. 2024 Apr 16:S0264-410X(24)00224-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
38. KONERU A, Wells K, Amanda Carnes C, Drumhiller K, et al
    A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years.
    Vaccine. 2024 Apr 8:S0264-410X(24)00369-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
39. DAHL BA, Tritter B, Butryn D, Dahlke M, et al
    Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021-2023.
    Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
40. CHATHAM-STEPHENS K, Carter RJ, Duggar C, Woodworth KR, et al
    An overview of the COVID-19 pediatric vaccine program – The U.S. experience vaccinating children ages 6 months through 17 years.
    Vaccine. 2024 Feb 29:S0264-410X(24)00166-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
41. MEANEY-DELMAN D, Carroll S, Polen K, Jatlaoui TC, et al
    Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic.
    Vaccine. 2024;42 Suppl 3.
    PubMed         Abstract available
42. DUGGAR C, Santoli JM, Noblit C, Moore LB, et al
    U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 – May 2023.
    Vaccine. 2024 Feb 14:S0264-410X(24)00167-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
43. MARKOWITZ LE, Hopkins RH Jr, Broder KR, Lee GM, et al
    COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.
    Vaccine. 2024 Feb 9:S0264-410X(23)01505-0. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
44. SCHARF LG, Adeniyi K, Augustini E, Boyd D, et al
    Monitoring and reporting the US COVID-19 vaccination effort.
    Vaccine. 2023 Dec 13:S0264-410X(23)01438-X. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
45. LINK-GELLES R, Britton A, Fleming-Dutra KE
    Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions.
    Vaccine. 2023 Dec 20:S0264-410X(23)01435-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
46. SURTEES TC, Granade CJ, Wells C, Banks M, et al
    CDC COVID-19 vaccination program: Healthcare provider compliance with COVID-19 vaccine requirements and recommendations.
    Vaccine. 2023 Dec 27:S0264-410X(23)01467-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
47. OLIVER SE, Wallace M, Twentyman E, Moulia DL, et al
    Development of COVID-19 vaccine policy – United States, 2020-2023.
    Vaccine. 2023 Dec 28:S0264-410X(23)01466-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
48. STONE ND, Parker Fiebelkorn A, Guo A, Mothershed E, et al
    Challenges and opportunities during the COVID-19 vaccination efforts in long-term care.
    Vaccine. 2024 Jan 5:S0264-410X(23)01510-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
49. FIEBELKORN AP, Adelsberg S, Anthony R, Ashenafi S, et al
    The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021-December 2022.
    Vaccine. 2024 Jan 17:S0264-410X(23)01507-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
50. ABAD N, Bonner KE, Kolis J, Brookmeyer KA, et al
    Strengthening COVID-19 vaccine confidence & demand during the US COVID-19 emergency response.
    Vaccine. 2024 Jan 23:S0264-410X(24)00029-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
51. RATTAY K, Thierry JM, Yeargin-Allsopp M, Griffin-Blake S, et al
    Lessons learned: COVID-19 vaccinations and people with disabilities.
    Vaccine. 2024 Jan 23:S0264-410X(24)00028-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
52. JONES-JACK N, El Kalach R, Yassanye D, Link-Gelles R, et al
    Advancing public health informatics during the COVID-19 pandemic: Lessons learned from a public-private partnership with pharmacies.
    Vaccine. 2024;42 Suppl 3:125667.
    PubMed         Abstract available

    Virology

53. KEGEL NB, Kaufmann A, Matrosovich M, Bauer S, et al
    Decomposition of L-glutamine and accumulation of ammonium in cell culture media inhibit infectivity of influenza viruses.
    Virology. 2024;602:110314.
    PubMed         Abstract available

#abstract #avianInfluenza #covid #COVID19 #health #influenzaA #news #research #SEASONALINFLUENZA #vaccine

#Safety and immunogenicity of #mRNA-1345 #RSV #vaccine coadministered with an #influenza or #COVID19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial

Source: Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00589-9/fulltext?rss=yes

Summary
Background
Coadministration of a respiratory syncytial virus (RSV) vaccine with seasonal influenza or SARS-CoV-2 vaccines could reduce health-care visits and increase vaccination uptake in older adults who are at high risk for severe respiratory disease. The RSV mRNA-1345 vaccine demonstrated efficacy against RSV disease with acceptable safety in the ConquerRSV trial in adults aged 60 years and older. We aimed to evaluate the safety and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine or SARS-CoV-2 mRNA vaccine.

Methods
We conducted a two-part, phase 3, observer-blinded, placebo-controlled, randomised trial in medically stable adults aged 50 years or older in the USA. In part A, participants were randomly assigned in a 7:10:10 ratio to receive 50 μg mRNA-1345 plus placebo (0·9% sodium chloride) or coadministered with 60 μg of a standard-dose quadrivalent inactivated influenza vaccine (SIIV4), or SIIV4 plus placebo. In part B, participants were randomly assigned in a 1:1:1 ratio to receive 50 μg mRNA-1345 plus placebo or coadministered with 50 μg SARS-CoV-2 mRNA-1273.214 (bivalent [Wuhan-Hu-1 plus omicron BA.1]), or mRNA-1273.214 plus placebo. Random allocation in both parts was stratified by age group (50–59 years, 60–74 years, and ≥75 years) and used interactive response technology. The coprimary objectives in each part were safety in the safety set throughout the study and non-inferiority for six immunogenicity endpoints in the per-protocol set comparing coadministered versus individual vaccines on day 29. Immunogenicity endpoints were geometric mean titre (GMT) ratios (GMRs) of RSV-A neutralising antibodies (nAbs; in parts A and B), GMRs of haemagglutination inhibition (HAI) titres to each of the four influenza strains in SIIV4 (A/Victoria/2570/2019 [H1N1]pdm09-like virus [A/H1N1], A/Cambodia/e0826360/2020 [H3N2]-like virus [A/H3N2], B/Washington/02/2019-like virus [B/Victoria], and B/Phuket/3073/2013-like virus [B/Yamagata]; in part A), GMRs of nAbs against SARS-CoV-2 (ancestral [D614G] and omicron BA.1; part B), and differences in seroresponse rates for nAbs against RSV-A (parts A and B) and SARS-CoV-2 (ancestral [D614G] and omicron BA.1; part B). Non-inferiority was declared when the lower bound of the 95% CI for GMRs was greater than 0·667 and for seroresponse rate differences was greater than −10%. This trial is registered with ClinicalTrials.gov (NCT05330975) and is ongoing.

Findings
Between April 1 and June 9, 2022, 1631 participants were randomly allocated in part A and 1623 received vaccinations on day 1 (685 [42%] received mRNA-1345 plus SIIV4, 249 [15%] mRNA-1345 plus placebo, and 689 [42%] SIIV4 plus placebo). Due to an interactive response technology error, the mRNA-1345 plus placebo group was smaller than planned (249 vs 420 participants). Of the 1623 participants in the safety set, 877 (54%) were female and 746 (46%) were male. Between July 27 and Sept 28, 2022, 1691 participants were randomly allocated in part B and 1681 received vaccinations on day 1 (564 [34%] received mRNA-1345 plus mRNA-1273.214, 558 [33%] mRNA-1345 plus placebo, and 559 [33%] mRNA-1273.214 plus placebo). Among the 1681 participants in the safety set, 924 (55%) were female and 757 (45%) were male. The reactogenicity profiles of the coadministered regimens were generally similar to the profiles when the vaccines were administered alone. As of the 6-month and 7-month follow-up times for parts A and B, respectively, no serious adverse events, adverse events of special interest, discontinuations due to adverse events, or fatal events considered related to study vaccination were reported. In part A, the GMR of nAbs against RSV-A in the mRNA-1345 plus SIIV4 group versus the mRNA-1345 alone group was 0·81 (95% CI 0·67 to 0·97), and the seroresponse rate difference in nAbs against RSV-A between the groups was −11·2% (95% CI −17·9 to −4·1). GMRs of anti-HAI titres in the mRNA-1345 plus SIIV4 versus SIIV4 alone groups were 0·89 (0·77 to 1·03) for A/H1N1, 0·97 (0·86 to 1·09) for A/H3N2, 0·93 (0·82 to 1·05) for B/Victoria, and 0·91 (0·81 to 1·02) for B/Yamagata. In part B, the GMR of nAbs against RSV-A in the mRNA-1345 plus mRNA-1273.214 versus the mRNA-1345 alone groups was 0·80 (95% CI 0·70 to 0·90), and the seroresponse rate difference was –4·4% (95% CI –9·9 to 1·0). Comparing the mRNA-1345 plus mRNA-1273.214 group with the mRNA-1273.214 alone group, the GMR of nAbs was 0·96 (0·87 to 1·06) for the ancestral (D614G) virus and 1·00 (0·89 to 1·14) for omicron BA.1; seroresponse rate differences were 0·2% (95% CI –6·0 to 6·3) for SARS-CoV-2 ancestral and –0·9% (–6·6 to 4·7) for omicron BA.1.

Interpretation
Coadministered mRNA-1345 plus SIIV4 or mRNA-1273.214 vaccines had acceptable safety profiles and elicited mostly non-inferior immune responses compared to individual vaccines in adults aged 50 years or older; only the seroresponse rate difference in nAbs against RSV-A in part A did not meet the non-inferiority criterion. Overall, these data support coadministration of mRNA-1345 with these vaccines in this population; longer-term evaluation continues in this study.

____

#abstract #covid #COVID19 #health #mrna #research #rsv #sarsCov2 #SEASONALINFLUENZA #vaccine #vaccines

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Nov. 23 ’24)

1. SELINGER S
   Patients surviving COVID-19 had lower risk for long COVID in the Omicron vs. earlier eras.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02441.
   PubMed         Abstract available
2. CHANDRA A, Hoeg TB, Ladhani S, Prasad V, et al
   School Mask Mandates and COVID-19: The Challenge of Using Difference-in-Differences Analysis of Observational Data to Estimate the Effectiveness of a Public Health Intervention.
   Ann Intern Med. 2024 Oct 8. doi: 10.7326/M23-2907.
   PubMed         Abstract available
3. GULICK RM, Pau AK, Daar E, Evans L, et al
   National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.
   Ann Intern Med. 2024 Oct 1. doi: 10.7326/ANNALS-24-00464.
   PubMed         Abstract available

   Antimicrob Agents Chemother

4. ZHANG M, Lian X, Gao Y, Jiang L, et al
   LDC000067, a CDK9 inhibitor, unveils promising results in suppressing influenza virus infections in vitro and in vivo.
   Antimicrob Agents Chemother. 2024 Nov 20:e0117224. doi: 10.1128/aac.01172.
   PubMed         Abstract available

   Arch Virol

5. ZHANG WX, Zou L, Cui Y, Zhou Y, et al
   Molecular epidemiology of herpangina in the subcenter of Beijing, China: a surveillance study during 2021-2022.
   Arch Virol. 2024;169:245.
   PubMed         Abstract available

   Biochemistry

6. HU J, Huynh DT, Boyce M
   Sugar Highs: Recent Notable Breakthroughs in Glycobiology.
   Biochemistry. 2024;63:2937-2947.
   PubMed         Abstract available

   Epidemiol Infect

7. WANG W, Li Q, Wang J
   A self-driven ESN-DSS approach for effective COVID-19 time series prediction and modelling.
   Epidemiol Infect. 2024;152:e146.
   PubMed         Abstract available
8. MARKELZ A, Zirnhelt Z, Morris K, Seys SA, et al
   Association between age of paediatric index cases and household SARS-CoV-2 transmission.
   Epidemiol Infect. 2024;152:e145.
   PubMed         Abstract available
9. ZHU W, Tang X, Chen Y, Chen M, et al
   Prediction of SARS-CoV-2 infection cases based on the meta-SEIRS model.
   Epidemiol Infect. 2024;152:e144.
   PubMed         Abstract available
10. FERRONI E, Mateo-Urdiales A, Bietta C, Cesaroni G, et al
    Sex differences in response to COVID-19 mRNA vaccines in Italian population.
    Epidemiol Infect. 2024;152:e139.
    PubMed         Abstract available

    J Exp Med

11. BELLOS E, Santillo D, Vantourout P, Jackson HR, et al
    Heterozygous BTNL8 variants in individuals with multisystem inflammatory syndrome in children (MIS-C).
    J Exp Med. 2024;221:e920240699.
    PubMed         Abstract available

    J Infect

12. LIU Q, Zhong P, Wei Q, Wang X, et al
    Mechanisms of MHC-II Binding by Novel Influenza A Viruses and Their Cross-Species Transmission Potential.
    J Infect. 2024 Nov 16:106354. doi: 10.1016/j.jinf.2024.106354.
    PubMed        

    J Infect Dis

13. MORO RN, Mehaffy C, De P, Phillips E, et al
    Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-like Reactions During Treatment of Latent Tuberculosis Infection.
    J Infect Dis. 2024 Apr 19:jiae180. doi: 10.1093.
    PubMed         Abstract available
14. GOSWAMI J, Baqui AH, Doreski PA, Perez Marc G, et al
    Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.
    J Infect Dis. 2024 Jun 18:jiae316. doi: 10.1093.
    PubMed         Abstract available
15. HARDING ER, Wildenbeest JG, Heikkinen T, Dacosta-Urbieta A, et al
    Inconsistent Increase in Age at Respiratory Syncytial Virus Hospitalization of Children Aged <2 Years During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: A Retrospective Multicenter Study in 4 European Countries.
    J Infect Dis. 2024;230:e985-e995.
    PubMed         Abstract available
16. LEVY ME, Chilunda V, Davis RE, Heaton PR, et al
    Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 Variant.
    J Infect Dis. 2024;230:1197-1201.
    PubMed         Abstract available
17. CHEW KW, Taiwo BO, Moser C, Daar ES, et al
    Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.
    J Infect Dis. 2024;230:1177-1186.
    PubMed         Abstract available
18. BLOOM N, Ramirez SI, Cohn H, Parikh UM, et al
    SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback.
    J Infect Dis. 2024 Jul 22:jiae371. doi: 10.1093.
    PubMed         Abstract available
19. BLAIR PW, Siddharthan T, Herrera PM, Cui E, et al
    Validation of Lung Ultrasound for Coronavirus Disease 2019 Prognostication in an International Multicenter Cohort Study.
    J Infect Dis. 2024;230:e1092-e1100.
    PubMed         Abstract available
20. LEWNARD JA, Hong V, Grant LR, Ackerson BK, et al
    Association of pneumococcal conjugate vaccination with SARS-CoV-2 infection among older adult recipients of COVID-19 vaccines: a longitudinal cohort study.
    J Infect Dis. 2024 Aug 5:jiae387. doi: 10.1093.
    PubMed         Abstract available
21. BRANCHE AR, Falsey AR, Finelli L, Walsh EE, et al
    Residency in Long-Term Care Facilities: An Important Risk Factor for Respiratory Syncytial Virus Hospitalization.
    J Infect Dis. 2024;230:e1007-e1011.
    PubMed         Abstract available

    J Virol

22. WANG W, Bhushan G, Paz S, Stauft CB, et al
    Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.
    J Virol. 2024 Oct 4:e0094824. doi: 10.1128/jvi.00948.
    PubMed         Abstract available
23. LI A, Zhao K, Duan Y, Zhang B, et al
    SARS-CoV-2 nsp13 suppresses hepatitis B virus replication by targeting cccDNA transcription.
    J Virol. 2024 Oct 7:e0104224. doi: 10.1128/jvi.01042.
    PubMed         Abstract available
24. HAN Y, Zhou H, Liu C, Wang W, et al
    SARS-CoV-2 N protein coordinates viral particle assembly through multiple domains.
    J Virol. 2024 Oct 16:e0103624. doi: 10.1128/jvi.01036.
    PubMed         Abstract available
25. ZHANG C, Jiang Q, Liu Z, Li N, et al
    SARS-CoV-2 NSP6 reduces autophagosome size and affects viral replication via sigma-1 receptor.
    J Virol. 2024 Oct 24:e0075424. doi: 10.1128/jvi.00754.
    PubMed         Abstract available
26. FUJIMOTO Y, Ozaki K, Ono E
    Chicken ANP32A-independent replication of highly pathogenic avian influenza viruses potentially leads to mammalian adaptation-related amino acid substitutions in viral PB2 and PA proteins.
    J Virol. 2024 Nov 21:e0184024. doi: 10.1128/jvi.01840.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

27. RESES HE, Segovia G, Dubendris H, Barbre K, et al
    Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents – National Healthcare Safety Network, United States, November 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1052-1057.
    PubMed         Abstract available
28. RICHARD DM, Susswein Z, Connolly S, Myers Y Gutierrez A, et al
    Detection of Real-Time Changes in Direction of COVID-19 Transmission Using National- and State-Level Epidemic Trends Based on R(t) Estimates – United States Overall and New Mexico, April-October 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1058-1063.
    PubMed         Abstract available
29. KRISS JL, Black CL, Razzaghi H, Meghani M, et al
    Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults – United States, Fall 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1044-1051.
    PubMed         Abstract available

    PLoS One

30. SHURO L, Lawrence E, Knight L, Schneider H, et al
    Enhancing childhood immunization coverage in Mozambique and Malawi: Study protocol of a mixed methods evaluation of the ‘Let’s talk about vaccines’ multisite community-based participatory project.
    PLoS One. 2024;19:e0311052.
    PubMed         Abstract available
31. RAZZAGHI S, Mousavi S, Jaberinezhad M, Farshbaf Khalili A, et al
    Time-Series analysis of short-term exposure to air pollutants and daily hospital admissions for stroke in Tabriz, Iran.
    PLoS One. 2024;19:e0309414.
    PubMed         Abstract available
32. ESONOVA G, Abdurakhimov A, Ibragimova S, Kurmaeva D, et al
    Complete genome sequencing of SARS-CoV-2 strains that were circulating in Uzbekistan over the course of four pandemic waves.
    PLoS One. 2024;19:e0298940.
    PubMed         Abstract available
33. MARTINEZ A, Soldevila N, Romero-Tamarit A, Torner N, et al
    Correction: Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype.
    PLoS One. 2024;19:e0314310.
    PubMed         Abstract available
34. YAU T, Chan J, McIntyre M, Bhogal D, et al
    Adverse events associated with the delivery of telerehabilitation across rehabilitation populations: A scoping review.
    PLoS One. 2024;19:e0313440.
    PubMed         Abstract available
35. ODENDAAL W, Tomlinson M, Goga A, Singh Y, et al
    Good practices to optimise the performance of maternal and neonatal quality improvement teams: Results from a longitudinal qualitative evaluation in South Africa, before, and during COVID-19.
    PLoS One. 2024;19:e0314024.
    PubMed         Abstract available
36. SCHENK H, Rauch W, Zulli A, Boehm AB, et al
    SARS-CoV-2 surveillance in US wastewater: Leading indicators and data variability analysis in 2023-2024.
    PLoS One. 2024;19:e0313927.
    PubMed         Abstract available
37. GHEZZAWI M, Fahme S, Naalbandian S, DeJong J, et al
    Impact of the COVID-19 pandemic on intra-household gender disparities in the Middle East and North Africa region: A scoping review protocol.
    PLoS One. 2024;19:e0313838.
    PubMed         Abstract available
38. WANG D, Mao Z, Yao X
    Evaluating the World Health Organization’s health promotion strategies: Sentiments, health beliefs, and the COVID-19 pandemic.
    PLoS One. 2024;19:e0311825.
    PubMed         Abstract available
39. SOFI-MAHMUDI A, Raittio E, Khazaei Y, Ashraf J, et al
    COVID-19-related research data availability and quality according to the FAIR principles: A meta-research study.
    PLoS One. 2024;19:e0313991.
    PubMed         Abstract available
40. TONI G, Consonni C, Montresor A
    Correction: A general method for estimating the prevalence of influenza-like-symptoms with Wikipedia data.
    PLoS One. 2024;19:e0314302.
    PubMed         Abstract available
41. SU J
    The bright side of supplier concentration: Investor attitudes towards the reopening policy in China.
    PLoS One. 2024;19:e0313682.
    PubMed         Abstract available
42. PAEZ-MORA CD, Zona DC, Angarita-Sierra T, Rojas-Paredes ME, et al
    Changes in lung function and dyspnea perception in Colombian Covid-19 patients after a 12-week pulmonary rehabilitation program.
    PLoS One. 2024;19:e0300826.
    PubMed         Abstract available
43. HAGGLUND S, Laloy E, Alvarez I, Guo Y, et al
    Effects of early treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) on the bronchoalveolar lavage proteome and oxylipids during bovine respiratory syncytial virus (BRSV) infection.
    PLoS One. 2024;19:e0309609.
    PubMed         Abstract available
44. NAKANISHI K, Mutoh M, Itoh S, Kobayashi S, et al
    Vitamin D concentration in maternal serum during pregnancy: Assessment in Hokkaido in adjunct study of the Japan Environment and Children’s Study (JECS).
    PLoS One. 2024;19:e0312516.
    PubMed         Abstract available
45. RUBINSTEIN F, Williams R, Dumville J, Kane B, et al
    Patient use of pulse oximetry to support management of COVID-19 in Greater Manchester: A non-randomised evaluation using a target trial approach.
    PLoS One. 2024;19:e0310822.
    PubMed         Abstract available
46. MEHTA SP, Faieta JM, Swartz MC, Blevins EW, et al
    COVID-19 and the risk and trajectory of frailty in community- or institution-dwelling individuals: Protocol for systematic review and meta-analysis.
    PLoS One. 2024;19:e0312163.
    PubMed         Abstract available
47. BRECKO J, Rozman C, Zgajnar J
    Price volatility and GHG emissions analysis on smaller cattle herds typical for the pre-Alpine region, the example of Slovenia.
    PLoS One. 2024;19:e0310713.
    PubMed         Abstract available
48. LEE YS, Kim H, Kwon S, Kim TH, et al
    Association between long COVID and nonsteroidal anti-inflammatory drug use by patients with acute-phase COVID-19: A nationwide Korea National Health Insurance Service cohort study.
    PLoS One. 2024;19:e0312530.
    PubMed         Abstract available
49. GOLDBLATT A, Loccisano MJ, Mahe MI, Dennehy JJ, et al
    Risk of infection due to airborne virus in classroom environments lacking mechanical ventilation.
    PLoS One. 2024;19:e0314002.
    PubMed         Abstract available
50. ABERA BT, Gebrecherkos T, Weledegebriel MG, Abreha GF, et al
    Prevalence of COVID-19 and associated factors among healthcare workers in the war-torn Tigray, Ethiopia.
    PLoS One. 2024;19:e0310128.
    PubMed         Abstract available
51. KANN RS, Snyder JS, Victor C, Cumbe ZA, et al
    Water, sanitation, and hygiene insecurity and disease prevention behaviors during the COVID-19 pandemic in low-income neighborhoods of Beira, Mozambique.
    PLoS One. 2024;19:e0310490.
    PubMed         Abstract available
52. KUTE NG, Ashley DL, Spears CA, Nyman AL, et al
    Association of tobacco purchasing behaviors with tobacco use by user groups during the COVID-19 pandemic: A mixed methods analysis.
    PLoS One. 2024;19:e0313566.
    PubMed         Abstract available
53. LEUNG LB, Santos JJ, Escarce JJ, Ettner SL, et al
    Protocol: A mixed-methods study to evaluate implementation and outcomes of U.S. state telemental health policy expansion during the COVID-19 pandemic.
    PLoS One. 2024;19:e0312665.
    PubMed         Abstract available
54. TOMLINSON C, Rajasekaran A, Brochu-Gaudreau K, Dubois C, et al
    A convenient analytic method for gel quantification using ImageJ paired with Python or R.
    PLoS One. 2024;19:e0308297.
    PubMed         Abstract available
55. OJALA O, Garke MA, El Alaoui S, Forsstrom D, et al
    The trajectory of anxiety and depressive symptoms and the impact of self-injury: A longitudinal 12-month cohort study of individuals with psychiatric symptoms.
    PLoS One. 2024;19:e0313961.
    PubMed         Abstract available
56. HAMDAN O, Amarin JZ, Potter M, Haddadin Z, et al
    Seasonal influenza vaccination: Attitudes and practices of healthcare providers in Jordan.
    PLoS One. 2024;19:e0314224.
    PubMed         Abstract available
57. THIAM F, Diouara AAM, Ndiaye CSCA, Diouf I, et al
    Serological survey in a university community after the fourth wave of COVID-19 in Senegal.
    PLoS One. 2024;19:e0298509.
    PubMed         Abstract available
58. FARSHIDGOHAR M, Oveisi S, Dodangeh S, Fawzi F, et al
    Evaluation of clinical and laboratory findings in MIS-C patients associated with COVID-19: An experience from the Northwest of Iran.
    PLoS One. 2024;19:e0313843.
    PubMed         Abstract available
59. LI LY, Napp AK, Adedeji A, Erhart M, et al
    The impact of neighborhood deprivation on mental health and quality of life in children and adolescents during the COVID-19 pandemic: Findings from the COPSY Hamburg study.
    PLoS One. 2024;19:e0313652.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

60. LIU L, Cui Z, Kunreuther H, Heal G, et al
    Modeling and testing strategic interdependence and tipping in public policy implementation.
    Proc Natl Acad Sci U S A. 2024;121:e2414041121.
    PubMed         Abstract available
61. KLEIN EY, Impalli I, Poleon S, Denoel P, et al
    Global trends in antibiotic consumption during 2016-2023 and future projections through 2030.
    Proc Natl Acad Sci U S A. 2024;121:e2411919121.
    PubMed         Abstract available
62. MEHMOOD S, Naseer S, Chen DL
    Teacher vaccinations enhance student achievement in Pakistan: The role of role models and theory of mind.
    Proc Natl Acad Sci U S A. 2024;121:e2406034121.
    PubMed         Abstract available

    Vaccine

63. MAO J, Kang HJ, Eom GD, Yoon KW, et al
    Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2.
    Vaccine. 2024;43.
    PubMed         Abstract available

    Virology

64. ZHAO Q, Zhang J, Yang S, Bai X, et al
    H1N1 swine influenza viruses upregulate NEU1 expression through histone H3 acetylation regulated by HDAC2.
    Virology. 2024;601:110305.
    PubMed         Abstract available

#abstract #avianInfluenza #covid #COVID19 #health #influenzaA #news #research #SEASONALINFLUENZA #vaccine

Source: Science, https://www.science.org/doi/10.1126/science.adq3003

Structured Abstract
INTRODUCTION
Despite the availability of updated seasonal influenza vaccines and treatments, annual influenza epidemics continue to cause millions of hospitalizations and substantial burden on health care systems. The global circulation of seasonal influenza lineages depends on continued virus antigenic evolution and patterns of human travel from regions with year-round transmission to temperate regions. A clearer understanding of how human influenza and other respiratory pathogens were affected by COVID-19–related restrictions will help predict how future pandemics might influence infectious diseases and help inform more effective interventions.

RATIONALE
During the COVID-19 pandemic, nonpharmaceutical interventions were introduced worldwide, which led to human behavioral changes on an unprecedented scale. This led to a decline in the global prevalence of endemic respiratory pathogens, including seasonal influenza subtypes H1N1pdm09 and H3N2 and lineages B/Victoria and B/Yamagata. The impact of changes in air travel connectivity among regions meant that the global circulation of seasonal influenza was perturbed. In this work, we assembled globally representative datasets to jointly analyze molecular, epidemiological, and international travel data to characterize how the global circulation of seasonal influenza was reshaped and when it returned to a pre-pandemic equilibrium.

RESULTS
Test positivity rates for influenza viruses dropped by >95% during the acute phase of the pandemic (April 2020 to March 2021) compared with the pre-pandemic period. We inferred that the locations where circulation of H1N1, H3N2, and B/Victoria influenza virus lineages was maintained during the acute phase were all in Asia. However, we also revealed that circulation continued in Africa, but with less influence on global circulation patterns, perhaps because of less frequent international travel. As pandemic-related restrictions weakened (albeit heterogeneously across the world), among-region virus lineage movements were detectable, and our statistical model showed strong support for association of international air travel with between-region influenza virus movements. In the post-pandemic period (after the World Health Organization’s International Health Regulations Emergency Committee declared the end of the global emergency in May 2023), the global circulation of seasonal influenza returned to pre-pandemic patterns characterized by continued viral movements and accumulation of genetic diversity—both important for maintaining transmission of seasonal influenza. The global lineage dynamics of seasonal influenza between May 2023 and March 2024 appears similar to that before the pandemic, albeit smaller in magnitude.

CONCLUSION
Our study revealed how seasonal influenza viruses are maintained during and reestablished after pandemic-related behavioral changes. The longer-term impact of the COVID-19 pandemic on influenza evolution and antigenicity will need continued monitoring through coordinated genomic surveillance and evaluation of the global transmission patterns. This is especially relevant as more regions become suitable for year-round circulation of influenza, including in Africa.

_____

https://etidioh.wordpress.com/2024/11/07/covid19-pandemic-interventions-reshaped-the-global-dispersal-of-seasonal-influenza-viruses/

#abstract #birdFlu #COVID19 #flu #health #influenza #news #research #sarsCov2 #seasonalInfluenza #socialDistancingMeasures

Source: BioRxIV, https://www.medrxiv.org/content/10.1101/2024.11.03.24316665v1

Abstract

Background

Following the 2021-2022 avian influenza panzootic in birds and wildlife, seasonal influenza vaccines have been advised to occupationally high-risk groups to reduce the likelihood of coincidental infection in humans with both seasonal and avian influenza A viruses.

Methods

We developed and launched a questionnaire aimed at poultry workers and people in direct contact with birds to understand awareness and uptake of seasonal influenza vaccination. We collected responses in-person at an agricultural trade event and online.

Findings

The questionnaire was completed by 225 individuals from across the UK. The most commonly reported reason for vaccination was protection against seasonal influenza (82%, 63 of 77). Nearly all individuals aged ≥65 years reported that the vaccine was recommended for them (24 of 28). There was no difference in recommendation for occupational groups. Most vaccinees were aged over 60 years (60%, 29 of 48), however coverage was lower than expected in the ≥65 target group. Vaccination in those exposed to avian influenza was low (32%, 9 of 28). Not having enough time was the single most reported reason for not getting vaccinated in those intending to. Individuals unintending to be vaccinated perceived natural immunity to be better than receiving the vaccine as well as lack of awareness and time.

Conclusions

Our findings suggest that targeted campaigns in occupationally exposed groups need to be undertaken to improve communication of information and access to vaccine clinics. We recommend co-production methods to optimise this public health strategy for increased knowledge and future vaccine uptake.

____

https://etidioh.wordpress.com/2024/11/05/seasonal-influenza-vaccination-in-people-who-have-contact-with-birds/

#abstract #avianInfluenza #flu #health #influenza #news #research #seasonalInfluenza #UK #vaccination #vaccine

Toward a consensus on fighting flu: prioritising childhood vaccination [Promoted content] https://www.euractiv.com/section/health-consumers/opinion/childhood-influenza-policy-steering-committee-cipsc-roundtable/?utm_source=dlvr.it&utm_medium=mastodon #childhoodvaccination #immunisation #seasonalinfluenza #vaccination

1. TANIGUCHI K, Noshi T, Omoto S, Sato A, et al.
   The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
   Arch Virol. 2024;169:29.
   PubMed: https://www.amedeo.com/p2.php?id=38216710&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38216710
2. LIU H, Wang J, Li S, Sun Y, et al.
   The unfolded protein response pathway as a possible link in the pathogenesis of COVID-19 and sepsis.
   Arch Virol. 2024;169:20.
   PubMed: https://www.amedeo.com/p2.php?id=38191819&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38191819
3. Update to living systematic review on SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission.
   BMJ. 2024;384:p2929.
   PubMed: https://www.amedeo.com/p2.php?id=38199645&s=flu&pm=2
    
   Share: https://m.amedeo.com/38199645
4. TANNE JH.
   Covid-19: Some US states and hospitals recommend masks again.
   BMJ. 2024;384:q26.
   PubMed: https://www.amedeo.com/p2.php?id=38182176&s=flu&pm=2
    
   Share: https://m.amedeo.com/38182176
5. NASSAR K, El-Mekawey D, Elmasry AE, Refaey MS, et al.
   The significance of caloric restriction mimetics as anti-aging drugs.
   Biochem Biophys Res Commun. 2024;692:149354.
   PubMed: https://www.amedeo.com/p2.php?id=38091837&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38091837
6. JIANG H, Zou X, Zhou X, Zhang J, et al.
   Crystal structure of SARS-CoV-2 main protease (M(pro)) mutants in complex with the non-covalent inhibitor CCF0058981.
   Biochem Biophys Res Commun. 2024;692:149352.
   PubMed: https://www.amedeo.com/p2.php?id=38056159&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38056159
7. KOHLBRAND AJ, Stokes RW, Sankaran B, Cohen SM, et al.
   Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants.
   Biochemistry. 2024 Jan 8. doi: 10.1021/acs.biochem.3c00536.
   PubMed: https://www.amedeo.com/p2.php?id=38190441&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38190441
8. LIEPINS T, Davie G, Miller R, Whitehead J, et al.
   Rural-urban variation in COVID-19 vaccination uptake in Aotearoa New Zealand: Examining the national roll-out.
   Epidemiol Infect. 2024;152:e7.
   PubMed: https://www.amedeo.com/p2.php?id=38174436&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38174436
9. BASTARD P, Gervais A, Taniguchi M, Saare L, et al.
   Higher COVID-19 pneumonia risk associated with anti-IFN-alpha than with anti-IFN-omega auto-Abs in children.
   J Exp Med. 2024;221:e20231353.
   PubMed: https://www.amedeo.com/p2.php?id=38175961&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38175961
10. JIANG W, Xu L, Wang Y, Hao C, et al.
    Exploring immunity debt: Dynamic alterations in RSV antibody levels in children under 5 years during the COVID-19 pandemic.
    J Infect. 2023 Oct 29:S0163-4453(23)00550-9. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=38009717&s=flu&pm=2
     
    Share: https://m.amedeo.com/38009717
11. PHAN J, Eslick GD, Elliott EJ.
    Demystifying the global outbreak of severe acute hepatitis of unknown aetiology in children: A systematic review and meta-analysis.
    J Infect. 2023 Nov 24:S0163-4453(23)00580-7. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=38007049&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38007049
12. BRENDISH NJ, Davis C, Chapman ME, Borca F, et al.
    Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation.
    J Infect. 2023 Nov 15:S0163-4453(23)00556-X. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37977337&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37977337
13. LIECHTI FD, Bijlsma MW, Brouwer MC, van Sorge NM, et al.
    Impact of the COVID-19 pandemic on incidence and serotype distribution of pneumococcal meningitis – A prospective, nationwide cohort study from the Netherlands.
    J Infect. 2023 Nov 8:S0163-4453(23)00555-8. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37949362&s=flu&pm=2
     
    Share: https://m.amedeo.com/37949362
14. HALL VJ, Insalata F, Foulkes S, Kirwan P, et al.
    Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
    J Infect. 2023 Nov 3:S0163-4453(23)00553-4. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37926119&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37926119
15. LUNT R, Quinot C, Kirsebom F, Andrews N, et al.
    The Impact of Vaccination and SARS-CoV-2 Variants on the Virological Response to SARS-CoV-2 Infections during the Alpha, Delta, and Omicron waves in England.
    J Infect. 2023 Nov 3:S0163-4453(23)00547-9. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37926118&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37926118
16. BRUHN M, Obara M, Chiyyeadu A, Costa B, et al.
    Memory B cells anticipate SARS-CoV-2 variants through somatic hypermutation.
    J Infect. 2023 Oct 30:S0163-4453(23)00551-0. doi: 10.1016/j.jinf.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37913848&s=flu&pm=2
     
    Share: https://m.amedeo.com/37913848
17. HOWARD LM, Jensen TL, Goll JB, Gelber CE, et al.
    Metabolomic Signatures Differentiate Immune Responses in Avian Influenza Vaccine Recipients.
    J Infect Dis. 2024 Jan 5:jiad611. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38181048&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38181048
18. DULIN H, Barre RS, Xu D, Neal A, et al.
    Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
    J Virol. 2024 Jan 11:e0157123. doi: 10.1128/jvi.01571.
    PubMed: https://www.amedeo.com/p2.php?id=38206036&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38206036
19. HE Y, Guo Z, Subiaur S, Benegal A, et al.
    Antibody inhibition of influenza A virus assembly and release.
    J Virol. 2024 Jan 5:e0139823. doi: 10.1128/jvi.01398.
    PubMed: https://www.amedeo.com/p2.php?id=38179944&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38179944
20. POURAKBARI R, Gholami M, Shakerimoghaddam A, Khiavi FM, et al.
    Comparison of RT-LAMP and RT-qPCR assays for detecting SARS-CoV-2 in the extracted RNA and direct swab samples.
    J Virol Methods. 2024;324:114871.
    PubMed: https://www.amedeo.com/p2.php?id=38103738&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38103738
21. HARRIS E.
    Using Throat Swabs Improved Sensitivity in Detecting SARS-CoV-2.
    JAMA. 2023 Dec 20. doi: 10.1001/jama.2023.25267.
    PubMed: https://www.amedeo.com/p2.php?id=38117510&s=flu&pm=2
     
    Share: https://m.amedeo.com/38117510
22. HARRIS E.
    Program Offering Free COVID-19 and Flu Services Expands Nationwide.
    JAMA. 2023 Dec 20. doi: 10.1001/jama.2023.25268.
    PubMed: https://www.amedeo.com/p2.php?id=38117506&s=flu&pm=2
     
    Share: https://m.amedeo.com/38117506
23. SURAN M.
    Studies Investigate Whether Antivirals Like Paxlovid May Prevent Long COVID.
    JAMA. 2023 Dec 13. doi: 10.1001/jama.2023.24103.
    PubMed: https://www.amedeo.com/p2.php?id=38090997&s=flu&pm=2
     
    Share: https://m.amedeo.com/38090997
24. PACIELLO I, Maccari G, Pantano E, Andreano E, et al.
    High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies.
    Proc Natl Acad Sci U S A. 2024;121:e2314730121.
    PubMed: https://www.amedeo.com/p2.php?id=38198525&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38198525
25. DEE TS.
    Higher chronic absenteeism threatens academic recovery from the COVID-19 pandemic.
    Proc Natl Acad Sci U S A. 2024;121:e2312249121.
    PubMed: https://www.amedeo.com/p2.php?id=38194454&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38194454
26. GOTTLIEB A, Pham HPT, Saltarrelli JG, Lindsey JW, et al.
    Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells.
    Proc Natl Acad Sci U S A. 2024;121:e2315857121.
    PubMed: https://www.amedeo.com/p2.php?id=38190525&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38190525
27. YU J, Zhao W, Chen X, Lu H, et al.
    A plant virus manipulates the long-winged morph of insect vectors.
    Proc Natl Acad Sci U S A. 2024;121:e2315341121.
    PubMed: https://www.amedeo.com/p2.php?id=38190519&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38190519
28. BAUM MY, Jacob BA.
    Racial differences in parent response to COVID schooling policies.
    Proc Natl Acad Sci U S A. 2024;121:e2307308120.
    PubMed: https://www.amedeo.com/p2.php?id=38190517&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38190517
29. VAUGHAN TG, Scire J, Nadeau SA, Stadler T, et al.
    Estimates of early outbreak-specific SARS-CoV-2 epidemiological parameters from genomic data.
    Proc Natl Acad Sci U S A. 2024;121:e2308125121.
    PubMed: https://www.amedeo.com/p2.php?id=38175864&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38175864
30. ZHANG H, Zhou J, Chen H, Mao J, et al.
    Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171.
    Antimicrob Agents Chemother. 2023 Dec 15:e0111523. doi: 10.1128/aac.01115.
    PubMed: https://www.amedeo.com/p2.php?id=38099673&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38099673
31. BAKER J, Ombredane H, Daly L, Knowles I, et al.
    Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice.
    Antimicrob Agents Chemother. 2024;68:e0105023.
    PubMed: https://www.amedeo.com/p2.php?id=38063402&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38063402
32. STRIZKI JM, Gaspar JM, Howe JA, Hutchins B, et al.
    Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Antimicrob Agents Chemother. 2024;68:e0095323.
    PubMed: https://www.amedeo.com/p2.php?id=38047645&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38047645

https://etidioh.wordpress.com/2024/01/13/influenza-and-covid19-research-references-by-amedeo-january-13-24/

#covid #COVID19 #flu #health #influenza #influenzaA #research #seasonalInfluenza

1. SUN X, Ma H, Wang X, Bao Z, et al.
   Broadly neutralizing antibodies to combat influenza virus infection.
   Antiviral Res. 2023 Dec 23:105785. doi: 10.1016/j.antiviral.2023.105785.
   PubMed: https://www.amedeo.com/p2.php?id=38145757&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38145757
2. MAHASE E.
   England and Scotland see sharp rise in covid and flu cases as hospitals struggle.
   BMJ. 2023;383:2977.
   PubMed: https://www.amedeo.com/p2.php?id=38128963&s=flu&pm=2
    
   Share: https://m.amedeo.com/38128963
3. LOOI MK.
   Covid-19: WHO adds JN.1 as new variant of interest.
   BMJ. 2023;383:p2975.
   PubMed: https://www.amedeo.com/p2.php?id=38128957&s=flu&pm=2
    
   Share: https://m.amedeo.com/38128957
4. MATTESON NL, Hassler GW, Kurzban E, Schwab MA, et al.
   Genomic surveillance reveals dynamic shifts in the connectivity of COVID-19
   epidemics.
   Cell. 2023;186:5690-5704.
   PubMed: https://www.amedeo.com/p2.php?id=38101407&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38101407
5. WIDAGDO W, Bastian AR, Jastorff AM, Scheys I, et al.
   Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and
   High-dose Influenza Vaccine in Adults 65 Years and Older: a Noninferiority Trial.
   J Infect Dis. 2023 Dec 22:jiad594. doi: 10.1093.
   PubMed: https://www.amedeo.com/p2.php?id=38134393&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38134393
6. MIURA K, Suzuki Y, Ishida K, Arakawa M, et al.
   Distinct motifs in the E protein are required for SARS-CoV-2 virus particle
   formation and lysosomal deacidification in host cells.
   J Virol. 2023 Oct 13:e0042623. doi: 10.1128/jvi.00426.
   PubMed: https://www.amedeo.com/p2.php?id=37830820&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37830820
7. MAHE D, Bourgeau S, da Silva J, Schlederer J, et al.
   SARS-CoV-2 replicates in the human testis with slow kinetics and has no major
   deleterious effects ex vivo.
   J Virol. 2023 Oct 13:e0110423. doi: 10.1128/jvi.01104.
   PubMed: https://www.amedeo.com/p2.php?id=37830818&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37830818
8. KIMURA I, Yamasoba D, Nasser H, Ito H, et al.
   Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological
   characteristics.
   J Virol. 2023 Oct 5:e0101123. doi: 10.1128/jvi.01011.
   PubMed: https://www.amedeo.com/p2.php?id=37796123&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37796123
9. ZHAO Y, Sui L, Wu P, Li L, et al.
   EGR1 functions as a new host restriction factor for SARS-CoV-2 to inhibit virus
   replication through the E3 ubiquitin ligase MARCH8.
   J Virol. 2023 Sep 29:e0102823. doi: 10.1128/jvi.01028.
   PubMed: https://www.amedeo.com/p2.php?id=37772822&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37772822
10. LI J, Gui Q, Liang FX, Sall J, et al.
    The REEP5/TRAM1 complex binds SARS-CoV-2 NSP3 and promotes virus replication.
    J Virol. 2023 Sep 28:e0050723. doi: 10.1128/jvi.00507.
    PubMed: https://www.amedeo.com/p2.php?id=37768083&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37768083
11. MCCOOL RS, Musayev M, Bush SM, Derrien-Colemyn A, et al.
    Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein
    elicits antibodies targeting a membrane-proximal epitope.
    J Virol. 2023 Sep 22:e0092923. doi: 10.1128/jvi.00929.
    PubMed: https://www.amedeo.com/p2.php?id=37737588&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37737588
12. SCHOEN A, Holzer M, Muller MA, Wallerang KB, et al.
    Functional comparisons of the virus sensor RIG-I from humans, the microbat Myotis
    daubentonii, and the megabat Rousettus aegyptiacus, and their response to
    SARS-CoV-2 infection.
    J Virol. 2023 Sep 20:e0020523. doi: 10.1128/jvi.00205.
    PubMed: https://www.amedeo.com/p2.php?id=37728614&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37728614
13. FUJITA S, Kosugi Y, Kimura I, Tokunaga K, et al.
    Determination of the factors responsible for the tropism of SARS-CoV-2-related bat coronaviruses to Rhinolophus bat ACE2.
    J Virol. 2023 Sep 19:e0099023. doi: 10.1128/jvi.00990.
    PubMed: https://www.amedeo.com/p2.php?id=37724881&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37724881
14. CAO J, Shi M, Zhu L, Li X, et al.
    The matrix protein of respiratory syncytial virus suppresses interferon signaling via RACK1 association.
    J Virol. 2023;97:e0074723.
    PubMed: https://www.amedeo.com/p2.php?id=37712706&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37712706
15. XING M, Wang Y, Wang X, Liu J, et al.
    Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants.
    J Virol. 2023 Sep 14:e0072423. doi: 10.1128/jvi.00724.
    PubMed: https://www.amedeo.com/p2.php?id=37706688&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37706688
16. EASTMAN Q.
    Study Shows Businesses Selling Unapproved Stem Cell Treatments Have Turned to Long COVID.
    JAMA. 2023 Nov 29. doi: 10.1001/jama.2023.23897.
    PubMed: https://www.amedeo.com/p2.php?id=38019493&s=flu&pm=2
     
    Share: https://m.amedeo.com/38019493
17. STEWART TG, Rebolledo PA, Mourad A, Lindsell CJ, et al.
    Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
    JAMA. 2023 Nov 17:e2323363. doi: 10.1001/jama.2023.23363.
    PubMed: https://www.amedeo.com/p2.php?id=37976072&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37976072
18. HARRINGTON PR, Cong J, Troy SB, Rawson JMO, et al.
    Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials – United States and International Sites, 2021-2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:1365-1370.
    PubMed: https://www.amedeo.com/p2.php?id=38127674&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127674
19. SMITH DJ, Lambrou A, Patel P.
    SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals.
    MMWR Morb Mortal Wkly Rep. 2023;72:1357-1364.
    PubMed: https://www.amedeo.com/p2.php?id=38127665&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127665
20. FINNEY J, Moseman AP, Kong S, Watanabe A, et al.
    Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin.
    Proc Natl Acad Sci U S A. 2024;121:e2316964120.
    PubMed: https://www.amedeo.com/p2.php?id=38147556&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38147556
21. CHEN Y, Gel YR, Marathe MV, Poor HV, et al.
    A simplicial epidemic model for COVID-19 spread analysis.
    Proc Natl Acad Sci U S A. 2024;121:e2313171120.
    PubMed: https://www.amedeo.com/p2.php?id=38147553&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38147553
22. YE Z, Bonam SR, McKay LGA, Plante JA, et al.
    Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.
    Proc Natl Acad Sci U S A. 2023;120:e2311752120.
    PubMed: https://www.amedeo.com/p2.php?id=38134199&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38134199
23. MIYAMOTO S, Nishiyama T, Ueno A, Park H, et al.
    Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection.
    Proc Natl Acad Sci U S A. 2023;120:e2314808120.
    PubMed: https://www.amedeo.com/p2.php?id=38134196&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38134196
24. GHARPURE R, Akumu AO, Dawa J, Gobin S, et al.
    Costs of seasonal influenza vaccine delivery in a pediatric demonstration project for children aged 6-23 months – Nakuru and Mombasa Counties, Kenya, 2019-2021.
    Vaccine. 2023 Dec 27:S0264-410X(23)01475-5. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=38154992&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38154992
25. FONSECA HAR, Zimerman A, Monfardini F, Guimaraes HP, et al.
    In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial.
    Vaccine. 2023 Dec 27:S0264-410X(23)01531-1. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=38154990&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38154990
26. SEPPALA E, Dahl J, Veneti L, Rydland KM, et al.
    Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023.
    Vaccine. 2023 Dec 22:S0264-410X(23)01496-2. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=38142215&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38142215
27. KRISTENSEN C, Larsen LE, Trebbien R, Jensen HE, et al.
    The avian influenza A virus receptor SA-alpha2,3-Gal is expressed in the porcine nasal mucosa sustaining the pig as a mixing vessel for new influenza viruses.
    Virus Res. 2023 Dec 22:199304. doi: 10.1016/j.virusres.2023.199304.
    PubMed: https://www.amedeo.com/p2.php?id=38142890&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38142890

https://etidioh.wordpress.com/2023/12/30/influenza-and-covid19-research-references-by-amedeo-december-30-23/

#COVID19 #flu #health #influenza #influenzaA #research #seasonalInfluenza #vaccine

1. NGO B, Rendell MS.
   Major Update: Masks for Prevention of SARS-CoV-2 in Health Care and Community
   Settings.
   Ann Intern Med. 2023;176:eL230358.
   PubMed: https://www.amedeo.com/p2.php?id=38109756&s=flu&pm=2
    
   Share: https://m.amedeo.com/38109756
2. BROWN TS, Mohareb AM, LaRocque RC.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230347.
   PubMed: https://www.amedeo.com/p2.php?id=38109751&s=flu&pm=2
    
   Share: https://m.amedeo.com/38109751
3. REZNICK SE.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230346.
   PubMed: https://www.amedeo.com/p2.php?id=38109749&s=flu&pm=2
    
   Share: https://m.amedeo.com/38109749
4. JIRMANUS LZ, Schwartzmann EG, Davids JD, Gullette MM, et al.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230350.
   PubMed: https://www.amedeo.com/p2.php?id=38109748&s=flu&pm=2
    
   Share: https://m.amedeo.com/38109748
5. SHENOY ES, Doron S, Branch-Elliman W.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230351.
   PubMed: https://www.amedeo.com/p2.php?id=38109747&s=flu&pm=2
    
   Share: https://m.amedeo.com/38109747
6. ALTMANN DM, Pagel C.
   Long covid: where are we, what does it say about our pandemic response, and where
   next?
   BMJ. 2023;383:p2972.
   PubMed: https://www.amedeo.com/p2.php?id=38114255&s=flu&pm=2
    
   Share: https://m.amedeo.com/38114255
7. IACOBUCCI G.
   Flu and covid levels rise in England.
   BMJ. 2023;383:p2965.
   PubMed: https://www.amedeo.com/p2.php?id=38114251&s=flu&pm=2
    
   Share: https://m.amedeo.com/38114251
8. IACOBUCCI G.
   Covid-19: Bereaved families group collects BMJ award for holding ministers to
   account.
   BMJ. 2023;383:2955.
   PubMed: https://www.amedeo.com/p2.php?id=38101907&s=flu&pm=2
    
   Share: https://m.amedeo.com/38101907
9. BALABAN N, Mohyuddin GR, Kashi A, Massarweh A, et al.
   Projecting complete redaction of clinical trial protocols (RAPTURE): redacted
   cross sectional study.
   BMJ. 2023;383:e077329.
   PubMed: https://www.amedeo.com/p2.php?id=38097263&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38097263
10. IACOBUCCI G.
    Covid inquiry: What did Johnson say about underestimated risks, excess deaths,
    and his missing WhatsApps?
    BMJ. 2023;383:2914.
    PubMed: https://www.amedeo.com/p2.php?id=38081644&s=flu&pm=2
     
    Share: https://m.amedeo.com/38081644
11. KHAN D, Fox PL.
    Aminoacyl-tRNA synthetase interactions in SARS-CoV-2 infection.
    Biochem Soc Trans. 2023;51:2127-2141.
    PubMed: https://www.amedeo.com/p2.php?id=38108455&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38108455
12. BROGAN DJ, Akbari OS.
    CRISPR Diagnostics: Advances toward the Point of Care.
    Biochemistry. 2023;62:3488-3492.
    PubMed: https://www.amedeo.com/p2.php?id=35325535&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/35325535
13. CHAVES-BLANCO L, de Salazar A, Fuentes A, Vinuela L, et al.
    Evaluation of a combined detection of SARS-CoV-2 and its variants using real-time
    allele-specific PCR strategy: an advantage for clinical practice.
    Epidemiol Infect. 2023;151:e201.
    PubMed: https://www.amedeo.com/p2.php?id=37997654&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997654
14. GULLE BT, Oren MM, Dal T.
    COVID-19 vaccine hesitancy in Turkey: A systematic review and meta-analysis.
    Epidemiol Infect. 2023;151:e199.
    PubMed: https://www.amedeo.com/p2.php?id=37997650&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997650
15. SEGHEZZO G, Nash SG, Aziz NA, Hope R, et al.
    Risk of severe outcomes among Omicron sub-lineages BA.4.6, BA.2.75, and BQ.1
    compared to BA.5 in England.
    Epidemiol Infect. 2023;151:e189.
    PubMed: https://www.amedeo.com/p2.php?id=37905583&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37905583
16. HALEVI A, Shkalim Zemer V, Embar T, Jacobson E, et al.
    Attitudes toward COVID-19 vaccination of healthcare workers in Israel and
    vaccination rates during vaccine rollout.
    Epidemiol Infect. 2023;151:e132.
    PubMed: https://www.amedeo.com/p2.php?id=37482675&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37482675
17. OMIYALE W, Holliday J, Doherty N, Callen H, et al.
    Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank
    SARS-CoV-2 Serology Study.
    J Epidemiol Community Health. 2023;78:3-10.
    PubMed: https://www.amedeo.com/p2.php?id=37699665&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37699665
18. YAMAMOTO S, Matsuda K, Maeda K, Horii K, et al.
    Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and
    Long COVID: A Propensity Score-Matched Analysis.
    J Infect Dis. 2023;228:1652-1661.
    PubMed: https://www.amedeo.com/p2.php?id=37756608&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37756608
19. PENETRA SLS, Santos HFP, Resende PC, Bastos LS, et al.
    SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de
    Janeiro.
    J Infect Dis. 2023;228:1680-1689.
    PubMed: https://www.amedeo.com/p2.php?id=37571849&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37571849
20. CHENE A, Desrames A, Tomlinson A, Ruffie C, et al.
    An ACE2-Based Bimodular Fusion Protein Enables Reorientation of Endogenous
    Anti-Epstein-Barr Virus Antibodies Toward SARS-CoV-2 Spike.
    J Infect Dis. 2023;228:1675-1679.
    PubMed: https://www.amedeo.com/p2.php?id=37562051&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37562051
21. VAN SLAMBROUCK J, Schoenaers C, Laenen L, Jin X, et al.
    The value of point-of-care tests for the detection of SARS-CoV-2 RNA or antigen
    in bronchoalveolar lavage fluid.
    J Virol Methods. 2024;323:114848.
    PubMed: https://www.amedeo.com/p2.php?id=37944670&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37944670
22. WANI AK, Chopra C, Dhanjal DS, Akhtar N, et al.
    Metagenomics in the fight against zoonotic viral infections: A focus on
    SARS-CoV-2 analogues.
    J Virol Methods. 2024;323:114837.
    PubMed: https://www.amedeo.com/p2.php?id=37914040&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37914040
23. CHARLIER P.
    Death and end of life in France after COVID-19.
    Lancet. 2023;402:2290.
    PubMed: https://www.amedeo.com/p2.php?id=38103938&s=flu&pm=2
     
    Share: https://m.amedeo.com/38103938
24. HORTON R.
    Offline: Boris Johnson and COVID-19-more light than heat.
    Lancet. 2023;402:2277.
    PubMed: https://www.amedeo.com/p2.php?id=38103935&s=flu&pm=2
     
    Share: https://m.amedeo.com/38103935
25. BLACK CL, Kriss JL, Razzaghi H, Patel SA, et al.
    Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage
    Among Adults – United States, Fall 2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:1377-1382.
    PubMed: https://www.amedeo.com/p2.php?id=38127675&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127675
26. RESES HE, Dubendris H, Haas L, Barbre K, et al.
    Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19
    Vaccines Among Nursing Home Residents – National Healthcare Safety Network,
    United States, December 2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:1371-1376.
    PubMed: https://www.amedeo.com/p2.php?id=38127673&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127673
27. Covid Update: ITT Episode 23.
    N Engl J Med. 2023;389:e52.
    PubMed: https://www.amedeo.com/p2.php?id=38118021&s=flu&pm=2
     
    Share: https://m.amedeo.com/38118021
28. COHN AC, Hall AJ.
    Continued Progress in the Development of Safe and Effective RSV Immunizations.
    N Engl J Med. 2023;389:2289-2290.
    PubMed: https://www.amedeo.com/p2.php?id=38091535&s=flu&pm=2
     
    Share: https://m.amedeo.com/38091535
29. RAO X, Zhao R, Tong Z, Guo S, et al.
    Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of
    immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2023;120:e2314193120.
    PubMed: https://www.amedeo.com/p2.php?id=38109549&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38109549
30. NAPOLI L, Sekara V, Garcia-Herranz M, Karsai M, et al.
    Socioeconomic reorganization of communication and mobility networks in response
    to external shocks.
    Proc Natl Acad Sci U S A. 2023;120:e2305285120.
    PubMed: https://www.amedeo.com/p2.php?id=38060564&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38060564
31. ZHANG H, Wang Z, Nguyen HTT, Watson AJ, et al.
    Integrin alpha(5)beta(1) contributes to cell fusion and inflammation mediated by
    SARS-CoV-2 spike via RGD-independent interaction.
    Proc Natl Acad Sci U S A. 2023;120:e2311913120.
    PubMed: https://www.amedeo.com/p2.php?id=38060559&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38060559
32. DAWA J, Jalang’o R, Mirieri H, Kalani R, et al.
    Comparing performance of year-round and campaign-mode influenza vaccination
    strategies among children aged 6-23 months in Kenya: 2019-2021.
    Vaccine. 2023 Dec 16:S0264-410X(23)01380-4. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=38105140&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38105140
33. JACKSON LA, Stapleton JT, Walter EB, Chen WH, et al.
    Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9
    inactivated vaccine given with and without AS03 adjuvant in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01434-2. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=38105137&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38105137
34. JIANG W, Lu C, Yan X, Tucker JD, et al.
    Vaccine confidence mediates the association between a pro-social pay-it-forward
    intervention and improved influenza vaccine uptake in China: A mediation
    analysis.
    Vaccine. 2023 Dec 15:S0264-410X(23)01392-0. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=38103961&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38103961
35. VASHI MD, Watkins M.
    Missed opportunities: Reducing zero dose children amongthe urban poor after
    COVID, Mumbai India, 2022.
    Vaccine. 2024;42:59-63.
    PubMed: https://www.amedeo.com/p2.php?id=38016846&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38016846
36. MIRIERI H, Nasimiyu C, Dawa J, Mburu C, et al.
    Resilience of routine childhood immunization services in two counties in Kenya in
    the face of the COVID-19 pandemic.
    Vaccine. 2023;41:7695-7704.
    PubMed: https://www.amedeo.com/p2.php?id=38008664&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38008664
37. TANG C, Carrera Montoya J, Fritzlar S, Flavel M, et al.
    Polyphenol rich sugarcane extract (PRSE) has potential antiviral activity against
    influenza A virus in vitro.
    Virology. 2023;590:109969.
    PubMed: https://www.amedeo.com/p2.php?id=38118269&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38118269
38. ZHANG Y, Wang D, Xiang Q, Hu X, et al.
    A potent neutralizing nanobody targeting a unique epitope on the receptor-binding
    domain of SARS-CoV-2 spike protein.
    Virology. 2024;589:109925.
    PubMed: https://www.amedeo.com/p2.php?id=37984151&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37984151
39. KODSI IA, Rayes DE, Koweyes J, Khoury CA, et al.
    Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon.
    Virus Res. 2024;339:199289.
    PubMed: https://www.amedeo.com/p2.php?id=38036064&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38036064
40. CHRIST W, Klingstrom J, Tynell J.
    SARS-CoV-2 variant-specific differences in inhibiting the effects of the
    PKR-activated integrated stress response.
    Virus Res. 2024;339:199271.
    PubMed: https://www.amedeo.com/p2.php?id=37979658&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37979658
41. CAI Z, Bai H, Ren D, Xue B, et al.
    Integrin alphavbeta1 facilitates ACE2-mediated entry of SARS-CoV-2.
    Virus Res. 2024;339:199251.
    PubMed: https://www.amedeo.com/p2.php?id=37884208&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37884208
42. TONG X, Keung W, Arnold LD, Stevens LJ, et al.
    Evaluation of in vitro antiviral activity of SARS-CoV-2 M(pro) inhibitor
    pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.
    Antimicrob Agents Chemother. 2023;67:e0084023.
    PubMed: https://www.amedeo.com/p2.php?id=37800975&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37800975

https://etidioh.wordpress.com/2023/12/25/influenza-and-covid19-research-references-by-amedeo-december-25-13/

#avianInfluenza #cdc #COVID19 #flu #health #influenza #research #seasonalInfluenza

1. CENTOR RM, Kotton CN.
   Annals On Call – Protecting Adults Against Respiratory Syncytial Virus Infection.
   Ann Intern Med. 2023;176:eA220022.
   PubMed: https://www.amedeo.com/p2.php?id=38059933&s=flu&pm=2
    
   Share: https://m.amedeo.com/38059933
2. APAA T, Withers AJ, Mackenzie L, Staley C, et al.
   Lack of detection of SARS-CoV-2 in British wildlife 2020-21 and first description
   of a stoat (Mustela erminea) Minacovirus.
   J Gen Virol. 2023;104.
   PubMed: https://www.amedeo.com/p2.php?id=38059490&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38059490
3. HSIAO A, Yee A, Fireman B, Hansen J, et al.
   Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age.
   N Engl J Med. 2023;389:2245-2255.
   PubMed: https://www.amedeo.com/p2.php?id=38091531&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38091531
4. STUMPFF JP 2ND, Kim SY, McFadden MI, Nishida A, et al.
   Pleural macrophages translocate to the lung during infection to promote improved
   influenza outcomes.
   Proc Natl Acad Sci U S A. 2023;120:e2300474120.
   PubMed: https://www.amedeo.com/p2.php?id=38100417&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38100417
5. DONG C, Ma Y, Zhu W, Wang Y, et al.
   Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection
   against heterosubtypic infection in mice.
   Vaccine. 2023 Dec 14:S0264-410X(23)01485-8. doi: 10.1016/j.vaccine.2023.
   PubMed: https://www.amedeo.com/p2.php?id=38097456&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38097456
6. OPRIESSNIG T, Gauger PC, Filippsen Favaro P, Rawal G, et al.
   An experimental universal swine influenza a virus (IAV) vaccine candidate based
   on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV
   challenge in pigs.
   Vaccine. 2023 Dec 11:S0264-410X(23)01445-7. doi: 10.1016/j.vaccine.2023.
   PubMed: https://www.amedeo.com/p2.php?id=38087714&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38087714
7. AKMATOVA R, Dzhangaziev B, Ebama MS, Otorbaeva D, et al.
   Knowledge, attitudes, and practices (KAP) towards seasonal influenza and
   influenza vaccine among pregnant women in Kyrgyzstan: A cross-sectional study.
   Vaccine. 2023 Dec 9:S0264-410X(23)01453-6. doi: 10.1016/j.vaccine.2023.
   PubMed: https://www.amedeo.com/p2.php?id=38072755&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38072755
8. BIALY D, Richardson S, Chrzastek K, Bhat S, et al.
   Recombinant A(H6N1)-H274Y avian influenza virus with dual drug resistance does
   not require permissive mutations to retain the replicative fitness in vitro and
   in ovo.
   Virology. 2023;590:109954.
   PubMed: https://www.amedeo.com/p2.php?id=38086284&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38086284

https://etidioh.wordpress.com/2023/12/16/influenza-and-covid19-research-references-by-amedeo-december-16-23/

#avianInfluenza #COVID19 #flu #fluShot #fluVaccine #influenza #influenzaA #research #seasonalInfluenza #vaccine

1. IOANNOU GN, Berry K, Rajeevan N, Li Y, et al.
   Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
   Ann Intern Med. 2023 Oct 31. doi: 10.7326/M23-1394.
   PubMed: https://www.amedeo.com/p2.php?id=37903369&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37903369
2. WU CY, Tseng YC, Kao SE, Wu LY, et al.
   Monoglycosylated SARS-CoV-2 receptor binding domain fused with
   HA(stem)-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses.
   Antiviral Res. 2023 Nov 18:105759. doi: 10.1016/j.antiviral.2023.105759.
   PubMed: https://www.amedeo.com/p2.php?id=37984568&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37984568
3. ABDUL-KAREEM HH, Al-Maqtoofi MY, Burghal AA.
   Impact of COVID-19 vaccination on saliva immune barriers: IgA, lysozyme, and lactoferrin.
   Arch Virol. 2023;168:293.
   PubMed: https://www.amedeo.com/p2.php?id=37973637&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37973637
4. LUNDBERG-MORRIS L, Leach S, Xu Y, Martikainen J, et al.
   Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study.
   BMJ. 2023;383:e076990.
   PubMed: https://www.amedeo.com/p2.php?id=37993131&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37993131
5. SHIN GY.
   Covid-19: excess death rates and the cost of living crisis.
   BMJ. 2023;383:p2612.
   PubMed: https://www.amedeo.com/p2.php?id=37957011&s=flu&pm=2
    
   Share: https://m.amedeo.com/37957011
6. HAM C.
   What have we learnt from the covid-19 inquiry so far?
   BMJ. 2023;383:p2654.
   PubMed: https://www.amedeo.com/p2.php?id=37957007&s=flu&pm=2
    
   Share: https://m.amedeo.com/37957007
7. KAWAHARA E, Yamamoto S, Shibata T, Hirai T, et al.
   CpG ODN enhances the efficacy of F protein vaccine against respiratory syncytial virus infection in the upper respiratory tract via CD4(+) T cells.
   Biochem Biophys Res Commun. 2023;686:149143.
   PubMed: https://www.amedeo.com/p2.php?id=37926041&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37926041
8. MERINO P, Kupferwasser D, Flores EA, Phan Tran D, et al.
   Skin and soft tissue infection incidence before and during the COVID-19 pandemic.
   Epidemiol Infect. 2023;151:e190.
   PubMed: https://www.amedeo.com/p2.php?id=37929620&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37929620
9. FLANNAGAN J, Chudasama DY, Hope R, Collin SM, et al.
   Attribution of nosocomial seeding to long-term care facility COVID-19 outbreaks.
   Epidemiol Infect. 2023;151:e191.
   PubMed: https://www.amedeo.com/p2.php?id=37876042&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37876042
10. ANDERSON R.
    Measuring mortality arising from the Covid-19 pandemic and the impact of vaccination.
    Eur J Epidemiol. 2023;38:1119-1123.
    PubMed: https://www.amedeo.com/p2.php?id=37924454&s=flu&pm=2
     
    Share: https://m.amedeo.com/37924454
11. JIA KM, Hanage WP, Lipsitch M, Johnson AG, et al.
    Estimated preventable COVID-19-associated deaths due to non-vaccination in the United States.
    Eur J Epidemiol. 2023;38:1125-1128.
    PubMed: https://www.amedeo.com/p2.php?id=37093505&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37093505
12. LEVITT M, Zonta F, Ioannidis JPA.
    Excess death estimates from multiverse analysis in 2009-2021.
    Eur J Epidemiol. 2023;38:1129-1139.
    PubMed: https://www.amedeo.com/p2.php?id=37043153&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37043153
13. RAO A, Westbrook A, Bassit L, Parsons R, et al.
    Sensitivity of rapid antigen tests against SARS-CoV-2 Omicron and Delta variants.
    J Clin Microbiol. 2023;61:e0013823.
    PubMed: https://www.amedeo.com/p2.php?id=37728336&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37728336
14. LOBBY JL, Danzy S, Holmes KE, Lowen AC, et al.
    Both Humoral and Cellular Immunity Limit the Ability of Live Attenuated Influenza Vaccines to Promote T Cell Responses.
    J Immunol. 2023 Nov 20:ji2300343. doi: 10.4049/jimmunol.2300343.
    PubMed: https://www.amedeo.com/p2.php?id=37982700&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37982700
15. TONG X, Deng Y, Cizmeci D, Fontana L, et al.
    Distinct Functional Humoral Immune Responses Are Induced after Live Attenuated and Inactivated Seasonal Influenza Vaccination.
    J Immunol. 2024 Nov 17:ji2200956. doi: 10.4049/jimmunol.2200956.
    PubMed: https://www.amedeo.com/p2.php?id=37975667&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37975667
16. LU X, Liu F, Tzeng WP, York IA, et al.
    Antibody-mediated Suppression Regulates the Humoral Immune Response to Influenza Vaccination in Humans.
    J Infect Dis. 2023 Nov 20:jiad493. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37981659&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37981659
17. JI W, Guthmiller J.
    Goldilocks zone of preexisting immunity: too little or too much suppresses diverse antibody responses against influenza viruses.
    J Infect Dis. 2023 Nov 18:jiad494. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37979157&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37979157
18. HARRIS E.
    Long COVID Linked With Viral Persistence, Serotonin Decline.
    JAMA. 2023;330:1827.
    PubMed: https://www.amedeo.com/p2.php?id=37910132&s=flu&pm=2
     
    Share: https://m.amedeo.com/37910132
19. HARRIS E.
    Audit Finds US National Stockpile “Was Not Equipped” for the Pandemic.
    JAMA. 2023;330:1828.
    PubMed: https://www.amedeo.com/p2.php?id=37910119&s=flu&pm=2
     
    Share: https://m.amedeo.com/37910119
20. WANG Q, Bowen A, Ho J, Zhang RM, et al.
    SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster.
    Lancet. 2023 Oct 31:S0140-6736(23)02278-X. doi: 10.1016/S0140-6736(23)02278.
    PubMed: https://www.amedeo.com/p2.php?id=37922920&s=flu&pm=2
     
    Share: https://m.amedeo.com/37922920
21. CEJTIN HE, Warren EF, Guidry T, Boss K, et al.
    Notes from the Field: Diagnosis of Congenital Syphilis and Syphilis Among Females of Reproductive Age Before and During the COVID-19 Pandemic – Chicago, 2015-2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:1288-1289.
    PubMed: https://www.amedeo.com/p2.php?id=37991996&s=flu&pm=2
     
    Share: https://m.amedeo.com/37991996
22. MINTA AA, Ferrari M, Antoni S, Portnoy A, et al.
    Progress Toward Measles Elimination – Worldwide, 2000-2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:1262-1268.
    PubMed: https://www.amedeo.com/p2.php?id=37971951&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37971951
23. ESPINOZA B, Adiga A, Venkatramanan S, Warren AS, et al.
    Coupled models of genomic surveillance and evolving pandemics with applications for timely public health interventions.
    Proc Natl Acad Sci U S A. 2023;120:e2305227120.
    PubMed: https://www.amedeo.com/p2.php?id=37983514&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37983514
24. LAW AW, Judy J, Atwell JE, Willis S, et al.
    Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the future.
    Vaccine. 2023 Nov 21:S0264-410X(23)01307-5. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37993354&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37993354
25. HAEDER SF.
    Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in the United States in late 2023.
    Vaccine. 2023 Nov 15:S0264-410X(23)01303-8. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37977941&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37977941
26. AMITAI N, Wertheimer R, Prais D, Wertheimer KO, et al.
    Influenza vaccination in children with pulmonary disease during the COVID-19 pandemic.
    Vaccine. 2023 Nov 15:S0264-410X(23)01338-5. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37977938&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37977938
27. JAMES WG, Stanberry LR, LaRussa PS, Grodman MD, et al.
    Vaccines and global health: COVID-19 vaccine development, strategy, and implementation symposium – Summary of the meeting at Vagelos College of Physicians and Surgeons (February 22-26, 2021, New York).
    Vaccine. 2023 Nov 1:S0264-410X(23)01254-9. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37923696&s=flu&pm=2
     
    Share: https://m.amedeo.com/37923696
28. CHEN GL, Yu XY, Luo LP, Zhang F, et al.
    Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
    Vaccine. 2023 Nov 2:S0264-410X(23)01278-1. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37925316&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37925316
29. SALLOUM M, Paviotti A, Bastiaens H, Van Geertruyden JP, et al.
    The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials’ records between 2018 and 2023.
    Vaccine. 2023 Oct 28:S0264-410X(23)01259-8. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37903681&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37903681
30. LIU Y, Sanchez-Ovando S, Carolan L, Dowson L, et al.
    Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
    Vaccine. 2023 Oct 28:S0264-410X(23)01217-3. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37903679&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37903679
31. WALLIAR T, Khan B, Newstead S, Al-Assadi G, et al.
    “Fighting the pandemic!” Western Australian pharmacists’ perspectives on COVID-19 vaccines: A qualitative study.
    Vaccine. 2023 Oct 25:S0264-410X(23)01243-4. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37891049&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37891049
32. ANASTASSOPOULOU C, Boufidou F, Hatziantoniou S, Vasileiou K, et al.
    Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01214-8. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37891048&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37891048
33. FLOR N, Garcia MI, Molineri A, Bottasso O, et al.
    Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01221-5. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37884413&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37884413
34. MCCLYMONT E, Atkinson A, Albert A, Av-Gay G, et al.
    Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19 vaccination during pregnancy in Canada: A national prospective cohort study.
    Vaccine. 2023 Oct 19:S0264-410X(23)01215-X. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37865598&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37865598
35. HAEDER SF.
    U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic.
    Vaccine. 2023 Oct 17:S0264-410X(23)01188-X. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37858447&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37858447
36. YANG H, Wang Z, Zhang Y, Xu M, et al.
    Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron
    subvariant BF.7 among outpatients in Beijing, China.
    Vaccine. 2023 Oct 17:S0264-410X(23)01219-7. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37852869&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37852869
37. FITZPATRICK MC, Laufer RS, Baral R, Driscoll AJ, et al.
    Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income
    countries, April 7-8, 2022.
    Vaccine. 2023;41:7047-7059.
    PubMed: https://www.amedeo.com/p2.php?id=37777450&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37777450
38. RAMEY AM, Scott LC, Ahlstrom CA, Buck EJ, et al.
    Molecular detection and characterization of highly pathogenic H5N1 clade 2.3.4.4b avian influenza viruses among hunter-harvested wild birds provides evidence for three independent introductions into Alaska.
    Virology. 2023;589:109938.
    PubMed: https://www.amedeo.com/p2.php?id=37977084&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37977084
39. LI X, Ye Z, Plant EP.
    5′ copyback defective viral genomes are major component in clinical and non-clinical influenza samples.
    Virus Res. 2023;339:199274.
    PubMed: https://www.amedeo.com/p2.php?id=37981214&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37981214

*** End ***

https://etidioh.wordpress.com/2023/11/25/influenza-and-covid19-research-references-by-amedeo-november-25-23/

#avianInfluenza #COVID19 #influenzaA #research #seasonalInfluenza

1. PALLA SR, Li CW, Chao TL, Lo HV, et al.
   Synthesis, evaluation, and mechanism of
   1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent
   reversible SARS-CoV-2 entry inhibitors.
   Antiviral Res. 2023 Oct 17:105735. doi: 10.1016/j.antiviral.2023.105735.
   PubMed: https://www.amedeo.com/p2.php?id=37858764&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37858764
2. LUGANINI A, Sibille G, Pavan M, Mello Grand M, et al.
   Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against
   respiratory syncytial virus replication.
   Antiviral Res. 2023;219:105734.
   PubMed: https://www.amedeo.com/p2.php?id=37852322&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37852322
3. KONKEL R, Milewska A, Do NDT, Barreto Duran E, et al.
   Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411.
   Antiviral Res. 2023 Oct 12:105731. doi: 10.1016/j.antiviral.2023.105731.
   PubMed: https://www.amedeo.com/p2.php?id=37838220&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37838220
4. WAN L, Li L, Zhang H, Liu C, et al.
   The changing pattern of common respiratory viruses among children from 2018 to
   2021 in Wuhan, China.
   Arch Virol. 2023;168:291.
   PubMed: https://www.amedeo.com/p2.php?id=37962775&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37962775
5. MEIJERS M, Ruchnewitz D, Eberhardt J, Luksza M, et al.
   Population immunity predicts evolutionary trajectories of SARS-CoV-2.
   Cell. 2023;186:5151-5164.
   PubMed: https://www.amedeo.com/p2.php?id=37875109&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37875109
6. WIMMERS F, Burrell AR, Feng Y, Zheng H, et al.
   Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth.
   Cell. 2023;186:4632-4651.
   PubMed: https://www.amedeo.com/p2.php?id=37776858&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37776858
7. DAVID JA, Kolipakkam B, Morales MK, Vissichelli NC, et al.
   Cell-free plasma next-generation sequencing assists in the evaluation of
   secondary pneumonia in patients with COVID-19: a case series.
   Epidemiol Infect. 2023;151:e185.
   PubMed: https://www.amedeo.com/p2.php?id=37886888&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37886888
8. RODRIGUEZ-DEL-RIO FJ, Barroso P, Fernandez-de-Mera IG, de la Fuente J, et al.
   COVID-19 epidemiology and rural healthcare: a survey in a Spanish village.
   Epidemiol Infect. 2023;151:e188.
   PubMed: https://www.amedeo.com/p2.php?id=37886846&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37886846
9. MIALL N, Pearce A, Moore JC, Benzeval M, et al.
   Inequalities in children’s mental health before and during the COVID-19 pandemic:
   findings from the UK Household Longitudinal Study.
   J Epidemiol Community Health. 2023;77:762-769.
   PubMed: https://www.amedeo.com/p2.php?id=37748928&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37748928
10. RANDALL RE, Young DF, Hughes DJ, Goodbourn S, et al.
    Persistent paramyxovirus infections: in co-infections the parainfluenza virus
    type 5 persistent phenotype is dominant over the lytic phenotype.
    J Gen Virol. 2023;104.
    PubMed: https://www.amedeo.com/p2.php?id=37962188&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37962188
11. GRAND RJ.
    SARS-CoV-2 and the DNA damage response.
    J Gen Virol. 2023;104.
    PubMed: https://www.amedeo.com/p2.php?id=37948194&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37948194
12. ZHONG S, Ng TWY, Skowronski DM, Iuliano AD, et al.
    Standard-dose versus MF59-adjuvanted, high-dose or recombinant-hemagglutinin
    influenza vaccine immunogenicity in older adults: comparison of A(H3N2) antibody
    response by prior season’s vaccine status.
    J Infect Dis. 2023 Nov 10:jiad497. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37950884&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37950884
13. LASRADO N, Barouch DH.
    SARS-CoV-2 Hybrid Immunity: The Best of Both Worlds.
    J Infect Dis. 2023;228:1311-1313.
    PubMed: https://www.amedeo.com/p2.php?id=37592872&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37592872
14. NOBLE CC, Messina NL, Pittet LF, Curtis N, et al.
    Interpreting the results of trials of BCG vaccination for protection against
    COVID-19.
    J Infect Dis. 2023 Aug 10:jiad316. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37558650&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37558650
15. YOON JG, Kim YE, Choi MJ, Choi WS, et al.
    Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease
    2019 vaccination: Analysis of National Health Insurance Database.
    J Infect Dis. 2023 Aug 7:jiad297. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37549237&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37549237
16. LIU J, Cao F, Luo C, Guo Y, et al.
    Stroke Following COVID-19 Vaccination: Evidence Based on Different Designs of
    Real-World Studies.
    J Infect Dis. 2023 Aug 3:jiad306. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37536364&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37536364
17. LOWENSTEYN YN, Zheng Z, Rave N, Bannier MAGE, et al.
    Year-Round Respiratory Syncytial Virus Transmission in The Netherlands Following
    the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study.
    J Infect Dis. 2023;228:1394-1399.
    PubMed: https://www.amedeo.com/p2.php?id=37477906&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37477906
18. JITTAMALA P, Schilling WHK, Watson JA, Luvira V, et al.
    Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An
    Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV).
    J Infect Dis. 2023;228:1318-1325.
    PubMed: https://www.amedeo.com/p2.php?id=37470445&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37470445
19. KYO M, Zhu Z, Shibata R, Fujiogi M, et al.
    Respiratory Virus-Specific Nasopharyngeal Lipidome Signatures and Severity in
    Infants With Bronchiolitis: A Prospective Multicenter Study.
    J Infect Dis. 2023;228:1410-1420.
    PubMed: https://www.amedeo.com/p2.php?id=37166169&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37166169
20. NAKAJO K, Nishiura H.
    Age-Dependent Risk of Respiratory Syncytial Virus Infection: A Systematic Review
    and Hazard Modeling From Serological Data.
    J Infect Dis. 2023;228:1400-1409.
    PubMed: https://www.amedeo.com/p2.php?id=37161934&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37161934
21. ELFAYRES G, Paswan RR, Sika L, Girard MP, et al.
    Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like
    particles.
    J Virol Methods. 2023;322:114835.
    PubMed: https://www.amedeo.com/p2.php?id=37871706&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37871706
22. LOWRY K, Bauer MJ, Buckley C, Wang C, et al.
    Evaluation of Illumina(R) COVIDSeq as a tool for Omicron SARS-CoV-2
    characterisation.
    J Virol Methods. 2023;322:114827.
    PubMed: https://www.amedeo.com/p2.php?id=37778540&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37778540
23. MOGLING R, Reimerink J, Stanoeva KR, Keramarou M, et al.
    Comparative study between virus neutralisation testing and other serological
    methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021.
    J Virol Methods. 2023;322:114825.
    PubMed: https://www.amedeo.com/p2.php?id=37778539&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37778539
24. ADHIKARI NKJ, Hashmi M, Tirupakuzhi Vijayaraghavan BK, Haniffa R, et al.
    Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized
    Randomized Clinical Trials.
    JAMA. 2023 Oct 25:e2321407. doi: 10.1001/jama.2023.21407.
    PubMed: https://www.amedeo.com/p2.php?id=37877585&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37877585
25. JABALEY CS, Coopersmith CM.
    Vitamin C for Patients With COVID-19: More Evidence of Lack of Efficacy in
    Patients With Sepsis.
    JAMA. 2023 Oct 25. doi: 10.1001/jama.2023.18592.
    PubMed: https://www.amedeo.com/p2.php?id=37877584&s=flu&pm=2
     
    Share: https://m.amedeo.com/37877584
26. GRABAR-KITAROVIC K, Phumaphi J.
    A crisis of trust in pandemic prevention, preparedness, and response.
    Lancet. 2023;402:1730-1732.
    PubMed: https://www.amedeo.com/p2.php?id=37918412&s=flu&pm=2
     
    Share: https://m.amedeo.com/37918412
27. SEITHER R, Yusuf OB, Dramann D, Calhoun K, et al.
    Coverage with Selected Vaccines and Exemption from School Vaccine Requirements
    Among Children in Kindergarten – United States, 2022-23 School Year.
    MMWR Morb Mortal Wkly Rep. 2023;72:1217-1224.
    PubMed: https://www.amedeo.com/p2.php?id=37943705&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943705
28. CHEN Y, Lei X, Jiang Z, Humphries F, et al.
    Cellular nucleic acid-binding protein restricts SARS-CoV-2 by regulating
    interferon and disrupting RNA-protein condensates.
    Proc Natl Acad Sci U S A. 2023;120:e2308355120.
    PubMed: https://www.amedeo.com/p2.php?id=37963251&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37963251
29. ALTMEJD A, Ostergren O, Bjorkegren E, Persson T, et al.
    Inequality and COVID-19 in Sweden: Relative risks of nine bad life events, by
    four social gradients, in pandemic vs. prepandemic years.
    Proc Natl Acad Sci U S A. 2023;120:e2303640120.
    PubMed: https://www.amedeo.com/p2.php?id=37943837&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943837
30. CUBIZOLLES C, Barjat T, Chauleur C, Bruel S, et al.
    Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis
    and to get a future vaccine against respiratory syncytial virus in pregnant
    women.
    Vaccine. 2023 Nov 12:S0264-410X(23)01280-X. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37957038&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37957038
31. JIANG X, Wang J, Li C, Yeoh EK, et al.
    Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal
    influenza vaccination in Hong Kong: A cross-sectional study.
    Vaccine. 2023 Nov 11:S0264-410X(23)01304-X. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37953098&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37953098
32. GRABENSTEIN JD, Ferrara P, Mantovani LG, McGovern I, et al.
    Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of
    adjuvanted influenza vaccine.
    Vaccine. 2023 Nov 10:S0264-410X(23)01302-6. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37953097&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37953097
33. FLEMING JA, Baral R, Higgins D, Khan S, et al.
    Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
    Vaccine. 2023 Jul 6:S0264-410X(22)01212-9. doi: 10.1016/j.vaccine.2022.
    PubMed: https://www.amedeo.com/p2.php?id=37422378&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37422378
34. NAIQING X, Tang X, Wang X, Cai M, et al.
    Hemagglutinin affects replication, stability and airborne transmission of the
    H9N2 subtype avian influenza virus.
    Virology. 2023;589:109926.
    PubMed: https://www.amedeo.com/p2.php?id=37952465&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37952465
35. ZHU M, Zeng H, He J, Zhu Y, et al.
    Reassortant H9N2 canine influenza viruses containing the pandemic H1N1/2009
    ribonucleoprotein complex circulating in pigs acquired enhanced virulence in
    mice.
    Virology. 2023;589:109927.
    PubMed: https://www.amedeo.com/p2.php?id=37951087&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37951087
36. ANTOON JW, Sarker J, Abdelaziz A, Lien PW, et al.
    Trends in Outpatient Influenza Antiviral Use Among Children and Adolescents in
    the United States.
    Pediatrics. 2023 Nov 13:e2023061960. doi: 10.1542/peds.2023-061960.
    PubMed: https://www.amedeo.com/p2.php?id=37953658&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37953658
37. PANNARAJ PS.
    Influenza Antivirals in Pediatrics: Why Aren’t We Using All the Available Tools?
    Pediatrics. 2023 Nov 13:e2023063481. doi: 10.1542/peds.2023-063481.
    PubMed: https://www.amedeo.com/p2.php?id=37953646&s=flu&pm=2
     
    Share: https://m.amedeo.com/37953646

https://etidioh.wordpress.com/2023/11/18/influenza-and-covid19-research-references-by-amedeo-november-18-23/

#avianInfluenza #COVID19 #influenzaA #research #seasonalInfluenza

1. SOMMER I, Ledinger D, Thaler K, Dobrescu A, et al.
   Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for
   the American College of Physicians (Version 2).
   Ann Intern Med. 2023 Sep 19. doi: 10.7326/M23-1626.
   PubMed: https://www.amedeo.com/p2.php?id=37722115&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37722115
2. Web Exclusive. Annals Video Summary – Outpatient Treatment of Confirmed COVID-19.
   Ann Intern Med. 2023 Sep 19:eM232064. doi: 10.7326/M23-2064.
   PubMed: https://www.amedeo.com/p2.php?id=37722114&s=flu&pm=2
    
   Share: https://m.amedeo.com/37722114
3. TAYLOR L.
   Treatment of TB is recovering after covid-19 but well short of 2025 targets, says
   WHO.
   BMJ. 2023;383:p2618.
   PubMed: https://www.amedeo.com/p2.php?id=37940183&s=flu&pm=2
    
   Share: https://m.amedeo.com/37940183
4. LANG K.
   Is convalescent plasma still useful as a covid treatment?
   BMJ. 2023;383:p2185.
   PubMed: https://www.amedeo.com/p2.php?id=37940147&s=flu&pm=2
    
   Share: https://m.amedeo.com/37940147
5. SHEPHERD A.
   Covid NHS memorial is named year’s top statue.
   BMJ. 2023;383:p2594.
   PubMed: https://www.amedeo.com/p2.php?id=37931944&s=flu&pm=2
    
   Share: https://m.amedeo.com/37931944
6. DYER C.
   Covid-19: Whitehall chaos and misplaced confidence undermined UK’s response,
   inquiry hears.
   BMJ. 2023;383:p2576.
   PubMed: https://www.amedeo.com/p2.php?id=37923326&s=flu&pm=2
    
   Share: https://m.amedeo.com/37923326
7. BIRTLES D, Lee J.
   SARS-CoV-2 Fusion Domain Provides Clues toward the Molecular Mechanism for
   Membrane Fusion.
   Biochemistry. 2023;62:3033-3035.
   PubMed: https://www.amedeo.com/p2.php?id=37862606&s=flu&pm=2
    
   Share: https://m.amedeo.com/37862606
8. MICALLEF B, Dogne JM, Sultana J, Straus SMJM, et al.
   An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on
   Masking Signal Detection in EudraVigilance.
   Drug Saf. 2023;46:1089-1103.
   PubMed: https://www.amedeo.com/p2.php?id=37707778&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37707778
9. KIM JY, Lee WJ, Suh JW, Kim SB, et al.
   Clinical impact of COVID-19 in patients with carbapenem-resistant Acinetobacter
   baumannii bacteraemia.
   Epidemiol Infect. 2023;151:e180.
   PubMed: https://www.amedeo.com/p2.php?id=37814587&s=flu&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37814587
10. EVANS JP, Liu SL.
    Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming
    Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies.
    J Immunol. 2023;211:1459-1467.
    PubMed: https://www.amedeo.com/p2.php?id=37931210&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37931210
11. HEDSKOG C, Rodriguez L, Roychoudhury P, Huang ML, et al.
    Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment
    Trial-1 (ACTT-1).
    J Infect Dis. 2023;228:1263-1273.
    PubMed: https://www.amedeo.com/p2.php?id=37466213&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37466213
12. ROA CC, de Los Reyes MRA, Plennevaux E, Smolenov I, et al.
    Superior boosting of neutralizing titers against Omicron SARS-CoV-2 variants by
    heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed adults.
    J Infect Dis. 2023 Jul 13:jiad262. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37439701&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37439701
13. FERNANDEZ-GONZALEZ M, Agullo V, Garcia JA, Padilla S, et al.
    T-cell immunity against SARS-CoV-2 measured by an interferon-gamma release assay is
    strongly associated with patient outcomes in vaccinated persons hospitalized with
    Delta or Omicron variants.
    J Infect Dis. 2023 Jul 7:jiad260. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37418551&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37418551
14. WONG JY, Cheung JK, Lin Y, Bond HS, et al.
    Intrinsic and Effective Severity of Coronavirus Disease 2019 Cases Infected With
    the Ancestral Strain and Omicron BA.2 Variant in Hong Kong.
    J Infect Dis. 2023;228:1231-1239.
    PubMed: https://www.amedeo.com/p2.php?id=37368235&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37368235
15. EVANS MV, Ramiadantsoa T, Kauffman K, Moody J, et al.
    Sociodemographic Variables Can Guide Prioritized Testing Strategies for Epidemic
    Control in Resource-Limited Contexts.
    J Infect Dis. 2023;228:1189-1197.
    PubMed: https://www.amedeo.com/p2.php?id=36961853&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/36961853
16. HARRIS E.
    COVID-19 Hospitalizations Up Among Older Adults.
    JAMA. 2023 Oct 18. doi: 10.1001/jama.2023.19796.
    PubMed: https://www.amedeo.com/p2.php?id=37851487&s=flu&pm=2
     
    Share: https://m.amedeo.com/37851487
17. HARRIS E.
    Previous COVID-19 Linked With Autoimmune Conditions.
    JAMA. 2023 Oct 18. doi: 10.1001/jama.2023.19798.
    PubMed: https://www.amedeo.com/p2.php?id=37851485&s=flu&pm=2
     
    Share: https://m.amedeo.com/37851485
18. BELL J, Meng L, Barbre K, Haanschoten E, et al.
    Influenza and Up-to-Date COVID-19 Vaccination Coverage Among Health Care
    Personnel – National Healthcare Safety Network, United States, 2022-23 Influenza
    Season.
    MMWR Morb Mortal Wkly Rep. 2023;72:1237-1243.
    PubMed: https://www.amedeo.com/p2.php?id=37943704&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943704
19. LYMON H, Meng L, Reses HE, Barbre K, et al.
    Declines in Influenza Vaccination Coverage Among Health Care Personnel in Acute
    Care Hospitals During the COVID-19 Pandemic – United States, 2017-2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:1244-1247.
    PubMed: https://www.amedeo.com/p2.php?id=37943698&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943698
20. SPACKMAN E, Suarez DL, Lee CW, Pantin-Jackwood MJ, et al.
    Efficacy of inactivated and RNA particle vaccines against a North American Clade
    2.3.4.4b H5 highly pathogenic avian influenza virus in chickens.
    Vaccine. 2023 Nov 4:S0264-410X(23)01285-9. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37932132&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37932132
21. ALIZADEH M, Raj S, Shojadoost B, Matsuyama-Kato A, et al.
    In ovo administration of retinoic acid enhances cell-mediated immune responses
    against an inactivated H9N2 avian influenza virus vaccine.
    Vaccine. 2023 Nov 1:S0264-410X(23)01261-6. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37923694&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37923694
22. AKHTAR Z, Gotberg M, Erlinge D, Christiansen EH, et al.
    Optimal timing of influenza vaccination among patients with acute myocardial
    infarction – Findings from the IAMI trial.
    Vaccine. 2023 Nov 2:S0264-410X(23)01211-2. doi: 10.1016/j.vaccine.2023.
    PubMed: https://www.amedeo.com/p2.php?id=37925315&s=flu&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37925315

https://etidioh.wordpress.com/2023/11/11/influenza-and-covid19-research-references-by-amedeo-november-11-23/

#avianInfluenza #COVID19 #influenzaA #research #seasonalInfluenza

Adverse #events associated with #oseltamivir and #baloxavir marboxil in against #influenza virus #therapy: A #pharmacovigilance study using the FAERS database

Source: PLoS One, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0308998

Abstract
Background
Influenza virus is a widespread pathogen that poses significant health risks to humans. Oseltamivir and Baloxavir Marboxil are commonly utilized medications for both treating and preventing influenza infections. Despite their widespread use, there remains a need to thoroughly investigate their safety profiles and potential adverse reactions.

Objective
This study aims to comprehensively analyze the adverse events associated with oseltamivir and baloxavir marboxil in real-world clinical settings, with the goal of assessing their safety and potential risks in the management of influenza virus infections.

Methods
We conducted a retrospective analysis utilizing data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database, spanning from the first quarter of 2004 to the third quarter of 2023. The analysis encompassed examination of drug utilization patterns, types of adverse events reported, patient demographics, and other pertinent factors.

Results
From the first quarter of 2004 to the third quarter of 2023, FAERS collected over 17,035,521 adverse event reports (AE reports). Among these reports, there were 38,384 reports associated with oseltamivir, and 3,364 reports associated with baloxavir marboxil. Oseltamivir and Baloxavir Marboxil were primarily used for the treatment of influenza virus infections, accounting for 62.43% and 67.49% of their total usage, respectively. The main adverse reactions reported for oseltamivir were vomiting (case reports = 1402) followed by confusional state (case reports = 353), while for baloxavir marboxil, adverse reactions mainly centered around off-label use (case reports = 378) and intentional product use issues (case reports = 278). In terms of systemic adverse reactions, oseltamivir primarily affected psychiatric disorders (n = 45), whereas baloxavir marboxil mainly impacted the gastrointestinal system (n = 7). Additionally, regarding adverse reactions in pregnant women, the occurrence of normal newborns was a significant signal for oseltamivir, suggesting a certain level of safety during maternal use. Conversely, reports of adverse reactions such as respiratory arrest were documented for baloxavir marboxil, while no such reports were associated with oseltamivir.

Conclusion
This study provides a comprehensive analysis of the adverse reactions observed with the clinical use of oseltamivir and baloxavir marboxil, revealing the safety and risks associated with these two drugs in the treatment and prevention of influenza virus infections. Firstly, although both drugs are used for influenza treatment, they exhibit different types of adverse reactions. Oseltamivir predominantly affects the psychiatric system, while baloxavir marboxil primarily impacts the gastrointestinal system. Additionally, oseltamivir demonstrates a certain level of safety for use in pregnant women, while reports of adverse reactions such as respiratory arrest are associated with baloxavir marboxil. Despite the clinical significance of this study, limitations exist due to the voluntary nature of data reporting, which may lead to reporting biases and incomplete information. Future research could employ more rigorous prospective study designs, integrating clinical trials and epidemiological studies, to more accurately assess the safety risks of oseltamivir and baloxavir marboxil.

____

#abstract #antivirals #baloxavir #birdFlu #drugsSafety #health #healthcare #news #oseltamivir #pregnancy #research #seasonalInfluenza

Adverse #events associated with #oseltamivir and #baloxavir marboxil in against #influenza virus #therapy: A #pharmacovigilance study using the FAERS database

Source: PLoS One, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0308998

Abstract
Background
Influenza virus is a widespread pathogen that poses significant health risks to humans. Oseltamivir and Baloxavir Marboxil are commonly utilized medications for both treating and preventing influenza infections. Despite their widespread use, there remains a need to thoroughly investigate their safety profiles and potential adverse reactions.

Objective
This study aims to comprehensively analyze the adverse events associated with oseltamivir and baloxavir marboxil in real-world clinical settings, with the goal of assessing their safety and potential risks in the management of influenza virus infections.

Methods
We conducted a retrospective analysis utilizing data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database, spanning from the first quarter of 2004 to the third quarter of 2023. The analysis encompassed examination of drug utilization patterns, types of adverse events reported, patient demographics, and other pertinent factors.

Results
From the first quarter of 2004 to the third quarter of 2023, FAERS collected over 17,035,521 adverse event reports (AE reports). Among these reports, there were 38,384 reports associated with oseltamivir, and 3,364 reports associated with baloxavir marboxil. Oseltamivir and Baloxavir Marboxil were primarily used for the treatment of influenza virus infections, accounting for 62.43% and 67.49% of their total usage, respectively. The main adverse reactions reported for oseltamivir were vomiting (case reports = 1402) followed by confusional state (case reports = 353), while for baloxavir marboxil, adverse reactions mainly centered around off-label use (case reports = 378) and intentional product use issues (case reports = 278). In terms of systemic adverse reactions, oseltamivir primarily affected psychiatric disorders (n = 45), whereas baloxavir marboxil mainly impacted the gastrointestinal system (n = 7). Additionally, regarding adverse reactions in pregnant women, the occurrence of normal newborns was a significant signal for oseltamivir, suggesting a certain level of safety during maternal use. Conversely, reports of adverse reactions such as respiratory arrest were documented for baloxavir marboxil, while no such reports were associated with oseltamivir.

Conclusion
This study provides a comprehensive analysis of the adverse reactions observed with the clinical use of oseltamivir and baloxavir marboxil, revealing the safety and risks associated with these two drugs in the treatment and prevention of influenza virus infections. Firstly, although both drugs are used for influenza treatment, they exhibit different types of adverse reactions. Oseltamivir predominantly affects the psychiatric system, while baloxavir marboxil primarily impacts the gastrointestinal system. Additionally, oseltamivir demonstrates a certain level of safety for use in pregnant women, while reports of adverse reactions such as respiratory arrest are associated with baloxavir marboxil. Despite the clinical significance of this study, limitations exist due to the voluntary nature of data reporting, which may lead to reporting biases and incomplete information. Future research could employ more rigorous prospective study designs, integrating clinical trials and epidemiological studies, to more accurately assess the safety risks of oseltamivir and baloxavir marboxil.

____

#abstract #antivirals #baloxavir #birdFlu #drugsSafety #health #healthcare #news #oseltamivir #pregnancy #research #seasonalInfluenza

Adverse #events associated with #oseltamivir and #baloxavir marboxil in against #influenza virus #therapy: A #pharmacovigilance study using the FAERS database

Source: PLoS One, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0308998

Abstract
Background
Influenza virus is a widespread pathogen that poses significant health risks to humans. Oseltamivir and Baloxavir Marboxil are commonly utilized medications for both treating and preventing influenza infections. Despite their widespread use, there remains a need to thoroughly investigate their safety profiles and potential adverse reactions.

Objective
This study aims to comprehensively analyze the adverse events associated with oseltamivir and baloxavir marboxil in real-world clinical settings, with the goal of assessing their safety and potential risks in the management of influenza virus infections.

Methods
We conducted a retrospective analysis utilizing data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database, spanning from the first quarter of 2004 to the third quarter of 2023. The analysis encompassed examination of drug utilization patterns, types of adverse events reported, patient demographics, and other pertinent factors.

Results
From the first quarter of 2004 to the third quarter of 2023, FAERS collected over 17,035,521 adverse event reports (AE reports). Among these reports, there were 38,384 reports associated with oseltamivir, and 3,364 reports associated with baloxavir marboxil. Oseltamivir and Baloxavir Marboxil were primarily used for the treatment of influenza virus infections, accounting for 62.43% and 67.49% of their total usage, respectively. The main adverse reactions reported for oseltamivir were vomiting (case reports = 1402) followed by confusional state (case reports = 353), while for baloxavir marboxil, adverse reactions mainly centered around off-label use (case reports = 378) and intentional product use issues (case reports = 278). In terms of systemic adverse reactions, oseltamivir primarily affected psychiatric disorders (n = 45), whereas baloxavir marboxil mainly impacted the gastrointestinal system (n = 7). Additionally, regarding adverse reactions in pregnant women, the occurrence of normal newborns was a significant signal for oseltamivir, suggesting a certain level of safety during maternal use. Conversely, reports of adverse reactions such as respiratory arrest were documented for baloxavir marboxil, while no such reports were associated with oseltamivir.

Conclusion
This study provides a comprehensive analysis of the adverse reactions observed with the clinical use of oseltamivir and baloxavir marboxil, revealing the safety and risks associated with these two drugs in the treatment and prevention of influenza virus infections. Firstly, although both drugs are used for influenza treatment, they exhibit different types of adverse reactions. Oseltamivir predominantly affects the psychiatric system, while baloxavir marboxil primarily impacts the gastrointestinal system. Additionally, oseltamivir demonstrates a certain level of safety for use in pregnant women, while reports of adverse reactions such as respiratory arrest are associated with baloxavir marboxil. Despite the clinical significance of this study, limitations exist due to the voluntary nature of data reporting, which may lead to reporting biases and incomplete information. Future research could employ more rigorous prospective study designs, integrating clinical trials and epidemiological studies, to more accurately assess the safety risks of oseltamivir and baloxavir marboxil.

____

#abstract #antivirals #baloxavir #birdFlu #drugsSafety #health #healthcare #news #oseltamivir #pregnancy #research #seasonalInfluenza

From consensus to action: sharing best practice for childhood flu vaccination [Promoted content] https://www.euractiv.com/section/health-consumers/opinion/from-consensus-to-action-sharing-best-practice-for-childhood-flu-vaccination/?utm_source=dlvr.it&utm_medium=mastodon #childhoodvaccination #EUhealth #immunisation #seasonalinfluenza

From consensus to action: sharing best practice for childhood flu vaccination [Promoted content] https://www.euractiv.com/section/health-consumers/opinion/from-consensus-to-action-sharing-best-practice-for-childhood-flu-vaccination/?utm_source=dlvr.it&utm_medium=mastodon #childhoodvaccination #EUhealth #immunisation #seasonalinfluenza